Exercise and insulin sensitivity: interaction with intrahepatic triglyceride and hepatokines by Jack A. Sargeant (7237637)
  
 
 
 
 
EXERCISE AND INSULIN SENSITIVITY: INTERACTION WITH 
INTRAHEPATIC TRIGLYCERIDE AND HEPATOKINES 
 
by 
 
Jack Alistair Sargeant 
 
A Doctoral Thesis 
Submitted in partial fulfilment of the requirements for the award of Doctor of 
Philosophy of Loughborough University 
 
December 2018 
 
 
 
© by J.A.Sargeant (2018)
~ I ~ 
 
Abstract 
Insulin resistance is central to the pathogenesis of non-alcoholic fatty liver disease (NAFLD) 
and type 2 diabetes mellitus (T2DM). Intrahepatic triglyceride (IHTG), the primary feature of 
NAFLD, strongly predicts insulin resistance in the liver and peripheral (skeletal muscle and 
adipose) tissues. Hepatokines (e.g. fibroblast growth factor 21 (FGF21), leukocyte cell-derived 
chemotaxin 2 (LECT2), follistatin, selenoprotein P, and fetuin-A) are liver-derived proteins 
with capacity to exert endocrine effects and may potentially modulate the link between IHTG 
and peripheral insulin sensitivity/glycaemic control. Exercise is integral to the management of 
NAFLD and T2DM, with evidence suggesting that high-intensity exercise may provide the 
greatest benefits.  
Chapter 4 of this thesis demonstrates that, in individuals without chronic metabolic disease, 
plasma concentrations of FGF21 and LECT2 are higher, and follistatin lower, in individuals 
with overweight or obesity compared with normal weight individuals. Furthermore, FGF21 
and follistatin are transiently elevated for up to 6 h after acute aerobic exercise (60 min at 60% 
V̇O2 peak). The response of follistatin to acute moderate-intensity exercise is also present in 
individuals with impaired glucose regulation (Chapter 5), but the response of FGF21 is 
abolished. A single bout of low-volume high-intensity interval training has no effect on FGF21, 
follistatin or fetuin-A in individuals with dysglycaemia (Chapter 5). Chapter 6 demonstrates 
that six weeks of sprint interval training (SIT) is feasible for men with NAFLD and reduces 
IHTG despite no change in body weight. Peripheral insulin sensitivity tends to increase after 
SIT but hepatic insulin sensitivity and circulating hepatokines remain unchanged. Through 
meta-analyses, Chapter 7 confirms that exercise training reduces IHTG, even in the absence of 
weight loss. However, the magnitude of this effect is greater when weight loss occurs and 
benefits increase proportionally. Exercise training improves basal hepatic insulin sensitivity, 
but evidence in this area is currently limited (Chapter 7). 
Collectively, the studies in this thesis demonstrate that some hepatokines may be sensitive to 
acute and chronic changes in energy metabolism. However, further evidence is required before 
definitive statements can be made. Exercise training, including SIT, has the potential to reduce 
IHTG in men with NAFLD, even in the absence of weight loss. However, the greatest benefits 
on IHTG will likely be elicited when exercise training is performed in combination with dietary 
energy restriction to elicit sustained reduction in body weight.  
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Obesity is a chronic disease characterised by the excess accumulation of body fat, which is 
associated with several physical and metabolic consequences, and increases risk of disease-
specific and all-cause mortality (Bray, 2004; Whitlock et al., 2009; The Global BMI Mortality 
Collaboration, 2016; Heymsfield and Wadden, 2017). The prevalence of obesity has risen 
globally over recent decades (NCD Risk Factor Collaboration, 2016) and, with the 
simultaneous improvement in the management of infectious diseases, has become established 
as a leading health concern in modern societies (Heymsfield and Wadden, 2017). If current 
trends continue, it is predicted that, by 2030, there may be as many as three billion individuals 
worldwide that are overweight or obese (Kelly et al., 2008). It is estimated that approximately 
27% of the United Kingdom (UK) population are obese, many of whom are severely obese, 
and a further 35% are overweight (NCD Risk Factor Collaboration, 2016). The high prevalence 
of obesity, and the number of associated co-morbidities, make obesity treatment a substantial 
economic burden; one that is predicted to increase (Wang et al., 2011; Bray et al., 2016).  
The pathogenesis of obesity is highly complex and obesity risk is determined by several 
modifiable and non-modifiable factors (Heymsfield and Wadden, 2017; Schwartz et al., 2017). 
With rare genetic conditions aside, however, obesity is predominantly the result of prolonged 
energy surplus. Consequently, physical inactivity and excessive energy intake (as well as 
deleterious dietary composition) are important modifiable risk factors that are independently 
associated with increased obesity risk (Yumuk et al., 2015). It is notable that reductions in 
physical activity over recent decades, particularly occupational physical activity, mirror the 
increased prevalence of overweight and obesity (Church et al., 2011) 
There has been increased recognition over recent years that adipose tissue is not simply a site 
for lipid storage but is, in fact, a metabolically-active endocrine organ (McGown, Birerdinc 
and Younossi, 2014). Accordingly, the metabolic consequences of obesity remain an area of 
growing interest and research. Obesity is associated with the increased risk of several metabolic 
co-morbidities, including type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), 
chronic kidney disease (CKD) and non-alcoholic fatty liver disease (NAFLD) (Bray et al., 
2016; Heymsfield and Wadden, 2017). As a result, the clinical management of obesity requires 
not only a focus on achieving and maintaining a healthy body weight, but must also consider 
the management of these associated conditions. 
In recent years, there has been a rapid growth in the attention dedicated to NAFLD from both 
researchers and clinicians alike. In the UK, the number of hospital admissions due to NAFLD 
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has risen exponentially since 1998 and this is likely due to a combination of both increased 
obesity prevalence and increased clinical awareness (Williams et al., 2014). NAFLD is 
characterised by the ectopic accumulation of lipid in the liver (hepatic steatosis), which occurs 
independently of excessive alcohol consumption (Marchesini et al., 2016; Chalasani et al., 
2018). Hepatic steatosis may occur in isolation, but it is the development of associated hepatic 
inflammation and/or fibrosis (non-alcoholic steatohepatitis; NASH), which substantially 
increases the risk of advanced liver complications (cirrhosis, hepatocellular carcinoma (HCC), 
and liver failure), as well as liver-specific and all-cause mortality (Rinella, 2015; Than and 
Newsome, 2015). NAFLD is now a leading chronic liver disease worldwide, with an estimated 
global prevalence of approximately 25% (Younossi et al., 2016). Furthermore, NASH-related 
HCC is the most rapidly growing cause of liver transplantation and is set to surpass hepatitis C 
as the principal indication (Wong, Cheung and Ahmed, 2014; Rinella and Sanyal, 2016).  
In the context of hepatic complications, therefore, the development of NASH represents an 
important aspect in the natural history of NAFLD. However, the clinical impact of hepatic 
steatosis per se should not be dismissed. Hepatic steatosis (measured as intrahepatic 
triglyceride; IHTG) is strongly associated with insulin resistance in several tissues, including 
skeletal muscle, adipose tissue and the liver (Korenblat et al., 2008; Bril, Barb, et al., 2017), 
and this has several implications for glycaemic control. Although the nature of these 
implications is highly complex, peripheral (skeletal muscle and adipose tissue) insulin 
resistance predominantly disrupts glucose uptake, whilst hepatic insulin resistance contributes 
to elevated endogenous glucose production (EGP) (Taylor, 2008). Unsurprisingly, therefore, 
NAFLD is commonly considered the hepatic component of the metabolic syndrome and is 
predictive of incident T2DM (Kotronen and Yki-Järvinen, 2008; Armstrong et al., 2014; Byrne 
and Targher, 2015; Mantovani et al., 2018). Insulin resistance is also heavily implicated in the 
pathogeneses of CKD and CVD (Laakso and Kuusisto, 2014; Artunc et al., 2016; Xu and 
Carrero, 2017) and may, therefore, represent a central feature underlying the relationships 
between NAFLD and the myriad of obesity-associated conditions mentioned previously 
(Armstrong et al., 2014; Byrne and Targher, 2015). It is notable that the leading cause of death 
in individuals with NAFLD is CVD (Targher, Day and Bonora, 2010; Targher et al., 2016). 
Several direct and indirect mechanisms have the potential to mediate the relationship between 
hepatic steatosis and peripheral insulin resistance (Byrne and Targher, 2015; Meex and Watt, 
2017). One exciting, novel mechanism has emerged from the recent identification of several 
exclusively or predominantly liver-synthesised proteins, which have capacity to be secreted 
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into the circulation and exert endocrine effects in peripheral tissues. Consistent with the 
nomenclature of myokines and adipokines, these liver-secreted proteins have been termed 
“hepatokines” (Stefan and Häring, 2013; Takamura, Misu and Kaneko, 2016). Several of these 
hepatokines appear to be regulated by nutritional status (both acute and chronic), with hepatic 
steatosis implicated as a mediator of their synthesis and/or secretion (Meex et al., 2015). 
Furthermore, some hepatokines have been shown to modulate peripheral insulin sensitivity or 
glycaemic control, attracting further interest into their clinical importance in NAFLD and other 
obesity-associated co-morbidities (Stefan and Häring, 2013; Meex et al., 2015; Takamura, 
Misu and Kaneko, 2016).  
There are currently no approved pharmacological treatments specifically for the treatment of 
NAFLD (Marchesini et al., 2016; Rinella and Sanyal, 2016). There may be many reasons for 
this, but one important issue is the methodological difficulties and ethical considerations of 
using repeated liver biopsy (Festi et al., 2013). Liver biopsy is highly invasive but, at present, 
regulatory bodies necessitate its use for the measurement of histological outcomes when testing 
pharmacological interventions. Several non-invasive imaging methods exist for the assessment 
of outcomes in NAFLD (Alkhouri and Feldstein, 2016; Bawden, Scott and Aithal, 2017). 
However, until suitable methods are developed, validated and approved by regulatory agencies 
for the measurement of histological outcomes (particularly hepatic inflammation and fibrosis), 
collecting sufficient experimental evidence to gain approval of pharmacological treatments in 
NAFLD will remain challenging (Rinella and Sanyal, 2016). 
Consequently, lifestyle interventions remain the cornerstone of treatment in NAFLD 
(Marchesini et al., 2016; Chalasani et al., 2018), and these are implemented with the primary 
aim of reducing body weight through the restriction of energy intake and increasing physical 
activity. The consumption of a more favourable dietary composition may also elicit 
independent benefits (Marchesini et al., 2016; Chalasani et al., 2018). These guidelines 
(discussed in more detail within Chapter 2 of this thesis) provide generic goals for individuals, 
including weight loss targets and recommendations for both daily energy restriction and total 
weekly physical activity. Notably, however, they also fully endorse the use of a personalised 
approach, where each patient’s treatment is discussed and agreed between a multidisciplinary 
team of healthcare professionals and, most importantly, in consultation with the patient 
themselves (Marchesini et al., 2016; Chalasani et al., 2018). Holistic patient care means that 
agreed treatments should target the favourable modification of as many lifestyle risk factors as 
possible (diet, physical activity, smoking status etc.). However, specific interventions should 
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be tailored to patient preferences and circumstances (Marchesini et al., 2016; Chalasani et al., 
2018). This applies to the broader treatment approach (some individuals may favour energy 
restriction, whilst others prefer to focus on increased physical activity) as well as the specific 
details of the intervention employed. For example, when attempting to engage in more regular 
structured exercise, some patients may favour continuous moderate-intensity aerobic exercise 
(CME) training, whilst others may prefer high-intensity interval training (HIIT) or progressive 
resistance exercise. This individualised approach does, however, necessitate the development 
of several interventions that vary in nature and are supported by strong experimental evidence, 
to provide patients with multiple options to explore. 
With this context in mind, the research reported in this thesis had three primary aims: 
1. To examine the effects of acute exercise on several circulating hepatokines and their 
associations with anthropometric and circulating clinical biomarkers in individuals of 
different weight status and glycaemic control. 
2. To test the feasibility and efficacy of sprint interval training (SIT) as a novel 
intervention for patients with NAFLD, particularly exploring its effects on IHTG and 
tissue-specific (hepatic and peripheral) insulin sensitivity. 
3. To collate the existing literature and summarise the effects of exercise training on IHTG 
and hepatic insulin sensitivity, exploring the mediating influence of weight loss. 
To do this, this thesis contains three laboratory-based experimental studies (Chapters 4, 5 and 
6), which collectively target aims one and two, and concludes with a systematic review and 
meta-analysis (Chapter 7), which targets aim three.  
Specifically, Chapter 4 investigates the influence of a single bout of CME on several candidate 
hepatokines in normal weight and overweight/obese men. Relationships between fasted plasma 
hepatokine concentrations, anthropometric measures and circulating cardiometabolic risk 
factors are also explored. Chapter 5 then extends these findings by conducting exploratory 
preliminary analyses on an ongoing clinical trial comparing the effects of acute CME or low-
volume HIIT (LV-HIIT) on hepatokine responses in a patient group with dysregulated glucose 
metabolism. Chapter 6 presents the results of a 6-week SIT intervention in patients with 
NAFLD on hepatic steatosis (assessed by magnetic resonance spectroscopy) and hepatic and 
peripheral insulin sensitivity (determined by dual-step hyperinsulinaemic, euglycaemic clamp). 
Hepatokines were also measured in Chapter 6 to explore changes in fasted circulating 
concentrations with training. Finally, the systematic review and meta-analysis presented in 
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Chapter 7 systematically collates the available literature investigating the impact of exercise 
training on hepatic steatosis and hepatic insulin sensitivity in individuals with, or at high risk 
of, NAFLD. Importantly, inclusion criteria restrict eligible studies to those using the same 
techniques implemented in Chapter 6. Subgroup analyses and meta-regression in Chapter 7 
explore the impact of exercise mode (aerobic, HIIT or resistance exercise) and intensity, 
intervention duration and the influence of associated weight loss on changes in hepatic steatosis. 
The studies described in this thesis were core studies conducted within the National Institute 
of Health Research (NIHR) Leicester-Loughborough Diet Lifestyle and Physical Activity 
Biomedical Research Unit (“Leicester-Loughborough BRU”). The studies outlined in Chapters 
4 and 5 were each designed and conducted in collaboration with other PhD students sponsored 
by the BRU.  The data presented in Chapter 4 has been published (Sargeant, Aithal, et al., 2018) 
and was selected by the editor as the featured article within its issue (Appendix I). Other 
outcomes of this trial have also been published (Douglas et al., 2017). The study presented in 
Chapter 6, which was a collaborative project with the NIHR Nottingham Digestive Diseases 
BRU, has also been published (Sargeant, Bawden, et al., 2018), as has the systematic review 
and meta-analysis presented in Chapter 7 (Sargeant, Gray, et al., 2018). 
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CHAPTER 2 
REVIEW OF LITERATURE 
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2.1  Purpose and overview of this chapter 
This chapter presents a detailed but succinct review of the literature that provides the 
underlying rationale for the studies presented in this thesis. The literature cited throughout is 
intended to be thorough, but is not an exhaustive list. Topics that are related but not specific to 
the focus of this thesis are mentioned in brief and appropriate published reviews are 
recommended for the interested reader. 
This chapter starts by providing an overview of the pathogenesis of obesity and ectopic lipid 
storage before presenting an outline of the discovery, prevalence and natural history of NAFLD. 
This is followed by a more detailed account of the pathogenesis and treatment of hepatic 
steatosis, the central component of NAFLD, and its relationship with obesity and T2DM; 
focussing particularly on the role of physical inactivity and structured exercise training. This 
chapter concludes by presenting recent evidence concerning a selection of exclusively or 
predominantly liver-secreted proteins, termed ‘hepatokines’, and their potential implications 
for metabolic health as a novel mechanism mediating ‘cross-talk’ between the liver and 
peripheral tissues.  
2.2  Obesity 
2.2.1 Pathogenesis of obesity 
The pathogenesis of obesity is highly complex, but in most individuals its development is 
ultimately governed by a chronic state of positive energy balance (Heymsfield and Wadden, 
2017; Schwartz et al., 2017). Energy balance is the sum of all processes related to energy intake 
and expenditure and, when intake exceeds expenditure, the excess energy is stored. Storage 
primarily occurs in the form of lipid (triglyceride; TG) accumulation in adipose tissue leading 
to increased body weight (Heymsfield and Wadden, 2017). Importantly, this increased storage 
is reversible and when a prolonged state of negative energy balance is achieved (through 
sufficient reductions in energy intake, increases in energy expenditure, or combinations of both) 
weight loss will occur (Heymsfield and Wadden, 2017). From an evolutionary perspective, the 
capacity of humans to store large amounts of energy in the form of lipid-rich adipose tissue is 
advantageous, conserving this energy during periods of surplus for times of relative famine 
(Schwartz et al., 2017). However, in the modern environment, where energy is freely available 
and the requirements for physical exertion are reduced, this adaptation predisposes individuals 
to excessive weight gain. 
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The underlying factors that determine energy intake and expenditure in humans are numerous 
and interested readers are directed to published reviews that discuss the pathogenesis of obesity 
in depth (Van Der Klaauw and Farooqi, 2015; Heymsfield and Wadden, 2017; Schwartz et al., 
2017). A combination of genetic, developmental and environmental factors interact to 
determine obesity risk for a given individual. Many of these factors are fundamental to the 
pathogenesis of NAFLD and will be discussed in more depth in subsequent sections of this 
literature review. 
2.2.2 Lipid storage in obesity 
During chronic energy surplus, lipid accumulation occurs in several different sites (or 
‘compartments’), including both adipose and non-adipose tissues. The relative distribution of 
lipids across these tissues varies between individuals and, importantly, the associated metabolic 
risk for each compartment is not equal (Shen et al., 2003; Blüher, 2013). Consequently, a given 
individual may have high levels of body fat yet remain relatively metabolically healthy in 
comparison to an apparently leaner person with a more adverse distribution of lipid storage 
(Thomas et al., 2012; Blüher, 2013). In most individuals, the majority of lipid storage occurs 
in subcutaneous adipose tissue (ScAT) and this compartment is associated with the lowest 
metabolic risk (Tchkonia et al., 2013). In a further level of complexity, the regional distribution 
of ScAT between upper body, lower body and abdominal sites may also be influential 
(Tchkonia et al., 2013; Karpe and Pinnick, 2015). The visceral adipose tissue (VAT) 
compartment is a smaller absolute site for fat accumulation compared to ScAT, but is 
associated with a greater risk of metabolic dysregulation (Tchkonia et al., 2013; Heymsfield 
and Wadden, 2017). Even in normal weight individuals, those with low ScAT and high VAT 
display greater metabolic risk compared to those with high ScAT and low VAT (Thomas et al., 
2012). In most individuals, when a state of chronic overnutrition and physical inactivity is 
sustained, the ability to preferentially store lipids within ScAT, becomes overwhelmed and an 
increased accumulation within VAT and other ectopic sites occurs. This may be further 
exacerbated by the development of adipose tissue dysfunction contributing to reduced storage 
capacity (Tan and Vidal-Puig, 2008; Blüher, 2013). Non-adipose sites of ectopic lipid storage 
include the vasculature, skeletal muscle, cardiac, renal and pancreatic tissues as well as, of 
particular relevance to this thesis, the liver (Szendroedi and Roden, 2009; Byrne and Targher, 
2014). The ectopic accumulation of lipids in the liver is termed ‘hepatic steatosis’ and is the 
fundamental component of NAFLD. 
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2.3  Non-alcoholic fatty liver disease (NAFLD) 
2.3.1 An introduction and historical overview 
Hepatic steatosis is defined clinically as the presence of TG in more than 5% of hepatocytes or 
a liver fat content (intrahepatic triglyceride; IHTG) greater than 5.56%, depending on the 
measurement technique used (Marchesini et al., 2016; Chalasani et al., 2018). Importantly, a 
diagnosis of NAFLD requires that hepatic steatosis occurs in the absence of excessive alcohol 
intake, viral infection and steatogenic medications, as well as other secondary sources. 
Consequently, most cases of NAFLD are fundamentally a result of deleterious lifestyle habits; 
usually a combination of excessive energy intake, adverse dietary composition and low 
physical activity (Marchesini et al., 2016; Chalasani et al., 2018). Given that these are 
underlying components of positive energy balance, it is not surprising that the majority of 
NAFLD diagnoses occur in the context of overweight or obesity (Chalasani et al., 2018). 
NAFLD describes a spectrum of conditions in which hepatic steatosis can either manifest in 
isolation (often referred to as ‘benign’ or ‘simple’ steatosis) or in combination with varying 
degrees of hepatic inflammation and/or fibrosis, known as NASH. In some cases, NAFLD may 
proceed to cirrhosis, HCC and liver failure, which may ultimately result in liver transplantation 
and/or death (Rinella, 2015; Than and Newsome, 2015; Marchesini et al., 2016).  
For decades, it was firmly believed that hepatic steatosis in the absence of viral infection was 
the result of excess alcohol consumption. Individuals who denied high alcohol intake were 
simply believed to be lying (Leslie, 2015). Then, in 1979, Adler and Schaffner reported 
findings from 29 overweight patients who, through individual interviews with three separate 
doctors, were considered to be no greater than “light social drinkers” (Adler and Schaffner, 
1979). Liver biopsy samples from these patients all showed signs of hepatic lipid accumulation 
and patients were equally distributed between the categories of ‘fatty liver’, ‘fatty hepatitis’, 
‘fatty fibrosis’ and ‘fatty cirrhosis’. These findings led the authors to conclude that “obesity 
per se can lead to “severe liver damage” (Adler and Schaffner, 1979). A year later, Jurgen 
Ludwig and colleagues, from the Mayo Graduate School of Medicine, published similar 
findings from 20 individuals undergoing serial biopsy between the years of 1969 and 1979 
(Ludwig et al., 1980). These individuals were moderately obese but “denied alcohol abuse 
categorically”, a claim that was supported by evidence from laboratory tests and consultation 
with relatives. Nonetheless, these patients presented with progressive histological changes that 
were compatible with alcoholic liver disease, including “striking fatty changes with evidence 
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of lobular hepatitis” and “evidence of fibrosis”. Three individuals also developed cirrhosis 
(Ludwig et al., 1980). As a result, Ludwig and colleagues were the first to propose the term 
NASH to describe this distinct medical entity (Ludwig et al., 1980). For clinicians who 
remained doubtful, the rapid increase in the prevalence of fatty liver in children and adolescents 
provided further compelling evidence (Leslie, 2015). 
2.3.2 Diagnosis 
Exact definitions of hepatic steatosis differ subtly depending on the measurement technique 
used. Liver biopsy with subsequent chemical or histological assessment of tissue composition 
is the longest-standing method for the diagnosis of NAFLD. Using this method, hepatic 
steatosis is considered a fat percentage greater than 5% of liver volume or weight, or when 
more than 5% of hepatocytes visibly contain TG under microscopy (Fabbrini and Magkos, 
2015). More recent advances in non-invasive imaging techniques, including ultrasound (US) 
and computed tomography (CT), has led to their routine use for early NAFLD diagnoses using 
similar diagnostic thresholds for liver fat content. Due to its high cost and invasive nature, liver 
biopsy is now reserved for when more progressive NAFLD is suspected, as it remains the only 
clinically approved method for the assessment of hepatic inflammation, fibrosis and cirrhosis. 
Circulating liver enzymes (alanine (ALT) and aspartate (AST) aminotransferases and gamma 
glutamyl transpeptidase (GGT)) are biomarkers of liver disease but are poorly correlated with 
IHTG and are insensitive to changes that occur (Charatcharoenwitthaya, Lindor and Angulo, 
2012). However, most cases of NAFLD are diagnosed during clinical follow-up of abnormal 
liver function tests. Improvements in magnetic resonance techniques have allowed more 
sensitive non-invasive methods to be developed, namely proton magnetic resonance 
spectroscopy (1H-MRS) and, more recently, magnetic resonance imaging (MRI). In a study of 
2,349 individuals deemed to be at low risk of developing NAFLD, the 95th percentile of IHTG 
as assessed using 1H-MRS was 5.56% (Szczepaniak et al., 2005). Subsequently, this value has 
become an established threshold for the diagnosis of NAFLD when using this technique. 
Notably, however, this threshold criteria is not based on any relationship between IHTG and 
metabolic or clinical outcomes (Fabbrini and Magkos, 2015). For example, non-linear 
relationships have been reported between IHTG and tissue-specific insulin sensitivity, with 
suggestions that hepatic insulin sensitivity in particular (measured as percentage suppression 
of EGP) may be substantially impaired at IHTG content much lower than 5.56% (Bril, Barb, 
et al., 2017). Furthermore, magnetic resonance procedures remain expensive and may not be 
practical in all individuals. As such, it is often reserved for clinical research studies. 
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2.3.3 General prevalence and common risk factors 
NAFLD is now a leading cause of liver disease worldwide and the most prevalent in Western 
countries (Marchesini et al., 2016; Cusi et al., 2017). Its rapid rise in prevalence over recent 
decades make it an important health concern in both adults and children (Vernon, Baranova 
and Younossi, 2011; Than and Newsome, 2015). Prevalence estimates vary, primarily 
depending on the diagnostic technique used, but a recent meta-analysis of 45 studies with a 
total of over 8.5 million individuals reported the global prevalence of NAFLD to be 
approximately 25% [95% CI: 22.10 to 28.65%] (Younossi et al., 2016). When analysed by 
region, data specific to Europe were similar (21 studies; 230,685 individuals; prevalence 23.71% 
[16.1 to 33.5%]), as were those in the single study from the UK (1,118 individuals; prevalence 
26.39% [23.82 to 29.07%]) (Armstrong et al., 2012). It is suggested that poor detection and 
referral of suspected NAFLD in at risk populations within primary care means that these 
research studies likely underestimate the true NAFLD prevalence (Armstrong et al., 2012; 
Blais et al., 2015).  
The prevalence of NAFLD in normal weight individuals with no metabolic risk factors is 
between seven and 16% (Vernon, Baranova and Younossi, 2011; Younossi et al., 2016). 
However, this is substantially increased in individuals who are obese and greater further in 
those with additional metabolic risk factors or co-morbidities (Rinella, 2015; Younossi et al., 
2016; Cusi et al., 2017). NAFLD risk increases with body mass index (BMI) and waist 
circumference (WC) (Bedgoni et al., 2005), and is prevalent in as many as 90% of severely 
obese individuals undergoing bariatric surgery (Machado, Marques-Vidal and Cortez-Pinto, 
2006). Furthermore, approximately 50% of individuals with dyslipidaemia, defined as elevated 
circulating TG and reduced high-density lipoprotein (HDL), satisfy diagnostic criteria for 
NAFLD (Assy et al., 2000; K.-T. Wu et al., 2016). Conversely, dyslipidaemia is present in 
approximately 70% of patients with NAFLD (Younossi et al., 2016). NAFLD is also tightly 
associated with insulin resistance and T2DM (Wanless and Lentz, 1990; Portillo Sanchez et 
al., 2015; Younossi et al., 2016; Cusi et al., 2017) and these relationships are discussed in 
greater depth within subsequent paragraphs of this literature review (2.3.6 Associations of 
NAFLD with insulin resistance and T2DM).  
The risk of NAFLD increases with age (Vernon, Baranova and Younossi, 2011; Attar and Van 
Thiel, 2013; Brea and Puzo, 2013), although this may be mediated by an increased likelihood 
of other metabolic risk factors (Frith et al., 2009). NAFLD appears to be more common in men 
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but the reasons for this disparity are unclear and evidence is not unanimous (Vernon, Baranova 
and Younossi, 2011). Prevalence may also differ between ethnicities, with the risk of NAFLD 
greatest in Hispanic individuals and lower in white Caucasian and African Americans, 
respectively (Browning et al., 2004; Vernon, Baranova and Younossi, 2011; Bril, Portillo-
Sanchez, et al., 2017). These differences may be partly accounted for by differences in the 
PNPLA3 gene (Vernon, Baranova and Younossi, 2011) and, although a number of genes have 
been potentially implicated in the incidence and progression of NAFLD, variants in the 
PNPLA3 and TM6SF2 genes remains the most widely studied (Anstee, Targher and Day, 2013). 
Individuals who have the I148M and E167K variants in the PNPLA3 and TM6SF2 genes, 
respectively, have greater risk of both initial NAFLD incidence and more severe disease 
progression (Anstee, Targher and Day, 2013; Dongiovanni, Petta, Maglio, et al., 2015).  
It is important to consider that NAFLD and alcoholic liver disease may co-exist (Marchesini et 
al., 2016) and that individuals with high alcohol intake may also have several unrelated 
metabolic risk factors that promote NAFLD (Adams, 2013; Marchesini et al., 2016). Whilst 
distinguishing individuals with each of these diagnoses is common and understandable in a 
research environment, the adoption of this dichotomy may result in an underestimation of true 
NAFLD prevalence.  
2.3.4 Natural history 
The natural history of NAFLD is complex and not fully understood; not least because there 
appears to be distinct prognoses in individuals who maintain isolated steatosis and those that 
develop NASH (Rinella, 2015). Evidence from longitudinal studies is limited in number and 
varies in the use of diagnostic criteria and length of follow-up available. It is suspected, 
however, that approximately 20 to 25% of individuals with steatosis proceed to NASH and, of 
these, a further 20 to 40% will develop advanced fibrosis and/or cirrhosis over a 15-year period 
(Angulo, 2010; Caldwell and Argo, 2010). In the largest paired biopsy study to date, 108 
patients were followed over a median of 6.6 years (McPherson et al., 2015). Approximately 
40% of patients showed worsening of NAFLD, 40% showed no change and 20% displayed 
improvements. Many of the patients that improved lost weight and presented with 
improvements in other metabolic factors (McPherson et al., 2015). Furthermore, in a separate 
retrospective study of 420 NAFLD patients, approximately 12.5% died over a median follow-
up of 7.5 years; a significantly lower survival rate than that of a matched control population 
(Adams et al., 2005). Notably, this study did not distinguish individuals with simple steatosis 
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from those with NASH and it remains unclear if steatosis alone increases risk of mortality. It 
is well established, however, that all-cause and liver-related morbidity and mortality are 
substantially increased in individuals with NASH, compared to those with isolated steatosis 
and to the general population (Ekstedt et al., 2006; Söderberg et al., 2010; D. Kim et al., 2013; 
Younossi et al., 2016). Unsurprisingly, therefore, the progression to NASH represents a 
significant clinical outcome, particularly to hepatologists (Rinella, 2015; Than and Newsome, 
2015; Marchesini et al., 2016; Younossi et al., 2016).  
2.3.5 Hepatic steatosis vs. NASH 
Given the evidence outlined above, it is not surprising that steatosis alone is sometimes 
considered to be a benign condition (Teli et al., 1995; Caldwell and Argo, 2010). Whilst this 
may be partly true in the context of hepatic complications, this opinion is somewhat short-
sighted with respect to wider multidisciplinary care (Bril and Cusi, 2017). The pathogenesis of 
NASH is highly complex and it seems an oversimplification to assume a dichotomous 
distinction between patients who are simply destined to develop NASH and those that are not 
(Peverill, Powell and Skoien, 2014). Instead, it is more likely that elevated IHTG is one of 
several factors that contribute to the increased risk of developing NASH, and that the threshold 
of resistance to this progression differs between individuals (Peverill, Powell and Skoien, 2014). 
Furthermore, whilst a number of non-invasive tools are in development, invasive liver biopsy 
remains the only way to definitively diagnose NASH and predicting individuals that proceed 
from isolated steatosis to NASH is difficult (Rinella, 2015; Marchesini et al., 2016; Chalasani 
et al., 2018). Therefore, until a better understanding of the pathogenesis of NASH is gained, 
along with more effective methods to identify high-risk individuals, the prevention and 
treatment of hepatic steatosis should be a clinical priority. Finally, the impact of NAFLD on 
metabolic health is not restricted to hepatic complications and the accumulation of IHTG is 
strongly associated with many extra-hepatic complications, including insulin resistance 
(Korenblat et al., 2008; Gaggini et al., 2013; Bril, Barb, et al., 2017). Risk of metabolic co-
morbidities, such as T2DM, CVD and CKD, is also increased in patients with NAFLD 
(Armstrong et al., 2014; Musso et al., 2014; Byrne and Targher, 2015; Sinn et al., 2017). It is 
the associations between NAFLD, insulin resistance and T2DM that are of particular interest 
to this thesis and are, therefore, the focus of the subsequent paragraphs. 
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2.3.6 Associations of NAFLD with insulin resistance and T2DM 
Elevated IHTG is strongly associated with insulin resistance and is an independent predictor 
of insulin action in the liver, adipose tissue and skeletal muscle (Fabbrini et al., 2009). A study 
of 42 non-diabetic individuals (IHTG range: 0.7 to 45.5%) demonstrated strong linear 
correlations between IHTG and insulin sensitivity in the same three tissues (Korenblat et al., 
2008). A further study of 144 individuals with and without T2DM has confirmed these 
associations, but more complex non-linear relationships are suggested for hepatic and skeletal 
muscle tissues (Bril, Barb, et al., 2017). Specifically, whilst a progressive reduction in adipose 
tissue insulin sensitivity is apparent with increasing IHTG, it is suggested that insulin 
sensitivity in the liver and skeletal muscle are maximally impaired at IHTG content of 
approximately 1.5 and 4%, respectively (Bril, Barb, et al., 2017). Given these strong 
associations, it is not surprising that NAFLD is widely described as the hepatic manifestation 
of the metabolic syndrome (Buzzetti, Pinzani and Tsochatzis, 2016; Marchesini et al., 2016).  
Approximately two thirds of patients with T2DM have NAFLD (Williamson et al., 2011; 
Portillo Sanchez et al., 2015; Cusi et al., 2017), whilst 22% of patients with NAFLD have 
diabetes (Younossi et al., 2016). The study by Younossi and colleagues (Younossi et al., 2016) 
does not distinguish between different classes of diabetes, but it is likely that the majority of 
these patients have T2DM. NAFLD also predicts T2DM incidence (Balkau et al., 2010; 
Mantovani et al., 2018) and is associated with a 2- to 5-times greater risk of disease 
development (Armstrong et al., 2014). In a 14-year follow-up of 129 patients undergoing serial 
liver biopsies, 46% of those with steatosis alone developed T2DM, and this was even greater 
(~70%) in those with NASH (Ekstedt et al., 2006). Importantly, the resolution of NAFLD is 
associated with a significant reduction of T2DM incidence (Sung, Wild and Byrne, 2013). 
Lastly, the presence of both NAFLD and T2DM is associated with greater severity of both 
conditions. Specifically, patients with both conditions are more likely to develop advanced 
NAFLD, are more insulin resistant and have more severe hyperinsulinaemia (Vernon, 
Baranova and Younossi, 2011; Loomba et al., 2012; Lomonaco et al., 2016).  
2.3.7 Pathogenesis of hepatic steatosis  
The liver is heavily involved in human lipid metabolism but, in healthy individuals, is not a 
preferred lipid storage site. A healthy 70 kg man with a body fat percentage of 20% may store 
as little as 125 g of fat in their liver (Leslie, 2015). This is clearly an oversimplification, 
however, and large individual differences are inevitable. That said, the liver has tremendous 
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potential to store large amounts of excess lipid when circulating concentrations are high. This 
adaptation may be important to avoid the potentially harmful effects of lipotoxicity in other 
tissues; a hypothesis that may be extended to explain the accumulation of intramyocellular 
lipids, which is common in individuals with obesity or associated conditions such as NAFLD 
(Watt, 2009). As mentioned previously, however, the sustained accumulation of lipid in the 
liver is not without consequence for most individuals. As little as 1.5% and 4% IHTG is 
associated with a substantial impairment in hepatic and peripheral insulin sensitivity, 
respectively (Bril, Barb, et al., 2017). Furthermore, the 95th percentile of IHTG in a healthy 
adult population is only 5.56% (Szczepaniak et al., 2005). Collectively, this evidence supports 
the proposition that hepatic steatosis may be an adaptive response with acute benefits, but when 
excessive or sustained over time, the accumulative effects become deleterious and pathogenic 
(Tilg and Moschen, 2010; Anstee, Targher and Day, 2013).  
In its simplest form, the underlying cause of steatosis is an imbalance in the relationship 
between lipid supply and utilisation; when the supply of lipids to the liver overwhelms its 
ability to remove them, accumulation occurs (Fabbrini, Sullivan and Klein, 2010; Birkenfeld 
and Shulman, 2014; Brouwers et al., 2016). As such, IHTG is determined by the balance 
between: a) fasted and post-prandial adipose tissue lipolysis, b) uptake of dietary lipids into the 
liver, c) hepatic de novo lipogenesis (DNL) of carbohydrate, d) hepatic lipid oxidation, and e) 
synthesis and export of lipid-rich very low-density lipoproteins (VLDL). These processes are 
presented in Figure 2.1. A more detailed account of these mechanisms at a molecular level, can 
be found in a thorough published review (Perry et al., 2014).  
In obese individuals undergoing liver biopsy for suspected NAFLD, the majority of IHTG can 
be accounted for by the delivery of circulating non-esterified fatty acid (NEFA) and hepatic 
DNL (Donnelly et al., 2005). As such, in most cases, it is likely that changes in lipid supply 
are primarily responsible for the initial development of hepatic steatosis in NAFLD. 
Conversely, in accordance with the hypothesis that lipid storage as inert TG may be a protective 
adaptation, it may be that only when mechanisms of utilisation become overwhelmed and 
dysfunctional are associated co-morbidities, such as hepatic insulin resistance and NASH, 
developed (Tilg and Moschen, 2010). The factors underlying the development of hepatic 
steatosis and hepatic insulin resistance are outlined in subsequent paragraphs of this literature 
review. Readers interested in the pathogenesis of NASH are directed to a comprehensive 
review presenting the ‘multiple parallel hits hypothesis’ (Tilg and Moschen, 2010).  
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Figure 2.1 An overview of factors contributing to the pathogenesis of hepatic steatosis. Blood supply to/from the liver has been simplified for ease 
of interpretation. * Malonyl-coA inhibits lipid oxidation by reducing mitochondrial NEFA uptake. However, despite this, lipid oxidation is reportedly 
elevated in individuals with NAFLD compared to non-NAFLD controls. DNL: de novo lipogenesis; IHTG: intrahepatic triglyceride; NEFAs: non-esterified 
fatty acids; TG: triglyceride; VLDL: very low-density lipoprotein. Adapted from Fabbrini, Sullivan  & Klein, 2010; Brouwers et al., 2016 and Perry et al., 
2014. 
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2.3.7.1 Regulation of fatty acid uptake 
NEFA uptake into the liver is determined by the combination of its delivery in the circulation 
and the capacity for transport into hepatocytes (Fabbrini, Sullivan and Klein, 2010). Hepatic 
NEFA uptake is not strictly regulated so increased circulating concentrations result in increased 
uptake, providing capacity for transport into the cell is not a limiting factor (Bradbury, 2006). 
Circulating NEFAs cross the cell membrane through specific transport proteins, including fatty 
acid translocase (FAT)/CD36 (Samuel, Petersen and Shulman, 2010). Circulating TG cannot 
be taken up directly, so it is first hydrolysed by hepatic lipoprotein lipase (LPL) to NEFA 
(Goldberg, Eckel and Abumrad, 2009). In individuals with obesity or NAFLD, hepatic 
expression of LPL is increased (Westerbacka et al., 2007; Pardina et al., 2009), whilst 
expression of FAT/CD36 correlates positively with IHTG (Greco et al., 2008; Fabbrini et al., 
2009). Notably, FAT/CD36 expression is reduced following bariatric surgery and this 
reduction correlates with improvements in steatosis (Pardina et al., 2017). In contrast, 
FAT/CD36 expression in adipose tissue is reduced in patients with NAFLD (Greco et al., 2008; 
Fabbrini et al., 2009) and the activation of adipocyte LPL in response to insulin is blunted in 
obese individuals compared to healthy controls (Sadur, Yost and Eckel, 1984). Peroxisome 
proliferator-activated receptor gamma (PPARγ) is a nuclear receptor coded by the PPARG gene, 
which regulates NEFA uptake into adipose tissue and the liver, as well as adipocyte 
differentiation (Schupp and Lazar, 2010). Individuals with dominant negative mutations of the 
PPARG gene in adipose tissue develop NAFLD (Savage et al., 2003), whilst the deletion of 
hepatic PPARG in rodents protects against the development of hepatic steatosis (Matsusue et 
al., 2003). 
2.3.7.2 Adipose tissue lipolysis 
In periods of relative fasting, when plasma insulin concentrations are low and glucagon high, 
TG stores in adipose tissue are broken down via lipolysis and NEFAs are released into the 
blood (Frühbeck et al., 2014). Conversely, in the post-prandial state, when insulin levels are 
elevated, lipolysis is suppressed as part of the shift to a state of energy storage. Accordingly, 
when insulin resistance occurs in the adipose tissue, the regulation of lipolysis is impaired, 
resulting in elevated circulating NEFA under fasting conditions and a blunted post-prandial 
suppression (Frühbeck et al., 2014). Consequently, NEFA supply to the liver is increased 
(Byrne, 2013). 
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Whole body rates of lipolysis are greater in obese compared with lean individuals (Fabbrini et 
al., 2008). Furthermore, when matched for body fat, obese individuals with NAFLD have up 
to 2-fold greater lipolytic rates in adipose tissue than obese individuals with normal IHTG 
(Sunny et al., 2011). The magnitude of suppression of lipolysis by insulin infusion is also 
negatively associated with IHTG (Korenblat et al., 2008). In the fasted state, the majority of 
lipid supply to the liver is from the breakdown of ScAT (Fabbrini, Sullivan and Klein, 2010) 
and, in an intricate study using multiple lipid tracers, Donnelly and colleagues (Donnelly et al., 
2005) suggested that in individuals with NAFLD approximately 60% of IHTG originates from 
circulating, non-dietary NEFA. There is an additional supply of lipids originating from VAT 
but, contrary to the now widely-disputed ‘portal vein hypothesis’ (which suggested that hepatic 
steatosis was primarily caused by increased visceral lipids draining into the portal vein), the 
contribution of NEFA from VAT to total circulating NEFA remains low (albeit increased in 
obese (~20%) vs. lean (~5%) individuals) (Nielsen et al., 2004). 
Circulating NEFA concentrations during an oral glucose tolerance test (OGTT) are 
independently associated with IHTG (Holt et al., 2006). This is primarily driven by a strong 
relationship between IHTG and post-prandial suppression of adipose tissue lipolysis. During 
both insulin infusion and an OGTT, the suppression of adipose tissue lipolysis is reduced in 
individuals with hepatic steatosis compared to either lean individuals or obese individuals with 
normal IHTG (Sanyal et al., 2001; Seppälä-Lindroos et al., 2002; Holt et al., 2006). Only one 
of these studies found a relationship between NAFLD and circulating NEFA in the fasted state 
(Holt et al., 2006), whilst several studies have shown no association (Sanyal et al., 2001; 
Seppälä-Lindroos et al., 2002; Tiikkainen et al., 2002). 
2.3.7.3 Dietary NEFA 
Ingested lipids may contribute to IHTG as TG-rich chylomicrons pass into the fenestrations of 
the liver, are hydrolysed by LPL, and subsequently taken up into hepatocytes (Brouwers et al., 
2016). Approximately 15% of IHTG in individuals with NAFLD is suggested to originate from 
dietary sources (Donnelly et al., 2005). Excessive energy intake and a high proportion of fat-
rich foods combine to substantially increase the dietary intake of lipids and, as a result, the 
supply of lipid-rich chylomicron remnants delivered to the liver in the postprandial state. In 
addition, dysfunctional adipose tissue results in a ‘spillover’ of NEFA into the circulation, 
further increasing supply to the liver (Jacome-Sosa and Parks, 2014).  
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Within an isocaloric diet, macronutrient composition may be important, with suggestions that 
diets high in fat (and low in carbohydrate) may result in greater IHTG than those with low-fat, 
high-carbohydrate (Westerbacka et al., 2005; Van Herpen et al., 2011). However, hypo- and 
hypercaloric diets result in an increase or decrease in IHTG, respectively, with dietary 
composition seeming to be of less importance (Sevastianova et al., 2012; Lecoultre et al., 2013; 
Green and Hodson, 2014; Jensen et al., 2018). Notably, however, the mechanisms by which 
diets high in fat or sugar promote hepatic steatosis may differ. 
2.3.7.4 Hepatic de novo lipogenesis 
De novo lipogenesis (DNL) is the conversion of glucose to palmitate, through various 
intermediates including acetyl-coA and malonyl-coA, for subsequent esterification to TG 
(Fabbrini, Sullivan and Klein, 2010). Hepatic DNL is regulated by several enzymes including 
fatty acid synthase (FAS) and diacylglycerol acyltransferase (DGAT) 1 and 2, as well as a 
range of transcription factors, such as sterol regulatory element binding protein 1c (SREBP-
1c), carbohydrate-responsive element binding protein (ChREBP), farnesoid X receptor (FXR) 
and various peroxisome proliferator-activated receptor (PPAR) isoforms (Musso, Gambino and 
Cassader, 2009). In healthy humans, the contribution of DNL to hepatocyte-synthesised TG is 
low, accounting for less than 5%; although this was measured in TG-rich VLDL, not IHTG 
directly (Diraison, Moulin and Beylot, 2003). Conversely, in patients with NAFLD, the 
percentage of lipids in IHTG originating from DNL is suggested to be approximately 26% 
(Donnelly et al., 2005).  
Hepatic DNL is increased in individuals with NAFLD (Lambert et al., 2014). Furthermore, it 
is independently stimulated by insulin (Ameer et al., 2014) and glucose (Yamashita et al., 2001) 
by activating SREBP1c and ChREBP, respectively (which are commonly increased in patients 
with NAFLD or T2DM). Obese individuals with hyperinsulinaemia have greater rates of 
hepatic DNL after five days of isocaloric high-fat diet (HFD) than insulin-sensitive lean and 
obese controls (Schwarz et al., 2003). Furthermore, a three week period of high-carbohydrate 
overfeeding in obese individuals results in an increase of IHTG which correlates directly with 
increases in hepatic DNL (Sevastianova et al., 2012). Notably, de novo synthesised NEFAs 
activate PPARα to further stimulate hepatic NEFA uptake (Chakravarthy et al., 2005) which, 
in combination with impaired mitochondrial uptake and utilisation (mediated by inhibition of 
carnitine palmitoyltransferase (CPT) 1 by malonyl-coA), will further promote accumulation of 
IHTG (McGarry and Foster, 1980). 
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It is important to mention here the impact of skeletal muscle insulin resistance, which is also 
highly correlated with IHTG (Korenblat et al., 2008). Mice lacking the skeletal muscle glucose 
transporter (GLUT)-4 develop severe hepatic steatosis and insulin resistance (Kotani et al., 
2004). Hyperinsulinaemia and hyperglycaemia, as a consequence of skeletal muscle insulin 
resistance, will further stimulate hepatic DNL as ingested carbohydrate is diverted away from 
skeletal muscle glycogen synthesis and towards the liver, where it is converted to palmitate and 
stored as IHTG (Petersen et al., 2007; Flannery et al., 2012). Fructose may be particularly 
important in this because the nature of its carbon phosphorylation means that it cannot be 
converted to glycogen and thus proceeds to DNL (Leclerq, 2013).  
2.3.7.5 Hepatic lipid oxidation 
Lipids are the preferred hepatic fuel in the fasted state (McGarry and Foster, 1980). Hepatic 
lipid oxidation occurs primarily in the mitochondria but also, to a lesser extent, in peroxisomes 
and microsomes (Fabbrini, Sullivan and Klein, 2010). The carnitine-dependent enzyme shuttle 
(involving CPT1 and CPT2 transporters along with carnitine acyltransferase) regulates 
transport of NEFAs into the mitochondria, where they are progressively shortened to produce 
acetyl-coA (Fabbrini, Sullivan and Klein, 2010). Acetyl-coA formed in this manner can then 
either provide a precursor for ketogenesis (to be exported and used as fuel in other tissues), or 
enter the tricarboxylic acid (TCA) cycle for β-oxidation (McGarry and Foster, 1980).  
Somewhat paradoxically, the contribution of lipid oxidation to hepatic fuel metabolism is 
increased in hepatic steatosis and hepatic insulin resistance (Sanyal et al., 2001; Iozzo et al., 
2010) and, in rodents, may be as high as 100% (Alves et al., 2011). This may be explained as 
an adaptive response to increase the hepatic rate of lipid utilisation in attempt to limit excessive 
accumulation of IHTG. However, evidence in humans is limited. Gene expression of key 
enzymes in oxidative processes are increased in individuals with NAFLD compared to those 
with normal IHTG content, but hepatic expression of CPT1 is reduced along with mRNA of 
key components in mitochondria biogenesis (Greco et al., 2008; Koliaki et al., 2015). 
Mitochondrial respiration is, however, increased in obese individuals with NAFLD and 
correlates with IHTG (Sunny et al., 2011), despite similar total mitochondrial content (Koliaki 
et al., 2015). Furthermore, plasma ketone concentration, which can be used as an indirect 
measure to infer hepatic lipid oxidation, is increased in humans with NAFLD in some, but not 
all, studies (Sanyal et al., 2001; Chalasani et al., 2003).  
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2.3.7.6 Synthesis and export of lipid-rich very low-density lipoprotein (VLDL) 
NEFAs that are not oxidised are esterified into TG and either stored as IHTG or exported in 
the form of TG-rich VLDL (Fabbrini, Sullivan and Klein, 2010). VLDL-TG secretion has 
repeatedly been shown to be greater in individuals with NAFLD compared to those with normal 
IHTG in both the fasted (Fabbrini et al., 2008, 2009) and post-prandial states (Cassader et al., 
2001; Annuzzi et al., 2004). However, there appears to be a ceiling effect whereby VLDL-TG 
secretion increases linearly throughout normal ranges of IHTG but may not increase further 
beyond IHTG of approximately 6%; suggesting that it may be an early adaptive response in 
attempt to limit IHTG accumulation (Fabbrini et al., 2008). 
2.3.8 Pathogenesis of hepatic insulin resistance 
As mentioned previously, insulin resistance is heavily implicated in the development of hepatic 
steatosis and, in most individuals, strong associations exist between IHTG and insulin 
sensitivity in a range of tissues, including the liver (Korenblat et al., 2008; Bril, Barb, et al., 
2017). Insulin resistance in skeletal muscle, hepatic and adipose tissues promotes steatosis, 
whilst steatosis, in turn, perpetuates insulin resistance. As such, the two are intricately linked 
within a myriad of conditions, which, in most cases, occur in the underlying context of obesity 
and physical inactivity.  
The molecular mechanisms underlying insulin resistance are vast and complex and may differ 
subtly between tissues and amongst different insulin-dependent processes (Fabbrini, Sullivan 
and Klein, 2010). There is also increasing evidence that the steatotic liver in NAFLD may 
display selective insulin resistance whereby the regulation of glucose production is impaired, 
whilst that of TG synthesis is maintained (Cook et al., 2015; Jelenik et al., 2017). However, 
this literature will not be discussed in depth. Rather, the following paragraphs will provide an 
overview of the established concepts surrounding ‘normal’ and impaired insulin signalling in 
hepatic and skeletal muscle tissues, focussing on the regulation of circulating glucose. For 
simplicity, these processes will be presented in a linear manner, highlighting key signalling 
proteins. The reality is that many more steps of signalling are involved and their interaction is 
highly complex. For more information, interested readers are directed to excellent published 
reviews (Samuel, Petersen and Shulman, 2010; Samuel and Shulman, 2012; Perry et al., 2014). 
Circulating insulin binds to the insulin receptor at the cell membrane of hepatocytes and 
myocytes, causing tyrosine phosphorylation of insulin receptor substrates 1 and 2 (IRS1, IRS2) 
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(Samuel, Petersen and Shulman, 2010; Perry et al., 2014; Shulman, 2014). In turn, IRS1/2 bind 
to and activate phosphatidylinositol 3-kinase (PI3K). In skeletal muscle, PI3K stimulates the 
translocation of GLUT4 to the cell membrane for the uptake of glucose from the circulation 
and subsequent conversion to intramuscular glycogen (Samuel, Petersen and Shulman, 2010; 
Perry et al., 2014; Shulman, 2014). Insulin-mediated glucose uptake in the liver is much less 
than that of skeletal muscle, with evidence suggesting that signals from oral ingestion are 
required beyond the elevation of circulating glucose and insulin per se (Moore et al., 2012). 
However, activation of hepatic PI3K by IRS1/2 results in the stimulation of Akt2 (also known 
as protein kinase B), which promotes glycogen synthesis and inhibits DNL, through the 
inhibition of glycogen synthase kinase 3 (GSK3) and forkhead box protein O1 (FoxO1), 
respectively (Samuel, Petersen and Shulman, 2010; Perry et al., 2014; Shulman, 2014).  
One established mechanism underlying insulin resistance is the activation of protein kinase C 
isoforms (PKCθ and PKCε in skeletal muscle and hepatic tissues, respectively), which 
translocate to the cell membrane and disrupt insulin signalling (Jornayvaz and Shulman, 2012; 
Birkenfeld and Shulman, 2014). Here, they cause phosphorylation of serine residues on IRS1 
and IRS2 to impair downstream insulin signalling processes, including those outlined above 
(Samuel, Petersen and Shulman, 2010; Samuel and Shulman, 2012; Perry et al., 2014). Insulin 
action may also be impaired through the activation of inflammatory pathways, mediated by 
nuclear factor-κB (NF-κB) (Fabbrini, Sullivan and Klein, 2010). Several factors associated 
with NAFLD mediate hepatic insulin resistance. The following paragraphs outline the impact 
of lipotoxicity, hepatic and peripheral inflammation and endoplasmic reticulum stress (Samuel 
and Shulman, 2012).  
2.3.8.1 Lipotoxicity 
In hepatocytes, NEFAs are progressively combined with glycerol-3-phosphate (a product of 
glycolysis) to form mono- (MAG), di- (DAG) and finally tri-acylglycerol (a term which is 
synonymous with triglyceride) (Samuel and Shulman, 2012). Whilst effective conversion and 
subsequent storage of NEFAs to TG may be considered a beneficial adaptation to energy 
surplus, it is an increase in many of these intermediates, particularly DAG, that is thought to 
have deleterious effects (Tilg and Moschen, 2010; Samuel and Shulman, 2012). In rodents, 
inhibition of hepatic DGAT2 (the enzyme which converts DAG to TG) results in a reduction 
of IHTG, a result that could be considered a beneficial shift in NAFLD risk/severity. However, 
this is accompanied by increased fatty acid oxidation, oxidative stress and liver injury 
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(Yamaguchi et al., 2007). Notably, the knockdown of mitochondrial glycerol-3-phosphate 
acyltransferase (mtGPAT) 1, which catalyses the formation of lysophosphatidic acid (LPA) 
from fatty acyl-coA, results in a reduction of TG, and DAG, but does not prevent the 
development of hepatic insulin resistance, suggesting that DAG may not be the only lipid 
intermediate mediating this effect (Neschen et al., 2005). Mice fed a 3-day HFD develop 
steatosis and hepatic insulin resistance, even before the development of obesity, peripheral 
insulin resistance or systemic inflammation (Samuel et al., 2004, 2007). In these circumstances, 
both insulin-dependent activation of glycogen synthesis and suppression of EGP are impaired, 
and this can be attributed to an increased hepatic DAG, activation of PKCε and subsequent 
reduction in tyrosine phosphorylation of IRS1/2 (Samuel et al., 2007). Importantly, knockdown 
of PKCε reduces HFD-induced hepatic insulin resistance despite similar hepatic DAG and TG 
content (Samuel et al., 2007; Raddatz et al., 2011). In humans with NAFLD, increased flux 
through TG-synthesis pathways results in increased production of lipid intermediates including 
LPA and DAG (Fabbrini, Sullivan and Klein, 2010; Samuel and Shulman, 2012). Hepatic 
PKCε and DAG are strong predictors of hepatic insulin resistance in human patients with 
NAFLD (Kumashiro et al., 2011).  
2.3.8.2 Local and peripheral inflammation 
In rodents, selective activation of hepatic NF-κB induces hepatic inflammation and hepatic 
insulin resistance (Cai et al., 2005). As adipose tissue expands, it can become infiltrated with 
macrophages, which consequently cause inflammation, insulin resistance and dysfunction 
(Samuel and Shulman, 2012). Recruited macrophages release cytokines and chemokines 
(including interleukin (IL) -6, tumor necrosis factor (TNF) α and monocyte chemoattractant 
protein (MCP) 1 into the circulation, which impair hepatic insulin signalling through the 
activation of hepatic NF-κB (Shoelson, Herrero and Naaz, 2007). Adipose tissue macrophage 
content and cytokine/chemokine production are increased in obese individuals compared to 
lean controls (Weisberg et al., 2003) and in obese individuals with NAFLD compared to 
matched individuals with normal IHTG content (Kolak et al., 2007). Lipid intermediates may 
also activate NF-κB to further contribute to hepatic insulin resistance beyond the direct effects 
of lipotoxicity mentioned above (Nagle et al., 2007; Schenk, Saberi and Olefsky, 2008). 
2.3.8.3 Endoplasmic reticulum stress 
The endoplasmic reticulum (ER) is a cellular organelle that coordinates the post-translational 
synthesis, folding and trafficking of proteins (Fabbrini, Sullivan and Klein, 2010). Un- or mis-
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folded proteins are identified by the ER for degradation by the proteasome (Samuel and 
Shulman, 2012). Under conditions of cellular stress, such as hypoxia or changes in substrate 
balance, unfolded proteins accumulate, resulting in impaired cellular function. In these 
circumstances, an unfolded protein response (UPR) is initiated in an attempt to restore normal 
function (Fabbrini, Sullivan and Klein, 2010). The UPR involves several cellular processes, 
including the activation of c-Jun N-terminal kinase (cJNK) which, in turn, activates NF-κB to 
induce insulin resistance (Özcan et al., 2004). Conversely, experimental reduction of ER stress 
improves insulin action (Özcan et al., 2006). Lipotoxicity is also a stimulus for the UPR in 
hepatocytes (Hotamisligil, 2010). Experimental research in humans is limited but individuals 
with NAFLD have been shown to have increased mRNA and/or activation of several proteins 
involved in the UPR (Puri et al., 2008). 
2.3.9 Treatment of NAFLD 
2.3.9.1 Pharmacological therapies 
No drug therapies are currently approved specifically for the treatment of NAFLD (Marchesini 
et al., 2016; Rinella and Sanyal, 2016). As such, the use of pharmacological treatment in 
patients with NAFLD is restricted to off-label prescription (Marchesini et al., 2016; Rinella 
and Sanyal, 2016), but due to the low prevalence of progressive liver complications in 
individuals with steatosis alone, this is usually reserved for individuals with progressive NASH 
or high risk of fibrosis (Singh et al., 2015). Individuals with NAFLD may, of course, take 
prescription medications for the treatment of other associated co-morbidities such as T2DM, 
dyslipidaemia and hypertension. A handful of pharmacological agents have been tested for 
efficacy in the direct management of NASH and those that have reached phase II clinical trials 
will be outlined briefly in the following paragraphs, along with those more novel that show 
promise. Interested readers are directed to published reviews for additional information 
(Mazzella et al., 2014; Ratziu, Goodman and Sanyal, 2015). 
Thiazolidinediones (TZDs) are PPARγ agonists with insulin-sensitizing effects. The PIVENS 
trial investigated the effects of 2-year treatment with Pioglitazone in non-diabetic patients with 
NASH, comparing it with placebo or Vitamin E supplementation (Sanyal et al., 2010). 
Pioglitazone successfully reduced all histological features of NASH except fibrosis and these 
benefits have been confirmed in a published meta-analysis (Mahady et al., 2011). However, 
concerns exist regarding the side-effects of TZDs, which include weight gain, increased risk of 
bone fractures (particularly in women) and, rarely, congestive heart failure (Marchesini et al., 
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2016). Other glucose-lowering agents show promise including incretin mimetics such as the 
GLP1-recpetor agonist, liraglutide, but large randomised controlled trials (RCTs) are required 
(Armstrong et al., 2016). Metformin is an established first line treatment in T2DM, improving 
hepatic insulin sensitivity to elicit benefits on glycaemic control (Cusi, Consoli and DeFronzo, 
1996). However, it appears to have no effect on histological features of NASH, including 
steatosis (Haukeland et al., 2009). 
One treatment arm of the PIVENS trial prescribed 800 IU/day of vitamin E and observed a 
reduction in steatosis, inflammation and lobular ballooning in 36% of patients (21% in the 
placebo group) (Sanyal et al., 2010). Steatosis was reduced in 54% of patients compared to 31% 
of patients prescribed placebo. The TONIC trial demonstrated that vitamin E also reduces 
steatosis in children (Lavine et al., 2011). However, its use has been limited following the 
results of a meta-analysis (19 clinical trials and almost 136,000 patients) suggesting that 
vitamin E at a dose of 800 IU/day is associated with increased risk of all-cause mortality (Miller 
et al., 2005).  
Obeticholic acid, a FXR agonist has also been investigated. Activation of FXR improves 
clamp-derived insulin sensitivity and decreases DNL (Mudaliar et al., 2013). In the FLINT 
trial, obeticholic acid improved steatosis in individuals with NASH but LDL was also increased, 
raising concerns of an increased cardiovascular risk (Neuschwander-Tetri et al., 2015). Issues 
of tolerability have also been reported (Marchesini et al., 2016; Rinella and Sanyal, 2016). 
Notably, a rodent study has demonstrated reduced atherosclerotic risk following treatment with 
obeticholic acid, despite elevations in circulating LDL (Miyazaki-Anzai et al., 2014). 
Supplementation with polyunsaturated fatty acids (PUFAs) has been shown to reduce IHTG in 
early clinical trials (Argo et al., 2015). However, despite its beneficial effects on insulin 
sensitivity and systemic inflammation giving clear rationale for expected benefits in NAFLD 
(Pettinelli et al., 2009; Patterson et al., 2012), phase II trials have failed to demonstrate 
histological improvements (Sanyal et al., 2014; Dasarathy et al., 2015). 
There is also early evidence for the effective use of lipid lowering agents such as pentoxifylline 
(Van Wagner et al., 2011; Zein et al., 2011) and orlistat (Zelber-Sagi et al., 2006; Harrison et 
al., 2009). However, whilst cheap and well tolerated, the effects of pentoxifylline may be 
reserved for only a subset of individuals (Rinella and Sanyal, 2016). Statins are safe for use in 
patients with NAFLD but their direct effects on histological outcomes have not been 
investigated properly (Dongiovanni, Petta, Mannisto, et al., 2015). 
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Part of the difficulty in gaining approval for pharmacological treatments in NAFLD is that 
regulatory bodies continue to demand the use of liver biopsy for the assessment of histological 
changes. This results in a number of practical difficulties, particularly regarding repeated 
testing of control groups in RCTs. It is hoped that with the ongoing development of non-
invasive methods to assess hepatic inflammation, fibrosis and cirrhosis, these alternative 
methods may gain approval and in turn increase the number of phase II and III trials. Ultimately, 
however, the lack of liver-related complications associated with steatosis alone means that the 
recommended use of pharmacological treatment in individuals with non-advanced NAFLD 
(other than treatment of co-morbidities) is unlikely in the near future. 
2.3.9.2 Bariatric and metabolic surgery 
Bariatric, or metabolic, surgery remains an option for weight loss in individuals where other 
weight management approaches have failed (Marchesini et al., 2016). A study in which 150 
overweight/obese patients with T2DM were randomised to either continued medical therapy, 
gastric bypass or sleeve gastrectomy, has recently published 5-yr follow-up data (Schauer et 
al., 2017). Both surgical interventions elicited reductions in body weight, HbA1c and lipid 
profile. Patients that underwent gastric bypass lost significantly more weight, but no 
differences between surgeries were reported for any other outcome (Schauer et al., 2017). It 
has also been reported that surgical intervention reverses steatosis, NASH and possibly fibrosis 
one year after surgery in individuals with biopsy-proven NASH (Lassailly et al., 2015). The 
median biopsy-derived steatosis (percentage of hepatocytes with evidence of steatosis) reduced 
from 60% (IQR 40 to 60%) at baseline to 10% (2.5 to 21.3%) at 1-year. Surgery is also reported 
to reduce liver enzymes and other outcomes of relevance to patients with NAFLD, including 
systemic inflammation and hypertension (Aguilar-Olivos et al., 2016). A recent study in 
rodents has demonstrated that sleeve gastrectomy reduces IHTG and improves hepatic insulin 
sensitivity independent of weight loss (Gazala et al., 2018). However, there are risks and 
expense associated with these procedures and they are not routinely recommended for 
individuals with NAFLD, particularly on the grounds of isolated steatosis alone. Studies 
investigating liver-specific mortality, liver transplantation and quality of life are required 
before this management approach is likely to change (Aguilar-Olivos et al., 2016). 
2.3.9.3 Lifestyle intervention 
Given the evidence outlined above, lifestyle intervention, consisting of changes to diet and 
physical activity, remains the cornerstone of treatment in NAFLD and is mandatory for all 
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patients, regardless of disease severity (Marchesini et al., 2016; Rinella and Sanyal, 2016). The 
underlying aims of this intervention are to reduce body weight and increase cardiorespiratory 
fitness (Rinella and Sanyal, 2016), as relatively small amounts of weight loss reduce IHTG and 
improve hepatic insulin sensitivity (Petersen et al., 2005). Furthermore, physical fitness is 
inversely related with NAFLD risk (Zelber-Sagi, Ratziu and Oren, 2011). One notable 
exception is the unique group of individuals with ‘lean NAFLD’ in which weight loss is not a 
valid treatment goal. However, even in these patients, a healthy dietary composition and active 
lifestyle should be encouraged (Marchesini, Petta and Dalle Grave, 2016). 
In a sub-analysis of patients enrolled in the Look AHEAD trial (a 12-month intensive lifestyle 
intervention aimed at reducing T2DM risk), participants completing the intervention lost 
significantly more weight, had greater reductions in IHTG and had lower risk of NAFLD 
progression compared to those who remained in standard care (Lazo et al., 2010). Whilst at 
least 5% weight loss is associated with improvement in hepatic steatosis, greater reductions 
may be required to elicit other histological improvements (Promrat et al., 2010; Vilar-Gomez 
et al., 2015). In a 12-month uncontrolled community healthcare intervention, where 261 
patients underwent paired liver biopsy, a dose-response relationship was apparent between the 
magnitude of weight loss and histological improvement. NASH resolution was observed in 
26%, 64% and 90% of patients when weight loss of 5-7.5%, 7.5-10% and >10% was achieved 
(Vilar-Gomez et al., 2015). Notably, only 30% of individuals randomised to the intervention 
(target energy restriction of 750 kcal per day and increased physical activity) achieved at least 
5% weight loss. In a separate trial in individuals with NASH, weight loss >7% was associated 
with histological improvement regardless of allocation to lifestyle intervention or standard care 
groups (Promrat et al., 2010). 
Using hypocaloric diet alone, a 5% reduction in body weight over a few weeks is associated 
with a 25% improvement in IHTG, up to the resolution of ‘healthy’ levels (Patel et al., 2015). 
In a large randomised trial, the composition (low-carbohydrate vs. low-fat) of a 6-month 
hypocaloric diet did not appear to have a substantial contribution to reductions in IHTG (Haufe 
et al., 2011). However, over a shorter duration (two weeks) carbohydrate restriction may be 
more effective than general caloric restriction in reducing IHTG (Browning et al., 2011), 
although evidence is limited. The Mediterranean diet, which is high in mono-unsaturated fatty 
acids (MUFAs) and fibre, and low in saturated fatty acids (SFAs), has been shown to reduce 
IHTG over six weeks in individuals with NAFLD, independent of weight loss (Ryan et al., 
2013). Furthermore, increases in IHTG as a result of overfeeding are attenuated in groups 
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consuming a diet low in SFAs compared to a high-SFA diet (Rosqvist et al., 2014). The 
consumption of dietary fructose in the form of high-fructose corn syrup, the principal 
sweetening component of sugar-sweetened beverages, is associated with hepatic steatosis 
(Zelber-Sagi et al., 2007; Maersk et al., 2012), and the addition of fructose to overfeeding 
protocols exacerbates increases in IHTG (Sobrecases et al., 2010). However, the consumption 
of fruit (which is also high in fructose) is considered safe and healthy for individuals with or at 
risk of NAFLD (Marchesini, Petta and Dalle Grave, 2016). Notably, however, a randomised 
trial in which participants consumed a diet high in either fructose or glucose under both 
isocaloric and hypercaloric circumstances (each for two weeks with a six-week washout 
between), reported significantly increased homeostatic model assessment of insulin resistance 
(HOMA-IR) by the high-fructose diet in the isocaloric period only (Johnston et al., 2013). 
There were no other differences between the diets in either isocaloric or hypercaloric periods 
in relation to measures of adiposity (including IHTG) or clamp-derived indices insulin 
sensitivity. 
Joint-guidelines from the European Associations for the Study of Liver, Diabetes and Obesity 
(EASL, EASD, and EASO) state the following components should be considered when 
designing a lifestyle intervention in the treatment of NAFLD (Marchesini et al., 2016): 
• Promotion of energy restriction with a target energy deficit of 500-1000 kcal/day. 
• Minimum target weight loss of 7-10% initial body weight. 
• Changes in dietary composition, if desired, according to the Mediterranean diet, whilst 
consumption of sugar-sweetened beverages should be avoided. 
• Strict adherence to recommended weekly alcohol limits (< 14 and 21 units for women 
and men, respectively). 
These are very similar to the joint-guidelines of the American College of Cardiology, American 
Heart Association and the Obesity Society for the management of overweight and obesity 
(Jensen et al., 2014). Guidelines also promote the incorporation of physical activity or exercise, 
and the reduction of sedentary time, as follows: 
• Completion of 150-200 min·wk-1 of moderate-intensity exercise, divided across three-
to-five sessions. 
• Gradual increase in physical activity with the aim of inducing an energy deficit of 400 
kcal·day-1. 
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• Addition of resistance exercise to elicit musculoskeletal benefits (this may replace 
aerobic exercise in individuals for whom it may not be feasible, appropriate or well 
adhered to). 
• Reduction in sedentary time and increase in daily steps (towards a target of 10,000 to 
12,000 steps·day-1). 
• Avoidance of sustained periods of inactivity to lower lethargy and increase compliance. 
All available guidelines for lifestyle interventions promote the use of individually tailored 
programmes and the setting of goals according to patient preferences (Jensen et al., 2014; 
Marchesini et al., 2016; Marchesini, Petta and Dalle Grave, 2016; Rinella and Sanyal, 2016). 
Cognitive behavioural therapies should be used to increase compliance and remove perceived 
barriers to weight loss and maintenance. Long-term evidence concerning the natural history of 
NAFLD following lifestyle intervention is lacking and no guide on the length of monitored 
weight maintenance exists (Marchesini et al., 2016; Marchesini, Petta and Dalle Grave, 2016; 
Rinella and Sanyal, 2016). However, providing structured monitoring and support to 
individuals for as long as possible will likely improve adherence and this may translate to 
greater benefits. 
2.3.9.4 Structured exercise training 
The effects of exercise alone in the treatment of NAFLD have also been investigated. Chapter 
7 of this thesis presents a systematic review and meta-analysis of the effects of exercise training 
on IHTG and hepatic insulin sensitivity in individuals with or at risk of NAFLD. As such, the 
following section of this literature review will remain brief.  
The potential for exercise to induce large energy deficits is much smaller than that of caloric 
restriction (Marchesini, Petta and Dalle Grave, 2016). However, meaningful benefits of 
exercise on IHTG have been reported (Keating et al., 2012; Katsagoni et al., 2017). This is of 
clinical importance, particularly for individuals who may struggle to adhere to sustained 
periods of energy restriction (Montesi et al., 2014). Exercise also elicits an array of wider 
cardiometabolic benefits, including increased fitness and insulin sensitivity, and reduced blood 
pressure (Kodama et al., 2009; Garber et al., 2011; James et al., 2014; Colberg et al., 2016). 
Both aerobic and resistance exercise have been shown to reduce IHTG and improve whole-
body insulin sensitivity (Hallsworth et al., 2011; Zelber-Sagi et al., 2014; Cuthbertson et al., 
2016; Zhang et al., 2016). Results from the STRRIDE-AT/RT trial suggests that the benefits 
of aerobic exercise may be greater than those of resistance training (Slentz et al., 2011), but 
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any form of physical activity that replaces time spent sedentary is likely to be of benefit to most 
individuals with NAFLD (Marchesini, Petta and Dalle Grave, 2016). Importantly, exercise may 
elicit beneficial reductions in IHTG even in the absence of weight loss (Johnson et al., 2009; 
Sullivan et al., 2012), highlighting its important role in the management of NAFLD.  
Given the mechanisms outlined previously that underlie the development of hepatic insulin 
resistance, it is feasible that exercise-induced reductions in IHTG and improvements in 
peripheral insulin sensitivity may correspond with improvements in hepatic insulin action. 
However, the effects of exercise training on hepatic insulin sensitivity in NAFLD are unclear. 
Stable or radioactive isotope-labelled glucose tracers are required to directly assess hepatic 
insulin sensitivity through the measurement of EGP in the basal and/or insulin stimulated states 
(Kim et al., 2016). Basal rates of EGP appear to be unaffected by moderate-intensity aerobic 
or combined aerobic-plus-resistance exercise training in adults (Shojaee-Moradie et al., 2007; 
Meex et al., 2010; Hickman et al., 2013; Cuthbertson et al., 2016). However, when EGP is 
combined with insulin to form an index of hepatic insulin sensitivity one study reported a 
tendency (P = 0.06) for an improvement (Hickman et al., 2013). Two studies by the same 
research group have also assessed the percentage suppression of EGP by low-dose insulin 
infusion before and after aerobic exercise training (Shojaee-Moradie et al., 2007; Cuthbertson 
et al., 2016), reporting contrasting findings. Hepatic insulin sensitivity was improved after six 
weeks of training despite no change in body weight or IHTG (Shojaee-Moradie et al., 2007). 
However, 12 weeks of training, which elicited weight loss and significant reduction in IHTG, 
was not associated with improved percentage suppression of EGP (Cuthbertson et al., 2016). 
None of these studies were formally powered to assess changes in hepatic insulin sensitivity 
and alternative forms of exercise, or different exercise intensities, have not been explored. 
2.3.10 Mechanisms by which exercise may reduce IHTG  
Prolonged negative energy balance reduces adipose tissue mass and body weight. After a 
sustained period of energy deficit, the greatest absolute changes in adipose tissue stores occur 
within subcutaneous sites, but substantial relative changes are also elicited in visceral and 
ectopic compartments including the liver (Lazo et al., 2010; Promrat et al., 2010; Vilar-Gomez 
et al., 2015). Alongside energy restriction, regular exercise training can facilitate negative 
energy balance, weight loss and reductions in IHTG (Brouwers et al., 2016). However, exercise 
training may also modulate the uptake and export of hepatic lipids beyond weight loss and 
changes in subcutaneous adipose tissue stores. These effects may underlie the benefits of 
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exercise that are reported independent of weight change (Johnson et al., 2009; Sullivan et al., 
2012). Studies investigating these mechanisms in humans are limited, but the best available 
evidence is presented below. 
2.3.10.1 Circulating NEFA in the fasted and post-prandial state 
Six weeks of aerobic exercise training and six months of combined diet-plus-exercise training 
have each been shown to reduce basal rates of adipose tissue lipolysis in obese, post-
menopausal women (You et al., 2004; Shojaee-Moradie et al., 2007). These benefits do not, 
however, always correspond to changes in IHTG (Shojaee-Moradie et al., 2007). Furthermore, 
several studies report that fasted NEFA, which can be attributed to basal adipose tissue lipolysis, 
is unchanged by exercise training in patients with NAFLD, even when IHTG is reduced 
(Hallsworth et al., 2011; Sullivan et al., 2012; Cuthbertson et al., 2016; Zhang et al., 2016). As 
such, changes in post-prandial lipid metabolism may be more influential on the reduction of 
IHTG elicited by exercise training.  
Shojaee-Moradie and colleagues reported that the suppression of adipose tissue lipolysis by 
insulin, measured using palmitate and glycerol tracers, was improved after six weeks of aerobic 
exercise training (Shojaee-Moradie et al., 2007). Similar findings have been reported after 12 
weeks of combined aerobic and resistance exercise in obese individuals with or without 
dysregulated glucose metabolism (Meex et al., 2010). It is notable, however, that Meex and 
colleagues did not measure IHTG and Shojaee-Moradie et al reported that it was unaffected by 
exercise. Other studies have found that 12 weeks of aerobic exercise training in individuals 
with dysregulated glucose metabolism has no effect on the suppression of circulating NEFA 
after steady-state insulin infusion (Solomon et al., 2009; Malin, Haus, et al., 2013). In a study 
of obese, sedentary women, nine months of high- but not moderate-intensity aerobic exercise 
training improved the percentage suppression of NEFA by insulin, but these results could be 
attributed to a much lower suppression at baseline in the high-intensity group, compared to the 
moderate-intensity and control groups (DiPietro et al., 2006). Similarly, 12 weeks of strength 
training in obese men has been reported to increase the percentage suppression of NEFA in 
response to insulin infusion. However, fasted circulating concentrations of NEFA were 
increased from pre- to post-training and the absolute concentrations in the insulin-stimulated 
state were unaffected (Polak et al., 2005).  
Collectively, the effects of exercise training on insulin-stimulated suppression of adipose tissue 
lipolysis in NAFLD are unclear. Whilst improved insulin-stimulated suppression of lipolysis 
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may be of theoretical benefit, these effects alone do not explain reductions in IHTG with 
exercise training. It should also be noted that reduced circulating concentrations of NEFA do 
not necessarily reflect a reduction in the rates of adipose tissue lipolysis and may instead be 
due to increased rates of clearance (Brouwers et al., 2016). In cross-sectional studies using 
labelled lipid tracers, it has been suggested that increased aerobic fitness is associated with a 
greater uptake of NEFA into skeletal muscle. This finding complements the paradoxical 
phenomenon of high, yet healthy, intramuscular triglyceride in trained individuals (Iozzo et al., 
2004; Hannukainen et al., 2007). 
2.3.10.2 Dietary lipids and VLDL metabolism 
The effects of exercise training on post-prandial hepatic lipid storage has not been explored 
directly so evidence is limited to inferences based on circulating fasted or post-prandial 
concentrations of VLDL or TG (Brouwers et al., 2016). Six months of supervised aerobic 
exercise training in individuals with NAFLD elicited a reduction in fasted VLDL secretion, 
with no difference in the density or clearance of secreted particles (Alam et al., 2004). Similar 
results have been demonstrated after an eight week programme of high-intensity interval 
training in obese, sedentary men (Tsekouras et al., 2008). In contrast, 16 weeks of moderate-
intensity aerobic training increased the clearance of large TG-rich VLDL particles, with no 
effect on rates of production (Shojaee-Moradie et al., 2016), whilst another study reported that 
16 weeks of aerobic exercise had no effect on VLDL metabolism (Sullivan et al., 2012). 
Circulating TG concentrations in the fasted state are not reduced by exercise training in patients 
with NAFLD (Sullivan et al., 2012; Hickman et al., 2013; Cuthbertson et al., 2016; Zhang et 
al., 2016). Collectively, the effects of exercise on fasted VLDL metabolism in individuals with 
NAFLD are ambiguous at present. It is noteworthy, however, that an increased secretion of 
TG-rich VLDL would be required to explain the reductions in IHTG seen with exercise training 
and no study has reported this to date. 
The circulating TG concentration in response to a meal is acutely attenuated by a single bout 
of moderate-intensity exercise for up to 24 hours and this may be mediated by increased 
clearance by skeletal muscle (Gill, 2004; Maraki and Sidossis, 2013). Cross-sectional studies 
have also reported that post-prandial triglyceridaemia is reduced in individuals that are 
physically active compared to sedentary individuals (Cohen, Noakes and Benade, 1989; Ziogas, 
Thomas and Harris, 1997). However, the benefits on post-prandial lipid metabolism with 
exercise may be restricted to the acute effects of the final exercise bout, rather than a true 
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training effect per se (Gill, 2004; Maraki and Sidossis, 2013). When assessments are made 
more than 24 hours after the final exercise bout of an exercise training programme, post-
prandial TG concentrations are unchanged (Aldred, Hardman and Taylor, 1995; Herd et al., 
1998; Altena et al., 2006). It could be speculated, however, that regular lowering of post-
prandial TG after each session of an exercise training intervention may play a role in the 
reduction of IHTG, but further research is required to explore this hypothesis in detail. 
2.3.10.3 De novo lipogenesis 
No studies have directly explored the effects of exercise training on hepatic DNL in humans. 
However, in a series of studies in OLETF rats, key enzymes involved in several steps of DNL 
are reduced by exercise training, when employed either as a strategy to prevent/attenuate the 
accumulation of IHTG, or as a therapeutic intervention once steatosis has developed (Rector et 
al., 2008, 2011, Linden et al., 2014, 2015). These results are accompanied by reductions in 
circulating insulin and glucose, which are potent stimulators of DNL (Yamashita et al., 2001; 
Ameer et al., 2014). Although fasted concentrations of circulating glucose and insulin are 
unaffected by exercise training in individuals with NAFLD (Hallsworth et al., 2011; Keating 
et al., 2015; Cuthbertson et al., 2016; Zhang et al., 2016), peripheral insulin sensitivity is 
improved (Hickman et al., 2013; Cuthbertson et al., 2016). This will plausibly lead to reduced 
post-prandial concentrations of insulin and glucose, which may in turn reduce DNL. These 
effects could at least partially mediate reductions in IHTG by exercise training. Notably, acute 
exercise in lean, insulin-resistant individuals has been shown to improve the skeletal muscle 
response to insulin, reduce hepatic triglyceride synthesis and reduce hepatic DNL (Rabøl et al., 
2011). However, this hypothesis remains speculative and the effects of exercise training on 
markers of DNL in humans with NAFLD require detailed investigation. 
2.3.10.4 Hepatic mitochondrial lipid oxidation 
In the same series of studies in OLETF rats, the research group of Rector and colleagues 
reported an increase in complete oxidation of palmitate after exercise training, which was 
accompanied by an increase in key markers of hepatic mitochondrial lipid oxidation (Rector et 
al., 2008, 2011, Linden et al., 2014, 2015). These findings suggest that improved capacity for 
oxidative phosphorylation of NEFAs in the liver may play a part in post-exercise reductions in 
IHTG, but data in humans are lacking.  
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2.3.11 Relevance of exercise intensity in the management of NAFLD 
Evidence suggests that exercise intensity may be an important parameter in determining the 
benefits of exercise training for individuals with NAFLD. In retrospective cross-sectional 
analyses, 813 individuals with biopsy-defined NAFLD were categorised according to whether 
they reported meeting United States guidelines for moderate- (150 min·wk-1) or vigorous- (75 
min·wk-1) intensity physical activity (Kistler et al., 2011). In these analyses, it was only 
individuals that met vigorous-intensity guidelines that had a significantly lower odds ratio of 
having advanced NAFLD (NASH and advanced fibrosis) (Kistler et al., 2011). Notably, these 
individuals all had diagnosed NAFLD and the effects of exercise intensity on IHTG per se 
were not explored. In a recent study in rodents, 40 mice were randomised into one of four 
different 16-week interventions: 1) control (chow diet), 2) high-fat overfeeding, 3) high-fat 
overfeeding with moderate-intensity exercise training and, 4) high-fat overfeeding with high-
intensity interval exercise training (Cho et al., 2015). Exercise was performed during the final 
8 weeks only. High-fat overfeeding resulted in the development of steatosis in all three groups 
but notably, the magnitude of IHTG accumulation was attenuated by exercise training in a step-
wise manner according to exercise intensity (Cho et al., 2015).  
It may be important that completing exercise at a high-intensity does not come at the expense 
of total intervention volume. Individuals completing more than 250 min·wk-1 of moderate-to-
vigorous physical activity during a 12 week lifestyle intervention demonstrated greater 
reductions in hepatic steatosis than those completing less than 250 min·wk-1 (Oh et al., 2015). 
Whilst not unexpected, this underscores the importance of exercise volume, as well as intensity, 
within the management of NAFLD.  
Collectively, these studies suggest that completing exercise of a higher intensity may elicit 
greater benefits on IHTG in individuals with NAFLD. Benefits may be greater still if a high 
training volume is maintained but something is better than nothing. A form of exercise training 
that may help support individuals to complete exercise of a greater intensity is HIIT.  
2.4  High-intensity interval training (HIIT) 
HIIT is a collective term describing several exercise protocols characterised by periods of high-
intensity exercise interspersed with periods of rest or active recovery (Gibala, Gillen and 
Percival, 2014; MacInnis and Gibala, 2016). A variety of HIIT protocols exist which utilise a 
range of exercise intensities and durations. The most prominent of these protocols are ‘sprint 
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interval training’ (SIT), comprising of 30-second bursts of ‘all-out’ activity (Burgomaster et 
al., 2005), ‘low-volume HIIT’ (LV-HIIT), where individuals perform 10 x one-minute intervals 
at ‘near-maximal’ aerobic capacity (Little et al., 2011), and ‘aerobic interval training’ (AIT), 
consisting of four-minute intervals at approximately 80-95% of maximum heart rate (HRmax) 
(Wisløff et al., 2007). This is not an exhaustive list and variations of the above exist. Efforts 
also continue to try and identify the ‘minimum dose’ of interval-based exercise required to 
elicit benefits leading to additional protocols such as ‘reduced exertion HIIT’ (‘REHIT’) 
(Metcalfe et al., 2012; Vollaard, Metcalfe and Williams, 2017). LV-HIIT and SIT are utilised 
in Chapters 5 and 6 of this thesis and, therefore, the following paragraphs will focus on the 
evidence surrounding these protocols and their relevance to the management of NAFLD.   
2.4.1 Sprint interval training (SIT) 
SIT is fundamentally modelled on performing repeated bouts of the Wingate Anaerobic test 
(Bar-Or, 1987). Participants complete 30-s intervals at maximal effort separated by periods of 
active recovery, usually 4.5 min. In 1998, it was demonstrated in young, recreationally active 
individuals that six weeks of SIT (three sessions per week) improved cardiorespiratory fitness, 
measured as peak oxygen uptake (V̇O2 peak), along with markers of skeletal muscle glycolytic 
and oxidative metabolism (MacDougall et al., 1998). However, it was not until 2005 and the 
study by Burgomaster and colleagues (Burgomaster et al., 2005), that research in this area 
started to gain momentum. In a series of studies, this research group demonstrated that SIT for 
as little as two weeks (total of six sessions) improved muscle oxidative capacity and endurance 
exercise performance (Burgomaster et al., 2005; Gibala et al., 2006). These effects remained 
after a 6-week intervention and benefits were comparable with those elicited by moderate-
intensity aerobic exercise training (Gibala et al., 2006; Burgomaster et al., 2008). These 
findings have since been confirmed by a separate research group, who also reported that 
skeletal muscle microvascular function is improved by SIT (Cocks et al., 2013). Notably, two 
weeks of SIT does not appear to improve cardiac output, suggesting that the early 
improvements in aerobic capacity may be limited to peripheral benefits in skeletal muscle 
(MacPherson et al., 2011; Gibala, Gillen and Percival, 2014). Whilst the origin of the molecular 
signals responsible for these benefits are yet to be fully determined, peripheral improvements 
with SIT appear to be mediated by similar pathways to that of traditional moderate-intensity 
continuous training (Gibala, Gillen and Percival, 2014). 
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SIT may also elicit benefits of relevance to cardiometabolic health. This is important because 
the interval-based approach of HIIT may support individuals to acquire the benefits of exercise 
that may be otherwise unachievable through continuous steady-state activity (Kessler, Sisson 
and Short, 2012). As mentioned previously, the study by MacDougall and colleagues reported 
an increase in V̇O2 peak with six weeks of SIT (MacDougall et al., 1998). This is important 
given the strong inverse relationship between cardiorespiratory fitness and mortality 
(cardiovascular and all-cause) (Blair et al., 1989; Kodama et al., 2009) These improvements in 
V̇O2 peak have since been confirmed with as little as two weeks of SIT in young healthy adults 
(Hazell et al., 2010; MacPherson et al., 2011; Astorino et al., 2012), as well as in overweight 
or obese, but otherwise healthy, men (Whyte, Gill and Cathcart, 2010; Cocks et al., 2015). A 
meta-analysis of RCTs has reported a moderate-to-large pooled effect size of SIT on V̇O2 peak 
(Gist et al., 2014). The study by Hazell and colleagues (Hazell et al., 2010) also reported a 
beneficial shift in body composition after six weeks of treadmill-based SIT with reductions in 
fat mass and increases in fat-free mass (FFM).  
SIT has also been shown to improve glycaemic control. Whilst fasted circulating insulin and 
glucose are unaffected, two weeks of SIT improves whole-body insulin sensitivity in healthy 
young active men, determined using both oral-glucose tolerance test and hyperinsulinaemic, 
euglycaemic clamp (Babraj et al., 2009; Richards et al., 2010). Six weeks of SIT also improves 
OGTT-derived insulin sensitivity (the Matsuda insulin sensitivity index; ISI) in young, inactive 
individuals (Shepherd et al., 2013). SIT is feasible for overweight or obese participants and, in 
accordance with evidence in normal-weight individuals, improves post-prandial insulin 
sensitivity and microvascular function to a similar extent as that of moderate-intensity training 
(Cocks et al., 2015). Similarly, two weeks of SIT does not appear to elicit sustained benefits in 
HOMA-IR in overweight individuals (72 hours post-training), although acute benefits for up 
to 24 hours are apparent (Whyte, Gill and Cathcart, 2010). 
2.4.2 Low-volume high-intensity interval training  
Whilst SIT may be feasible in healthy overweight and obese volunteers (Whyte, Gill and 
Cathcart, 2010; Cocks et al., 2015), it was suggested by Gibala and colleagues that SIT, as 
implemented in their initial studies, may not be safe or well-tolerated for all individuals (Little 
et al., 2010). With these considerations in place, LV-HIIT was developed as a more feasible 
protocol for populations with, or at risk of, chronic disease (Little et al., 2010). LV-HIIT retains 
a high exercise intensity, but one that is near to maximal aerobic capacity (approximately 80 
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to 95% of V̇O2 peak) as opposed to the supramaximal efforts of SIT. LV-HIIT is traditionally 
performed as 10 exercise intervals, each lasting one minute, separated by equal periods of low-
intensity active recovery. Notably, these recovery periods were 75-seconds in the initial study 
by Little and colleagues (Little et al., 2010), but reduced to 60 seconds thereafter (Hood et al., 
2011; Little et al., 2011). 
LV-HIIT has been shown to elicit similar benefits to those of SIT, in that V̇O2 peak, exercise 
performance and skeletal muscle mitochondrial function are all increased in young healthy 
individuals after as little as two weeks of training (Little et al., 2010; Jacobs et al., 2013). 
Furthermore, early benefits appear to be limited to skeletal muscle as cardiac output, 
haemoglobin concentration, haemoglobin mass and haematocrit are all reportedly unaffected 
(Jacobs et al., 2013). In overweight but otherwise healthy individuals, two weeks and six weeks 
of LV-HIIT have each been shown to improve mitochondrial capacity which, over a longer 
intervention, is accompanied by reduced fat mass (FM) and increased FFM (Hood et al., 2011; 
Gillen et al., 2013). At present, however, the effects of LV-HIIT on glycaemic control are 
unclear. Hood and colleagues (Hood et al., 2011) reported a reduced HOMA-IR in overweight 
individuals after two weeks of training, but OGTT-derived insulin sensitivity (Matsuda ISI) 
was unchanged after six weeks in a similar population (Gillen et al., 2013). However, when 
patients with T2DM perform two weeks of LV-HIIT, glycaemic control, determined by 
continuous glucose monitoring, is reportedly improved (Little et al., 2011). Over a 24-h period 
(measured 48 h after the final exercise bout), glucose concentrations in the interstitial fluid 
were reduced in response to standardised lunch and dinner meals. Furthermore, the mean 
glucose concentration over the whole 24-h period was lower after the LV-HIIT intervention. 
These benefits were accompanied by improved muscle mitochondrial capacity and higher 
protein content of GLUT-4 (Little et al., 2011). LV-HIIT has also been shown to improve V̇O2 
peak in patients with coronary artery disease (Currie et al., 2013). 
2.4.3 Perceptual benefits of SIT and LV-HIIT 
One of the most prominent perceptual barriers to physical activity is a lack of time (Trost et al., 
2002; Kelly et al., 2016). It has been suggested that SIT and LV-HIIT, along with other HIIT 
protocols, provide attractive and time-efficient strategies for individuals to incorporate 
structured exercise into their habitual routines (Gibala et al., 2006; Hood et al., 2011). A six-
interval SIT session and 10-interval LV-HIIT session contain just three and 10 minutes of high-
intensity exercise, respectively, which may be highly appealing to many individuals. 
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Furthermore, comparative studies by Gibala et al (2006) and Burgomaster et al (2008) reported 
that the benefits of SIT on exercise performance and muscle mitochondrial capacity were 
similar to traditional continuous moderate-intensity aerobic training, despite substantially 
lower weekly training time. It should be noted, however, that when accounting for recovery 
periods, warm-up and cool down (assuming five minutes each for the latter two) the absolute 
durations of SIT or LV-HIIT sessions are 40 and 30 minutes, respectively. 
Another important barrier to physical activity is the perception that exercise is not enjoyable 
(Salmon et al., 2003). It is plausible that some inactive individuals may find the prospect of 
completing intense but brief bursts of activity more appealing than that of prolonged CME. In 
turn, this may result in greater interest, motivation and, ultimately, adherence (Weston, Wisløff 
and Coombes, 2014). Sedentary young adults report greater enjoyment with LV-HIIT than 
when performing CME and more than 50% of participants in this study suggested that LV-
HIIT was a form of exercise that they would consider if training unsupervised (Jung, Bourne 
and Little, 2014). In a separate study in which individuals were randomised to a six-week 
intervention of LV-HIIT or CME training, perceived enjoyment of LV-HIIT increased 
throughout the programme whereas enjoyment was either unaffected or declined with the CME 
programme (Heisz et al., 2016). Interestingly, the rate of perceived exertion (RPE) during 
exercise training progressively decreases with intervals of shorter duration (Kilpatrick et al., 
2015), whilst protocols utilising 30- or 60-second intervals are more enjoyable than those using 
two-minute intervals (Martinez et al., 2015). In a study comparing LV-HIIT and SIT directly, 
active individuals report no differences in measures of affect, including enjoyment, between 
the two protocols (Wood et al., 2016). In overweight or obese individuals, measures of pleasure 
and enjoyment are no different when completing LV-HIIT compared to work-matched CME, 
despite a greater RPE (Little et al., 2014). Patients with coronary heart disease or T2DM report 
that a general interval-based approach to exercise is more enjoyable than a session containing 
CME (Coquart et al., 2008; Guiraud et al., 2011). However, neither of these studies assessed 
the perceptions of LV-HIIT or SIT specifically.  
Collectively, LV-HIIT and SIT appear to elicit physiological adaptations that are of relevance 
to cardiometabolic health, including cardiorespiratory fitness and insulin sensitivity. The 
magnitude of these effects are comparable to those elicited by CME and may occur with a 
lower total training volume. LV-HIIT and SIT may also be perceived by some individuals as 
more appealing, therefore representing an alternative strategy to engage in structured exercise 
that may be utilised within a personalised medicine approach. However, research in large 
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clinical trials with patient groups is required before definitive conclusions or wider 
recommendations can be made.  
2.5  Hepatokines 
The mechanisms underlying the relationship between hepatic steatosis and peripheral insulin 
resistance/glycaemic control are not fully understood (Takamura, Misu and Kaneko, 2016). 
Recent work has characterised the hepatic proteome as a group of 538 proteins, of which 168 
have the capacity to be secreted into the circulation (Meex et al., 2015). Many of these proteins 
have been shown to exert endocrine effects in peripheral tissues and as such, in analogy to 
‘myokines’ and ‘adipokines’, have been termed ‘hepatokines’ (Stefan and Häring, 2011). With 
evidence that hepatokine secretion is modulated by hepatic steatosis (Meex et al., 2015), it has 
been suggested that hepatokines may be one such mechanism that mediates the association 
between IHTG and peripheral insulin action/glucose homeostasis (Takamura, Misu and 
Kaneko, 2016). 
2.5.1 Fibroblast growth factor (FGF) 21 
The most widely studied hepatokine to date is fibroblast growth factor 21 (FGF21). While 
expressed in multiple tissues (including the liver, skeletal muscle and adipose tissue) (Fon 
Tacer et al., 2010), circulating concentrations are predominantly liver-derived (Markan et al., 
2014). FGF21 has been implicated in a number of metabolic processes, including the regulation 
of glucose and lipid metabolism (Cuevas-Ramos, Aguilar-Salinas and Gómez-Pérez, 2012; 
Jung, Yoo and Choi, 2016).  
The first evidence of FGF21 as a novel metabolic regulator was a series of experiments by 
Kharitonenkov and colleagues (Kharitonenkov et al., 2005). In these (and subsequent) 
experiments, administration of FGF21 increased glucose uptake in rodent and human 
adipocytes, independent of insulin action (Kharitonenkov et al., 2005; Xu, Lloyd, et al., 2009), 
and this may was potentially mediated by increased expression of the GLUT1 transporter 
(Kharitonenkov and Adams, 2014). Transgenic rodent models with FGF21 knockout gain 
weight, have impaired glycaemic control and develop hepatic steatosis (Badman et al., 2009; 
Kim et al., 2015). Conversely, overexpression of FGF21 results in lower body weight, 
adiposity, IHTG and improved glucose regulation (Kharitonenkov et al., 2005). 
In rodents, short term (< 14 days) treatment with FGF21 elicits reductions in circulating glucose, 
TG and insulin, as well as improved glucose tolerance, whole-body glucose disposal and 
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hepatic insulin sensitivity (Kharitonenkov et al., 2005; Berglund et al., 2009; Xu, Stanislaus, 
et al., 2009). These benefits are sustained following longer treatment (two to fifteen weeks) 
and are accompanied by reductions in body weight, body fat and IHTG, as well as enhanced 
insulin sensitivity in skeletal muscle and adipose tissue, and resistance to diet-induced obesity 
(Kharitonenkov et al., 2005; Coskun et al., 2008; Xu, Lloyd, et al., 2009; Camporez et al., 
2013). Reductions in circulating TG and IHTG may be mediated by reduced adipocyte lipolysis 
and hepatic expression of SREBP1c, and increased hepatic lipid oxidation (Gimeno and Moller, 
2014). Improved β-cell function has also been observed, but this finding has proved difficult 
to replicate in humans (Wente et al., 2006; Stefan and Häring, 2013). In obese, diabetic humans, 
28 days of treatment with an FGF21 analog (LY2405319) elicits an improved lipid profile 
(Gaich et al., 2013). At higher doses (10 or 20 mg per day), body weight and circulating insulin 
are reduced compared to baseline, but these changes are not significantly different when 
compared to a placebo (Gaich et al., 2013; Reitman, 2013). 
Somewhat paradoxically, circulating FGF21 concentrations are, in fact, elevated in obese 
adults with both normal or dysregulated glucose metabolism (Zhang et al., 2008; Chavez et al., 
2009; Mraz et al., 2009). Furthermore, it is positively correlated with BMI and WC, each of 
which have been reported as independent predictors of circulating FGF21 in groups of healthy 
individuals and those with impaired glycaemic control or NAFLD (Zhang et al., 2008; Li et 
al., 2010; Mashili et al., 2011; Cuevas-Ramos et al., 2012). FGF21 is also elevated in patients 
with NAFLD (Dushay et al., 2010; Li et al., 2010), but while hepatic expression and circulating 
concentrations of FGF21 appear to increase with severity of steatosis (Li et al., 2010; Yilmaz, 
Eren, et al., 2010), it is unable to distinguish individuals with isolated steatosis from those with 
NASH (Dushay et al., 2010). 
Circulating FGF21 is also higher in individuals with T2DM compared to those with normal 
glucose tolerance, but this may be mediated by increased adiposity rather than glycaemic 
dysregulation per se (Chavez et al., 2009; Mraz et al., 2009; Chen et al., 2011; Mashili et al., 
2011). FGF21 is, however, predictive of T2DM incidence (Chen et al., 2011; Bobbert et al., 
2013) and correlates with a number of markers of glucose homeostasis, including fasted insulin 
and glucose, and 2-h glucose determined during an OGTT (Zhang et al., 2008; Chavez et al., 
2009; Cuevas-Ramos et al., 2010; Mashili et al., 2011). FGF21 is also correlated with both 
whole-body and hepatic insulin sensitivity as measured using hyperinsulinaemic, euglycaemic 
clamp (Chavez et al., 2009). It is suggested that increased circulating FGF21 in individuals 
with, or at elevated risk of, metabolic dysfunction may be a result of ‘FGF21 resistance’ 
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whereby, in analogy to insulin resistance, impairments in tissue signalling in response to 
FGF21 result in increased secretion (Fisher et al., 2010; Potthoff, Kliewer and Mangelsdorf, 
2012). Notably, obese mice have been shown to have impaired signalling responses to FGF21 
infusion compared to lean controls (Fisher et al., 2010). However, this hypothesis requires 
further investigation. 
FGF21 is also positively correlated with self-reported physical activity (Cuevas-Ramos et al., 
2010, 2012) and V̇O2 peak is an independent predictor of circulating FGF21 concentrations 
(Taniguchi et al., 2014). Furthermore, aerobic or combined aerobic and resistance exercise 
training for three to twelve weeks elicits a reduction in circulating FGF21 concentrations in 
young and elderly individuals at risk of metabolic disease (Yang, Hong, et al., 2011; Scalzo et 
al., 2014; Taniguchi et al., 2016). In one of these studies, the reduction in FGF21 over five 
weeks of aerobic training was significantly positively associated with a reduction in IHTG, 
measured using 1H-MRS (Taniguchi et al., 2016). 
A single run to exhaustion in healthy rodents results in elevated concentrations of FGF21, and 
this increase has been attributed to increased hepatic expression (K. H. Kim et al., 2013). 
Circulating concentrations of FGF21 are also increased in humans after acute moderate- and 
high-intensity exercise in a stepwise manner, and these elevations are liver-derived (K. H. Kim 
et al., 2013; Hansen et al., 2015; Hansen, Pedersen, et al., 2016). Notably, this response may 
be blunted in obese individuals with impaired glycaemic control and completely abolished in 
individuals with overt T2DM (Slusher et al., 2015; Hansen, Pedersen, et al., 2016). 
The regulation of FGF21 expression is highly complex and not fully understood. It appears that 
its induction during states of fasting or overfeeding may be regulated by different mechanisms. 
Circulating NEFA, which occurs not only during fasting but also after strenuous exercise, may 
increase FGF21 expression in the liver and adipose tissue via activation of PPARα and PPARγ, 
respectively (Gälman et al., 2008; Cuevas-Ramos et al., 2012). Conversely, during energy 
surplus, increased circulating glucose may stimulate ChREBP to increase FGF21 expression 
(Iizuka, Takeda and Horikawa, 2009). FGF21 has also been shown to be regulated by the 
glucagon-to-insulin ratio (Hansen et al., 2015; Hansen, Pedersen, et al., 2016) and this may 
explain, at least in part, the increase in circulating FGF21 with acute exercise. When individuals 
exercise under the conditions of a pancreatic clamp, in which a change in the glucagon-to-
insulin ratio is prevented, circulating FGF21 is unchanged (Hansen et al., 2015; Hansen, 
Pedersen, et al., 2016). 
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2.5.2 Leukocyte cell-derived chemotaxin (LECT) 2 
LECT2 is a 16kDa secretory protein that is preferentially expressed in human liver cells and 
secreted into the circulation (Yamagoe, Mizuno and Suzuki, 1998). LECT2 was originally 
discovered when screening for novel neutrophil chemotactic proteins (Yamagoe et al., 1996) 
and has been previously shown to exert anti-inflammatory and tumour-suppressive effects in 
the liver (Anson et al., 2012). More recently, LECT2 has also been linked with obesity and its 
associated co-morbidities. Circulating concentrations of LECT2 are elevated with obesity and 
ultrasound-derived NAFLD (Okumura et al., 2013), and correlate with BMI, waist 
circumference, HOMA-IR, FPI, TG, and the Matsuda ISI (Okumura et al., 2013; Lan et al., 
2014).  
A series of experimental studies by Lan and colleagues (Lan et al., 2014) strongly implicates 
LECT2 in the development of obesity and insulin resistance. In liver biopsy tissue from 10 
individuals with T2DM and seven lean controls, hepatic mRNA levels of LECT2 are 
significantly correlated with BMI, whilst gene expression of LECT2 is increased in mice with 
HFD-induced obesity (Lan et al., 2014). LECT2 appears to be highly sensitive to acute changes 
in diet and transitioning between periods of HFD and regular chow results in elevation and 
normalisation of LECT2 concentrations, respectively (Chikamoto et al., 2016). Throughout 
these weight cycles, serum concentrations of LECT2 correlated with IHTG, but not adipose 
tissue weight (Chikamoto et al., 2016). 
LECT2 knockout (KO) attenuates increased body mass resulting from high-fat feeding (Lan et 
al., 2014). Compared to wild-type controls, LECT2 KO mice also display greater insulin-
stimulated Akt phosphorylation in skeletal muscle, but not in the liver or adipose tissue (Lan 
et al., 2014). Accordingly, KO mice require greater glucose infusion rate to maintain 
euglycaemia during steady-state hyperinsulinaemia than wild-type controls, but the 
suppression of EGP is no different between groups (Lan et al., 2014). In contrast, however, 
LECT2 treatment in cultured hepatocytes has been shown to induce steatosis, which is 
accompanied by significant reduction in hepatic IRS-1 phosphorylation and a tendency towards 
reduced Akt activation, suggesting a degree of hepatic insulin resistance (Hwang et al., 2015). 
Interestingly, there are no differences in body mass, blood glucose, plasma insulin and 
circulating LECT2 between KO and wild-type mice after 60 days of starvation, suggesting that 
LECT2 may play a role in states of over- but not under-nutrition (Lan et al., 2014). Very little 
is known about the influence of exercise on LECT2. However, LECT2 KO mice display greater 
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muscular endurance than wild-type controls (Lan et al., 2014). Furthermore, when wild-type 
mice perform three hours of aerobic treadmill exercise, hepatic expression and protein content 
of LECT2, as well as circulating concentrations, are all reduced (Lan et al., 2014). 
Little is known about the molecular regulation of LECT2 in obesity or during exercise. 
However, LECT2 expression is negatively regulated by adenosine monophosphate-activated 
protein kinase (AMPK) in cultured hepatocytes and hepatic AMPK expression is decreased 
and increased during high-fat feeding and acute exercise, respectively (Lan et al., 2014). 
Treatment of C2C12 myotubes with recombinant LECT2 leads to insulin resistance by 
increasing phosphorylation of cJNK, which in turn decreases insulin-stimulated Akt 
phosphorylation (Lan et al., 2014).  
2.5.3 Follistatin 
Follistatin is a glycosylated protein and member of the transforming growth factor (TGF) -β 
superfamily. It was originally discovered in ovarian fluid but has since been shown to be 
expressed in several tissues including the liver and skeletal muscle (Phillips and de Kretser, 
1998). Many of the functions of follistatin are facilitated through its natural inhibition of other 
TGFs, such as activin and myostatin (Phillips and de Kretser, 1998; Gilson et al., 2009).  
Serum follistatin concentrations are elevated in patients with NAFLD or T2DM (Yndestad et 
al., 2009; Hansen et al., 2013) and correlate with markers of insulin resistance including 
HOMA-IR, fasted plasma glucose (FPG) and 2-h glucose in some, but not all, studies (Wu et 
al., 2012; Hansen et al., 2013). Interestingly, one previous study reported lower plasma 
follistatin concentrations  in individuals with T2DM compared with healthy controls (Ueland 
et al., 2012). However, the activin to follistatin ratio was higher in these individuals. The 
potential that this ratio may be more important than concentrations of follistatin alone may 
explain discrepant findings. 
Follistatin has been shown to promote muscle growth, via the negative regulation of both 
myostatin and activin (Gilson et al., 2009; Yaden et al., 2014). Greater skeletal muscle mass 
may increase glycaemic control via an increased absolute capacity for post-prandial glucose 
uptake. Rodent models in which follistatin was overexpressed display substantially increased 
muscle mass compared to wild-type controls (Lee and McPherron, 2001). Follistatin is also 
reported to increase proliferation of pancreatic β-cells. Overexpression of follistatin in the 
pancreas of diabetic mice results in increased β-cell mass, lower circulating glucose 
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concentrations, greater insulin production and, ultimately, greater lifespan (Zhao et al., 2015). 
Administration of follistatin to rat β-cells in vitro lowers spontaneous cell death (Hansen, Rutti, 
et al., 2016) but follistatin treatment of islet cells from healthy human donors had no effect on 
insulin secretion in response to low or high doses of glucose (Hansen, Rutti, et al., 2016). 
Given that a variety of tissues express follistatin, identifying which of these contribute 
substantially to circulating concentrations is difficult. Historically, the consensus has been that 
plasma follistatin is the sum of spillover from autocrine and paracrine actions within the many 
tissues in which it is expressed (Hansen and Plomgaard, 2016). However, a series of intricate 
studies has offered greater insight into the regulation of systemic follistatin at rest and during 
exercise (Hansen et al., 2011; Hansen, Pedersen, et al., 2016; Hansen, Rutti, et al., 2016). 
Circulating follistatin is increased following acute aerobic and resistance exercise, but 
expression and secretion from the exercising muscle are unaffected (Hansen et al., 2011). This 
supports previous research reporting no changes in skeletal muscle expression of follistatin 
following acute or chronic exercise training (Jensky et al., 2007, 2010; Besse-Patin et al., 2014). 
Conversely, follistatin expression in the liver is increased with acute swimming exercise in 
rodents (Hansen et al., 2011). In follow-up experiments (during which the splanchnic 
circulation was isolated by the insertion catheters into the brachial artery and hepatic vein), 
follistatin was constantly secreted from the livers of healthy human men at rest and this was 
increased 5-fold by acute aerobic exercise (Hansen, Rutti, et al., 2016).  
The altered secretion of follistatin by the liver reported by Hansen et al was regulated by 
changes in the glucagon to insulin ratio (Hansen, Rutti, et al., 2016) and when acute exercise 
is performed under the conditions of a pancreatic clamp the increase in circulating follistatin is 
substantially attenuated (Hansen, Pedersen, et al., 2016). Changes in the glucagon to insulin 
ratio can also be detected in the systemic circulation and a smaller shift in this ratio in 
individuals with T2DM may explain a blunted follistatin response to exercise (Hansen, 
Pedersen, et al., 2016). The fact that the follistatin response is not completely abolished during 
pancreatic clamp indicates that other mechanisms are also responsible to some degree. Whilst 
these mechanisms remain unknown, evidence exists suggesting that hyperglycaemia, systemic 
low-grade inflammation and circulating NEFA are not responsible (Hansen et al., 2013; 
Hansen, Pedersen, et al., 2016). However, it has been speculatively suggested that activation 
of cyclic adenosine monophosphate (cAMP) by adrenaline may be an alternative mechanism 
that warrants investigation (Hansen, Pedersen, et al., 2016). 
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2.5.4 Selenoprotein P (SeP) 
SeP is a 60kDa glycoprotein encoded by the SEPP1 gene (Lebensztejn et al., 2016). It is 
primarily expressed in the liver and approximately 75% of circulating SeP is thought to be 
liver-derived (Burk and Hill, 2005, 2009). The role of SeP as a selenium supply protein is well 
established (Saito and Takahashi, 2002). More recently, however, potential roles within 
glucose homeostasis and insulin sensitivity have been revealed (Misu et al., 2010). From the 
same analyses that identified the link between BMI and LECT2 (Lan et al., 2014), an 8-fold 
greater hepatic expression of SeP was identified in individuals with T2DM along with a 
negative correlation between hepatic SEPP1 mRNA and peripheral insulin sensitivity (Misu et 
al., 2010). Circulating concentrations of SeP are also elevated in individuals with T2DM, 
compared with healthy controls, and positively correlate with FPG and HbA1c (Misu et al., 
2010). Positive associations have also been reported between circulating concentrations of SeP 
and BMI, WC, VAT, HOMA-IR, FPG and TG in individuals with normal and impaired glucose 
regulation (Yang, Hwang, et al., 2011). When 120 non-diabetic Korean individuals (60 with 
ultrasound-defined NAFLD and 60 controls matched for age and sex) were divided into tertiles 
based on circulating SeP concentrations, NAFLD prevalence increased from the lowest to the 
highest tertile (H. Y. Choi et al., 2013). Furthermore, a negative relationship has been reported 
between plasma concentrations of SeP and the liver attenuation index (LAI), a semi-
quantitative method of measuring intrahepatic fat whereby lower LAI is indicative of greater 
steatosis (H. Y. Choi et al., 2013).  
Treatment of cultured hepatic cell lines and primary mouse hepatocytes with glucose or 
palmitate increases expression of SEPP1 and SeP protein content (Misu et al., 2010). 
Conversely, gene expression and protein content are reduced by insulin in a time- and dose-
dependent manner (Misu et al., 2010), which may be mediated by inhibition of FoxO1 
(Speckmann et al., 2008). Activation of AMPK by salsalate results in greater FoxO1 activation 
and reverses palmitate-induced upregulation of SEPP1 (Jung, Choi, et al., 2013).  
When H4IIHEC hepatocytes and C2C12 myotubes are treated with SeP protein in vitro, 
insulin-stimulated phosphorylation of the insulin receptor and Akt are reduced, indicative of 
impaired insulin signalling. Accordingly, insulin-stimulated glucose uptake is decreased in 
myotubes, whilst glucose output from hepatocytes is increased (Misu et al., 2010). Injection of 
purified SeP in C57BL/6J mice causes glucose intolerance and insulin resistance at a dose 
which increases circulating concentrations by a magnitude that is physiologically similar to the 
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difference between healthy and T2DM humans (Misu et al., 2010). Phosphorylation of Akt 
was reduced in the liver and skeletal muscle of SeP-treated mice and this was associated with 
impaired hepatic suppression of EGP and peripheral glucose uptake, determined using 
hyperinsulinaemic euglycaemic clamp (Misu et al., 2010). Glucose intolerance and insulin 
resistance are improved in SeP KO mice and they are protected against the deleterious effects 
of a high-fat, high-sucrose diet (Misu et al., 2010). No study has investigated the effects of 
acute or chronic exercise on SeP. 
The mechanisms by which SeP disrupts hepatic and peripheral insulin signalling remains an 
area of investigation. The phosphorylation of AMPK and acetyl-coA carboxylase (ACC) is 
increased in the livers of SeP KO mice (Misu et al., 2010), whilst SeP treatment in cultured 
hepatocytes inhibits phosphorylation of these proteins. Furthermore, co-treatment with AICAR, 
a known activator of AMPK, prevents SeP-induced reductions in Akt phosphorylation (Misu 
et al., 2010). It is of note, however, that the phosphorylation of AMPK in skeletal muscle is 
unaffected by SeP administration, suggesting that tissue-specific mechanisms may exist (Misu 
et al., 2010). 
2.5.5 Fetuin-A 
Fetuin-A, also known as α2 Heremans-Schmid glycoprotein, is a 64kDa phosphorylated 
glycoprotein that is primarily expressed in, and secreted from, the liver (Denecke et al., 2003). 
Fetuin-A secretion is modulated by IHTG (Meex et al., 2015). Single nucleotide 
polymorphisms in the human AHSG gene (which codes for fetuin-A) are associated with 
susceptibility to T2DM (Siddiq et al., 2005; Andersen et al., 2008), whilst fetuin-A KO mice 
display improved insulin sensitivity (Mathews et al., 2002). Circulating fetuin-A is increased 
in obese and morbidly obese individuals when compared with healthy controls (Brix et al., 
2010; Ismail et al., 2012) and, when participants with varying degrees of glycaemic control are 
grouped into quartiles based on circulating fetuin-A concentrations, BMI progressively 
increases from the lowest to highest quartile (Ix et al., 2006; Xu et al., 2011; Dutta et al., 2014). 
Fetuin-A has also been shown to correlate with V̇O2 peak and is significantly greater in low 
compared to highly active individuals (Jenkins et al., 2011). 
Circulating fetuin-A is increased in patients with NAFLD when compared with healthy 
controls and NAFLD has been shown to be a strong predictor of fetuin-A, even after adjustment 
for age, sex, and other metabolic risk factors (Yilmaz, Yonal, et al., 2010; Haukeland et al., 
2012; von Loeffelholz et al., 2016). Fetuin-A has also been shown to correlate positively with 
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IHTG determined using 1H-MRS or histological analysis of liver biopsy tissue (Stefan et al., 
2006; Kantartzis et al., 2010; von Loeffelholz et al., 2016). Interestingly, this increase with 
NAFLD is reported in individuals with normal and impaired glycaemic control (Ou, Yang, et 
al., 2012).  
Fetuin-A is also increased in individuals with T2DM versus non-diabetic controls (Ishibashi et 
al., 2010; Song et al., 2011; Dutta et al., 2014). It has also been reported as an independent 
predictor of incident T2DM, even after adjustment for appropriate confounding variables (Ix 
et al., 2012; Stefan et al., 2014). Studies have also reported a stepwise increase in fetuin-A 
from normal glucose tolerance, through impaired fasted glucose (IFG) or impaired glucose 
tolerance (IGT) to overt T2DM (Ishibashi et al., 2010; Ou, Yang, et al., 2012; Dutta et al., 
2014; H.-T. Wu et al., 2016). Fetuin-A is also significantly greater in insulin resistant obese 
individuals, compared with insulin-sensitive controls matched for age and adiposity (Klöting 
et al., 2010). It should be noted that the insulin resistant group in this study also had 
significantly greater VAT but, unfortunately, IHTG was not measured. Independent 
associations have also been identified between fetuin-A and HOMA-IR, as well as peripheral 
insulin sensitivity measured using hyperinsulinaemic, euglycaemic clamp (Song et al., 2011; 
Xu et al., 2011; Kaess et al., 2012; Stefan et al., 2014). 
Fetuin-A was first reported in 1989 as a strong natural inhibitor of insulin receptor tyrosine 
kinase in rat hepatocytes, a finding that was consequently confirmed in humans (Auberger et 
al., 1989; Srinivas et al., 1993). Fetuin-A promotes an inflammatory profile in mouse and 
human adipocytes and monocytes, and in the adipose tissue of mice (Hennige et al., 2008; 
Dasgupta et al., 2010). Fetuin-A attenuates lipogenic pathways in adipose tissue via inhibition 
of the PPARγ signalling pathway and promotion of lipolysis (Dasgupta et al., 2010), and serves 
as an adaptor protein for the activation of Toll-like receptor 4 (TLR4) to induce inflammatory 
signalling and insulin resistance (Pal et al., 2012). It has also been shown to inhibit GLUT-4 
translocation in C2C12 myotubes via inhibition of the insulin receptor (Dasgupta et al., 2010; 
Goustin, Derar and Abou-Samra, 2013; Malin, Mulya, et al., 2013). Finally, incubation of 
HepG2 cells and rat hepatocytes with fetuin-A promotes steatosis, which is associated with 
increased expression of SREBP-1c (Jung, Youn, et al., 2013). 
Positive energy balance increases circulating concentrations of fetuin-A (Lin et al., 1998; 
Samocha-Bonet et al., 2014). Treatment of HepG2 cells and rat hepatocytes with palmitate 
increases the expression, synthesis and secretion of fetuin-A and this is dependent on NF-κβ 
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(Dasgupta et al., 2010). Treatment of HepG2 cells with glucose also increases expression of 
AHSG (Takata et al., 2009). In humans, fetuin-A tends to increase after 48 hours low-dose (30 
mL·h-1) intralipid infusion (Hussey et al., 2014). ER stress may mediate both glucose and 
palmitate-induced responses (Ou, Wu, et al., 2012).  
Circulating fetuin-A is reduced by weight loss resulting from combined diet and exercise 
(Stefan et al., 2006; Reinehr and Roth, 2008), energy restriction alone (Blüher et al., 2012; K. 
M. Choi et al., 2013; Baldry et al., 2017) and bariatric surgery (Brix et al., 2010). Moderate-
intensity aerobic exercise, with or without resistance training, failed to reduce fetuin-A in obese, 
healthy individuals or those with NAFLD or T2DM (Mori et al., 2008; Schultes et al., 2010; 
Yang, Hong, et al., 2011; Cuthbertson et al., 2016). This is despite a significant reduction in 
body weight, WC and BF%. In healthy sedentary men, 12 weeks of CME is associated with a 
mean 20% reduction in circulating fetuin-A (but this was not statistically significant) (Oh et 
al., 2017). Continuous exercise of higher intensity (85% HRmax) does elicit reductions 
circulating fetuin-A over as little as seven days, when exercise is performed each day (Malin, 
Mulya, et al., 2013). This beneficial reduction is sustained when similar exercise was 
performed five days per week over the course of 12 weeks (Malin et al., 2014). However, the 
lack of control group and the short duration between the final exercise session and post-training 
assessments (16-18 h) are important limitations to these studies. Nonetheless, these interesting 
data provide rationale to further investigate the effects of exercise on fetuin-A. No studies have 
investigated the effects of acute exercise. 
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CHAPTER 3 
GENERAL METHODS
~ 51 ~ 
 
The following chapter provides details of procedures that are, with the exception of magnetic 
resonance and dual-step hyperinsulinaemic, euglycaemic clamp procedures, common to two or 
more experimental studies contained within this thesis. Each experimental chapter also 
contains a separate methods section that outlines further details unique to that study. 
3.1  Ethical approvals and participant recruitment 
Studies involving human participants (Chapters 4, 5 and 6) were conducted with full ethical 
approval from an appropriate governing body. Chapters 4 and 5 obtained approval from the 
East Midlands NHS research ethics committee and were sponsored by the University Hospitals 
of Leicester NHS Trust. Chapter 6 was sponsored by Loughborough University and approved 
by its research ethics committee (human participants sub-committee). Chapter 6 also gained 
subsequent approval by the research ethics committee of the University of Nottingham. 
Confirmation of approval for each study can be found in Appendix II. All studies were 
performed in accordance with the Declaration of Helsinki (World Health Organisation, 2013). 
Accordingly, all participants gave informed, written consent having been provided with all 
study information in writing and verbally, and having had the chance to discuss these with 
members of the research team. 
In all experimental chapters, participants were recruited by word-of-mouth and poster 
advertisement. Posters were distributed around local venues at which they would be visible to 
potential participants. Posters were also delivered to individual addresses within chosen 
postcodes via Royal Mail and distributed on social media platforms. Participants that had taken 
part in previous studies and given consent to be contacted in future were also contacted when 
they were identified as being potentially eligible. Furthermore, short online press releases were 
issued by Loughborough University and/or the University of Leicester. In Chapters 4 and 5 
(which gained NHS ethical approval) participants were also recruited through local primary 
care services and supported by the NIHR Clinical Research Network. General practice 
surgeries that volunteered to participate were provided with information about the study 
including participant eligibility criteria. They were also provided with pre-screening packs, 
which were posted to individuals that they identified as being potentially eligible. These packs 
contained more detailed study information and a contact details form, along with a pre-
addressed envelope so that interested individuals could return this information to the research 
team. Individuals who returned these packs were then contacted directly to discuss the study 
further and, if they remained interested, the formal recruitment process was initiated.  
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3.2  Participant pre-screening 
All participants completed pre-participation screening to assess their suitability for exercise 
testing/training according to the standard operating procedures and risk assessment (SOP/RA) 
of the NIHR Leicester-Loughborough BRU. These procedures (detailed in Appendix III) were 
developed in accordance with common best practice and guidance set out by the European 
Association for Cardiovascular Prevention and Rehabilitation (Borjesson et al., 2011). The 
specific components of screening that participants undertake differ according to the intensity 
of exercise for which participants are being screened, defined according to the metabolic 
equivalents of task (METs) associated with the exercise to be performed. All studies within 
this thesis include exercise greater than 3 METs and, therefore, participants were screened 
according to the ‘moderate to vigorous’ exercise pathway. This pathway is outlined below.  
Briefly, participants were first categorised as ‘active’ or ‘inactive’ according to self-reported 
weekly physical activity, assessed using the short version of the International Physical Activity 
Questionnaire (IPAQ; www.ipaq.ki.se [accessed 03/12/2017]; Appendix IV). ‘Active’ 
participants were those that reported performing at least 20 min of vigorous exercise on three 
or more days per week. These individuals completed the physical activity readiness 
questionnaire (PAR-Q; www.csep.ca/en/publications [accessed 03/12/2017]; Appendix V) and 
when all questions were answered ‘no’, they were cleared for exercise testing. If one or more 
questions were answered ‘yes’, participants were stratified as ‘low’, ‘moderate’ or ‘high’ risk. 
All inactive individuals were also stratified in this manner. Stratification was based on the 
results of a face-to-face screening session conducted by a healthcare professional (research 
nurse, senior cardiac nurse or general practitioner) and within this session, participants 
provided a medical history, underwent a physical exam, gave a fingertip capillary blood sample, 
were assessed for 10-year CVD risk (via the ‘SCORE’ algorithm; see Appendix VI), and 
received a resting electrocardiogram (ECG). When no clear risk factors were identified, 
participants were considered ‘low’ risk and were cleared for exercise testing. Participants were 
considered ‘high’ risk when any of the following were identified:  
• Diagnosis of chronic disease 
• BMI > 35 kg·m-2 
• 10-year risk of CVD ≥ 10%  
• Strong family history of CVD in first degree relatives < 50 years of age 
• Elevated total (> 8 mmol·L-1) or LDL-cholesterol (6 mmol·L-1) 
• Elevated blood pressure (>180/110 mmHg) 
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Participants who did not meet criteria for either ‘low’ or ‘high’ risk categories were considered 
‘moderate’ risk and, along with ‘high’ risk individuals, underwent an exercise ECG that was 
supervised by a qualified member of clinical staff. According to the NIHR Leicester-
Loughborough BRU SOP/RA, only high-risk individuals were required to undergo exercise 
ECG screening within a clinical setting. However, within the studies contained in this thesis, 
all exercise ECGs were performed in a clinical setting with access to a resuscitation team and 
post-arrest management. Provided there were no contraindications to exercise, participants 
were cleared for further exercise testing/training.  
3.3  Anthropometrics 
Participant height was measured to the nearest 0.1 cm using a vertical stadiometer (Seca Ltd, 
Germany), whilst body weight (to 0.01 kg) and total body fat percentage (BF%) (to 0.1 %) 
were measured using a segmental body composition analyser (BC-418, TANITA Europe BV, 
Amsterdam, the Netherlands). WC was measured to the nearest 0.1 cm using a tape measure at 
the level of the umbilicus. BMI was calculated as follows: 
BMI = body mass (kg) / height (m)2 
3.4  Blood pressure 
Systolic and diastolic blood pressure were measured from the left arm using an automated 
monitor (M6 Comfort, Omron, Milton Keynes, UK) and with an appropriately sized cuff. 
Participants were seated for a minimum of 15 min before measurements and sat quietly 
(without talking) for at least the final 5 min of this period. A minimum of three measurements 
were taken, the first of which was excluded, until blood pressure was stable. The mean of stable 
measurements was calculated. 
3.5  Fingertip capillary blood sampling 
Fingertip capillary blood sampling (CardioCheck, PTS diagnostics, Indianapolis, USA) was 
used to measure fasted glucose, TG, total cholesterol and HDL during screening procedures 
only (see Section 3.12 for details regarding the measurement of these biomarkers as study 
outcomes). Capillary (whole-blood) samples were analysed immediately after collection and 
LDL was estimated using the Friedewald equation (Friedewald, Levy and Fredrickson, 1972): 
LDL = total cholesterol – HDL – (TG / 2.2) 
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3.6  Measurement of expired gases 
In Chapters 4, 5 and 6, expired gases were measured continuously during submaximal and 
maximal exercise testing by indirect calorimetry (Metalyser 3B, Cortex Biophysik GmbH, 
Germany). Expired gases were also collected during experimental trials in Chapter 4. These 
gas analysers were serviced annually during the period these studies were undertaken and were 
calibrated prior to each use. A manual 3 L syringe was used to calibrate gas volume and a two-
stage calibration of air composition was performed. The latter involved calibration first against 
ambient air and then against a bottled cylinder of known gas composition (approximately 17% 
O2 and 5% CO2; supplied by Cranlea Human Performance Ltd., UK). Participants were fitted 
with an appropriately sized mask (Hans Rudolph 7450 Series, Cranlea Human Performance 
Ltd., UK), which was kept consistent for each visit. The same gas analyser was used for each 
participant across multiple visits. 
3.7  Submaximal exercise testing 
3.7.1 Exercise protocol 
During the exercise trial of Chapter 4, participants were required to run for 60 min at an 
intensity relative to V̇O2 peak (60%). To predict the treadmill speed required to elicit this 
intensity, a submaximal exercise test was performed. During this test, participants completed 
four stages of steady-state exercise on a motorised treadmill, each lasting four minutes. All 
stages were performed at 0% gradient but intensity increased progressively by increasing 
treadmill speed. Treadmill speeds were chosen in consultation with the participant (considering 
their habitual activity levels) with the intention of progressing from a light jog during stage one 
through to a hard, but not exhaustive, run in the final stage.  
3.7.2 Determination of treadmill speed required to elicit target relative intensity 
Mean steady-state values of oxygen uptake (V̇O2), carbon dioxide production (V̇CO2) and 
respiratory exchange ratio (RER) were calculated for each submaximal exercise stage using 
data collected during the penultimate 30 s of each stage (i.e. 3:01 to 3:30 min). Any stage in 
which RER was > 1.0 was excluded. Bivariate regression was performed between treadmill 
speed and steady state V̇O2 to predict the treadmill speed required to elicit 60 % of V̇O2 peak 
for use in experimental trials. 
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3.8  Maximal exercise testing 
3.8.1 Exercise protocols 
Maximal exercise tests were also performed in Chapters 4, 5 and 6 to assess V̇O2 peak as a 
marker of cardiorespiratory fitness. In Chapter 6, peak power output (PPO) was also assessed. 
Tests were performed using the same exercise mode as that utilised within experimental testing 
of each study. Accordingly, a motorised treadmill was used in Chapters 4 (Excite Med 
Technogym, Italy) and 5 (Woodway PPS 70 Plus, Woodway Inc., USA), whilst a stationary 
electromagnetically-braked cycle ergometer (Excalibur Sport, Lode BV, the Netherlands) was 
used in Chapter 6. 
In Chapter 4, participants completed maximal exercise testing using a treadmill speed predicted 
to elicit a steady-state heart rate (HR) of approximately 150 beats·min-1. This was determined 
using data from the submaximal exercise test performed approximately 15 min prior (see 
Section 3.7). In Chapter 5, participants were asked to self-select a speed that constituted a ‘brisk 
walk’. In both chapters, participants completed a 3 min warm-up at the selected speed on a 
minimal gradient (Chapter 4 = 1 %; Chapter 5 = 0 %), after which the test commenced and the 
gradient was increased by 1 % each min.  
In Chapter 6, participants completed a 5 min warm-up at 50 W, after which a ramp protocol 
was initiated with workload increasing by 16 W·min-1. Participants were instructed to maintain 
a pedalling cadence of approximately 80 revolutions·min-1 (rpm). Participants were 
familiarised with this test approximately seven days before baseline assessments. 
In each of these protocols, HR (T31, Polar Electro (UK) Ltd., United Kingdom) and rating of 
perceived exertion (RPE) (Borg, 1970) were recorded during the penultimate 10 s of each 
minute, whilst expired gases were measured throughout (see Section 3.6). Tests continued until 
one of the following occurred: 
• Test aborted due to abnormal ECG or other adverse event beyond expected levels of 
fatigue (this was classified as an incomplete test). 
• HR within 10 beats of age-predicted maximum (220 – age) AND respiratory exchange 
ratio (RER) > 1.15. 
• Volitional exhaustion (all chapters) OR participants unable to maintain a pedalling 
cadence of 80 rpm (Chapter 6 only). 
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3.8.2 Determination of peak oxygen uptake (V̇O2 peak) and peak power output (PPO) 
Breath-by-breath data were exported at 1 s intervals. V̇O2 peak was considered the maximum 
V̇O2 value when a rolling 30 s mean was calculated throughout maximal exercise tests. This 
invariably occurred within the final 2 min of the exercise test. No validation stage was 
performed in the studies within this thesis. PPO was measured as the power elicited at the point 
at which the test was stopped (Chapter 6 only).  
3.9  Magnetic resonance procedures  
In Chapter 6, magnetic resonance spectroscopy and imaging (MRS / MRI) were used for the 
measurement of IHTG, VAT and ScAT. All MR measurements were performed, after an 
overnight fast, on a Philips Achieva 3T system using a 32 channel XL-Torso coil, with a total 
scan duration of approximately 60 minutes.  
IHTG was measured from a 20x20x20 mm voxel within the right lobe of the liver using proton-
MRS (1H-MRS) with Stimulated Echo Acquisition Mode (STEAM) localization (repetition 
time=2046 ms to remove T1 bias) (Bawden, Scott and Aithal, 2017). Water-suppressed and 
unsuppressed spectra were acquired at four echo times (20, 30, 40 and 60 ms) and used to 
determine T2-corrected lipid-to-water ratios (lipid:water). IHTG was quantified as follows 
(Stephenson et al., 2013): 
 IHTG = (lipid:water) / [1+(lipid:water)] x 100 
VAT and ScAT were measured by MRI using a two-point modified Dixon technique (Philips), 
acquired in the transverse plane centred in L4/L5 of the spine. A fat mask was generated from 
fat images using a minimum threshold cut-off in intensity histograms (Nakai et al., 2010) and 
an in-house algorithm generated fat boundaries of visceral and subcutaneous regions to 
calculate VAT and ScAT volumes. 
3.10  Dual-step hyperinsulinaemic, euglycaemic clamp procedures  
In Chapter 6, hepatic and peripheral insulin sensitivity were assessed using a modified version 
of the hyperinsulinaemic, euglycaemic clamp technique as previously described (DeFronzo, 
Tobin and Andres, 1979; Johnston et al., 2013). All procedures were performed after an 
overnight fast.  
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A dual-stepped protocol was employed with stages of low- (20 mU·m-2·min-1) and high-dose 
(50 mU·m-2·min-1) insulin infusion, each lasting 120 minutes. A primed (4 mg·kg-1), 
continuous (0.04 mg·kg-1·hour-1) infusion of [6,6-D2] glucose tracer was started 120 minutes 
before the first hyperinsulinaemic stage and continued throughout to quantify the rate of 
endogenous glucose production (EGP). Arterialised venous blood glucose was measured every 
five minutes (YSI 2300 Stat plus, United Kingdom) and euglycaemia (4.5 mmol·L-1) was 
maintained by a variable infusion of 20% dextrose (mean coefficient of variation (CV) ± SD = 
1.6 ± 0.9 and 2.7 ± 1.1% at steady-state low- and high-dose insulin infusion, respectively). 
Each 100g bag of 20% dextrose was spiked with 1g of [6,6-D2] glucose to maintain plasma 
tracer enrichment. Aliquots of plasma and serum were collected every 15 minutes for 
subsequent batch analysis of glucose tracer enrichment and insulin concentration, respectively. 
An example data collection sheet can be found in Appendix VIII. 
Plasma glucose isotope enrichment (atoms percent excess) was quantified as the 
oxime/trimethylsilyl derivative via gas chromatography mass spectrometry (GC-MS; 7890B, 
MSD 5977A; Agilent Technologies, UK) using selected ion monitoring of the ions at m/z 319 
and 321 (CV = 6.4%). Rates of EGP in the basal state and at low-dose insulin infusion were 
calculated (Wolfe and Chinkes, 2005; Vella and Rizza, 2009) to allow assessment of hepatic 
insulin sensitivity in the basal and insulin-stimulated states, using the hepatic insulin sensitivity 
index (HISI) and percentage suppression of EGP during low-dose insulin infusion (%EGPsupp), 
respectively. Full details of glucose tracer calculations can be found in Appendix VIII, whilst 
HISI and %EGPsupp were calculated as outlined below (see Section 3.14). 
3.11  Isolation and storage of plasma and serum 
Venous blood samples were collected into ice-cooled tubes (Chapters 4 and 5: Monovette, 
Sarstedt, Leicester, UK; Chapter 6: Vacutainer, BD and Co., NJ, USA) which, apart from two 
exceptions (outlined below), were pre-treated with anticoagulant for the isolation of plasma. 
EDTA or Lithium Heparin were used as anticoagulant, dependent on analytical instructions. 
After collection, tubes were gently inverted 7-10 times and spun immediately in a refrigerated 
centrifuge (4 oC) for ≥10 min at 2383 x g. The plasma supernatant was removed and aliquoted 
for storage at -80 oC. During hyperinsulinaemic, euglycaemic clamps (Chapter 6), samples for 
the measurement of serum insulin were collected into tubes pre-treated with a clotting factor 
and left for 30 min prior to centrifugation. Plasma samples collected for the measurement of 
glucose tracer enrichment were pre-treated with fluoride and heparin. 
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3.12  Biochemical analyses 
Commercially available enzyme-linked immunosorbent assays (ELISAs) were used to measure 
plasma concentrations of FGF21, follistatin, fetuin-A (R & D Systems, Oxford, UK), LECT2 
(MBL International, Massachusetts, USA), insulin (Chapters 4 and 5 only) and glucagon 
(Chapter 4 only) (Mercodia, Uppsala, Sweden). All assays were performed according to 
manufacturer instructions, including respective curve fitting, with dilutions and washes 
performed manually using an automated multi-channel pipette (Sartorius, NY, USA). 
Measurement of absorbance and subsequent curve fitting were performed on an automated 
plate reader (Varioskan Flash Multiple Mode Reader, Thermo Scientific, Vantaa, Finland). In 
Chapter 6, serum insulin was quantified using radioimmunoassay (Millipore, USA). Plasma 
concentrations of full-length SeP were measured using a sol particle homogeneous 
immunoassay, utilising two types of SeP monoclonal antibody, as previously reported (Saito 
et al., 2001; Tanaka et al., 2016). In Chapters 4 and 6, circulating concentrations of glucose, 
TG, NEFA, total cholesterol, HDL, AST, ALT and GGT were analysed by enzymatic 
colorimetric methods using a benchtop analyser (Pentra 400; HORIBA ABX Diagnostics, 
Montpellier, France). In Chapter 5, plasma glucose, TG, total cholesterol, HDL and HbA1c 
were measured by the pathology laboratories of the University Hospitals of Leicester NHS 
Trust, whilst NEFA was sent to specialist laboratories at Nottingham University Hospitals NHS 
Trust. 
3.13  Calculation of plasma volume and adjustment of plasma protein 
concentrations 
In Chapter 4, where samples were collected on multiple occasions throughout trial days, blood 
haematocrit and haemoglobin concentrations were determined in each sample to monitor 
changes in plasma volume, calculated using established equations (Dill and Costill, 1974). 
Haematocrit was measured in triplicate with the collection of whole blood into heparinised 
microtubes, which were subsequently spun in a microliter-haematocrit centrifuge (MIKRO 20, 
Andreas Hettich GmbH and Co., Tuttlingen, Germany). Haemoglobin was measured in 
duplicate by the cyanmethaemoglobin method using a spectrophotometer (CECIL CE1011, 
Cecil Instruments Ltd., Cambridge, UK) from samples collected into a micropipette and 
dispensed into Drabkin’s solution. Circulating protein concentrations were corrected, as 
previously described (Sherk et al., 2013), when plasma volume deviated significantly from 
baseline. In Chapter 5, haematocrit and haemoglobin were requested from the pathology 
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laboratories of the University Hospitals of Leicester NHS Trust but, due to large amounts of 
missing data (~33%), adjustments for changes in plasma volume were not performed. 
3.14  Calculation of indices of insulin resistance 
Throughout this thesis, HOMA-IR (Matthews et al., 1985), adipose tissue insulin resistance 
index (Adipo-IR) (Gastaldelli et al., 2007) and HISI (Matsuda and DeFronzo, 1999) were 
calculated as follows: 
HOMA-IR = fasted plasma glucose [mmol∙L-1] x fasted plasma insulin [mU∙L-1] / 22.5 
Adipo-IR = fasted plasma NEFA [mmol∙L-1] x fasted plasma insulin [pmol∙L-1] 
HISI = 1000 / basal EGP [mg·m-2·min-1] x fasted plasma insulin [mU∙L-1] 
In Chapters 6 and 7, hepatic insulin sensitivity was also assessed in the insulin-stimulated state 
using the percentage suppression of EGP during low-dose insulin infusion (%EGPsupp), 
calculated as follows: 
 %EGPsupp = (EGP at low-dose insulin infusion – basal EGP) / basal EGP x 100 
3.15  Calculation of area under the curve (AUC) 
In Chapters 4 and 5, the total area under the concentration-time curve (AUC) for circulating 
biomarkers in each experimental trial was calculated using the trapezoid method. Total AUC 
was calculated as the sum of the areas between each consecutive measurement: 
Area between measurement A and B = (TB – TA) x (0.5 x [CA + CB]) 
where T = time and C = concentration. 
3.16  Statistical analyses 
Statistical analyses were performed using commercially available software (Chapters 4, 5 and 
6: SPSS version 23.0, SPSS Inc., USA; Chapter 7: Stata IC, Version 14.1, StataCorp LP, Texas, 
USA). In Chapters 4, 5 and 6, data were first assessed for their suitability for parametric 
statistical testing. Specifically, Shapiro-Wilk tests were performed to assess the distribution of 
data and in Chapter 4, which contained a between-subjects factor, Levene’s test was used to 
assess homogeneity of variance between groups. In bivariate correlation analyses, the 
distribution of each individual variable and the standardised residuals were assessed. If either 
the normality of distribution or homogeneity of variance assumptions were violated, a natural 
logarithmic transformation was applied to the raw data and the parametric assumptions were 
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re-assessed. If the assumptions were still not met, non-parametric statistical tests were used. 
All experimental studies in this thesis involved at least one within-measures factor and thus, 
when parametric tests were performed, Mauchly’s test of sphericity was used to determine 
whether the variances between all the pairs of measurements were similar. When sphericity 
could not be assumed, a correction was applied to the degrees of freedom. In these instances, 
the Greenhouse-Geisser epsilon was consulted and when < 0.75, this correction was used. 
When the Greenhouse-Geisser epsilon was > 0.75 the Huynh-Feldt correction was applied 
(Atkinson, 2001).  
All normally distributed data are presented as the arithmetic mean with either standard 
deviation or standard error of mean (Lydersen, 2015). Non-normally distributed data are 
presented as the median with interquartile range (IQR). Statistical significance was considered 
at the 5% level (P ≤ 0.05) and, where appropriate, probability (P-) values were adjusted for 
multiple comparisons using the Holm-Bonferroni correction (Holm, 1979), to reduce the 
chance of type I statistical error. 
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CHAPTER 4 
 
THE INFLUENCE OF ADIPOSITY AND ACUTE EXERCISE 
ON CIRCULATING HEPATOKINES IN NORMAL WEIGHT 
AND OVERWEIGHT/OBESE MEN 
 
 
 
 
 
 
 
 
The study presented in this chapter has been published and has the following citation: 
Sargeant JA, Aithal GP, Takamura T et al. (2018). Applied Physiology Nutrition and 
Metabolism. 43: 482-490. 
This manuscript was also selected by the editor as the featured content for the May issue of 
Applied Physiology, Nutrition and Metabolism (Appendix I).  
This chapter presents the published manuscript but with some aspects of the methods section 
condensed or removed to avoid repetition within this thesis. When this occurs, readers are 
directed to the appropriate sections of the General Methods for more information. 
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4.1  Abstract 
Background: Hepatokines are liver-secreted proteins with potential to influence glucose 
regulation and other metabolic parameters. This study investigated differences in adiposity 
status on five novel hepatokines and characterised their response to acute moderate-intensity 
exercise in groups of normal weight and overweight/obese men.  
Methods: Twenty-two men were recruited into normal weight and overweight/obese groups 
(BMI: 18.5 to 24.9 and 25.0 to 34.9 kg∙m-2). Each completed two experimental trials, exercise 
and control. During exercise trials, participants performed 60 min of moderate-intensity 
treadmill exercise (~60% V̇O2 peak) and then rested for 6 h. Participants rested throughout 
control trials. Circulating fibroblast growth factor-21 (FGF21), follistatin, leukocyte cell-
derived chemotaxin 2 (LECT2), fetuin-A and selenoprotein-P (SeP) were measured throughout.  
Results: Fasted (resting) FGF21 and LECT2 were higher in overweight/obese individuals (129% 
and 55%; P ≤ 0.01) and correlated with indices of adiposity and insulin resistance; whereas 
circulating follistatin was lower in overweight/obese individuals throughout trial days (17%, P 
< 0.05). In both groups, circulating concentrations of FGF21 and follistatin were transiently 
elevated after exercise for up to 6 h (P ≤ 0.02). Circulating fetuin-A and SeP were no different 
between groups (P ≥ 0.19) and, along with LECT2, were unaffected by exercise (P ≥ 0.06). 
Conclusions: These findings show that increased adiposity is associated with a modified 
hepatokine profile, which may represent a novel mechanism linking excess adiposity to 
metabolic health. Furthermore, acute perturbations in circulating FGF21 and follistatin after 
exercise may contribute to the health benefits of an active lifestyle. 
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4.2  Introduction 
Recent work characterising the hepatic proteome has identified 168 proteins which can be 
secreted and potentially exert endocrine-like effects in distal sites (Meex et al., 2015). A 
number of these ‘hepatokines’ are associated with measures of adiposity (Chen et al., 2011; 
Xu et al., 2011; Yang, Hwang, et al., 2011; Lan et al., 2014) and have been shown to exert 
metabolic effects within various central and peripheral tissues (Misu et al., 2010; Camporez et 
al., 2013; Malin, Mulya, et al., 2013; Lan et al., 2014; Hansen, Rutti, et al., 2016). Together, 
this evidence has prompted suggestions that hepatokines represent a potential mechanism 
linking adiposity and metabolic health and may be novel therapeutic targets to combat obesity-
related insulin resistance and associated metabolic disease. 
To date, much of the research concerning hepatokine function and metabolism has focused on 
their direct influence on tissue-specific insulin sensitivity and systemic glucose metabolism. 
The most frequently studied, fibroblast growth factor-21 (FGF21), has been shown to improve 
glucose metabolism in the liver, skeletal muscle and adipose tissue (Camporez et al., 2013); 
whilst follistatin may promote pancreatic beta cell survival and suppress circulating glucagon 
(Hansen, Rutti, et al., 2016). Other hepatokines may act to promote insulin resistance. For 
example, within skeletal muscle, leukocyte cell-derived chemotaxin 2 (LECT2) (Lan et al., 
2014), selenoprotein-P (SeP) (Misu et al., 2010) and fetuin-A (Malin, Mulya, et al., 2013) have 
each been shown to directly interfere with distinct aspects of glucose metabolism. 
Observational evidence in humans has identified associations between these hepatokines and 
adiposity, insulin resistance, ectopic lipid and the metabolic syndrome (Zhang et al., 2008; Li 
et al., 2010; Chen et al., 2011; Xu et al., 2011; Yang, Hwang, et al., 2011; H. Y. Choi et al., 
2013; Hansen et al., 2013; Okumura et al., 2013; Lan et al., 2014). However, human 
experimental research is now required to scrutinise the pathophysiological relevance of these 
novel proteins in vivo.  
Current evidence demonstrates that exercise training reduces circulating levels of fetuin-A and 
FGF21, and responses correlate with improvements in insulin sensitivity and intrahepatic fat 
(Malin, Mulya, et al., 2013; Malin et al., 2014; Taniguchi et al., 2016). Given that single bouts 
of exercise transiently enhance insulin sensitivity (Sylow et al., 2017), a handful of studies 
have also investigated the acute influence of exercise on circulating hepatokines, speculating 
that modulation of the hepatokine profile may be implicated in the benefits induced. This 
hypothesis is strengthened by the knowledge that exercise acutely increases circulating non-
~ 64 ~ 
 
esterified fatty acids (NEFA) and glucagon, and activates hepatic AMP-activated protein 
kinase (AMPK) (Camacho et al., 2006; Hansen, Pedersen, et al., 2016). Each of these have 
been implicated in the regulation of at least one of the hepatokines outlined above (Jung, Choi, 
et al., 2013; Lan et al., 2014; Trepanowski, Mey and Varady, 2014; Hansen, Pedersen, et al., 
2016). Whilst these studies remain limited in number, the available evidence shows that 
moderate- to high-intensity aerobic exercise acutely increases circulating levels of FGF21 and 
follistatin (Slusher et al., 2015; Hansen, Pedersen, et al., 2016; Hansen, Rutti, et al., 2016), but 
responses may differ between normal weight and obese individuals, and between individuals 
with normal and dysregulated glucose metabolism (Slusher et al., 2015; Hansen, Pedersen, et 
al., 2016). Additional work is required to determine whether the FGF21 and follistatin 
responses to acute exercise differ between normal weight and overweight/obese individuals 
who are free of diagnosed metabolic disease, and whether similar responses occur in other 
relevant hepatokines.  
The purpose of this study was two-fold. Firstly, we sought to investigate differences in 
adiposity status on FGF21, follistatin, LECT2, SeP and fetuin-A in normal weight and 
overweight/obese men. Secondly, we characterised the effect of an acute bout of moderate-
intensity exercise on circulating concentrations of these hepatokines in order to explore their 
potential role as mediators of exercise-induced improvements in glycaemic control and other 
metabolic parameters. We hypothesised that overweight/obese individuals would have elevated 
circulating concentrations of hepatokines at rest and that an acute bout of moderate-intensity 
exercise would beneficially alter circulating hepatokine profiles; by reducing LECT2, SeP, and 
fetuin A, whilst increasing FGF21 and follistatin. 
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4.3  Materials and methods 
4.3.1 Ethical approval and participant recruitment 
After receiving approval from the East Midlands NHS Research Ethics committee 
(13/EM/0290), 22 non-smoking men were recruited equally into normal weight and 
overweight/obese groups (BMI: 18.5 to 24.9 and 25.0 to 34.9 kg∙m-2, respectively); providing 
written, informed consent to participate (see Section 3.1 for more details). This sample size 
was chosen based on previous studies that documented significant changes in hepatokines 
(FGF21 and follistatin) in response to acute exercise; as well as differences between participant 
groups (normal weight vs. obese and normal vs. impaired glucose regulation) (Slusher et al., 
2015; Hansen, Pedersen, et al., 2016; Hansen, Rutti, et al., 2016). Participants in the current 
study were free of diagnosed chronic disease and were not taking medications known to affect 
glucose or lipid metabolism, or blood pressure. Participants were also ‘inactive’ or ‘moderately 
active’ according to the IPAQ (www.ipaq.ki.se [accessed 03/01/2017]) and were weight stable 
in the three months prior to enrolment (< 2 kg self-reported weight change). 
4.3.2 Participant pre-assessment 
During a pre-assessment visit, participants were screened to determine eligibility and suitability 
for exercise testing as outlined in General Methods (see Section 3.2). Height, weight, BF % 
and WC were also measured (see Section 3.3). In this study, participants were excluded if blood 
pressure was greater than 160/100 mmHg. 
On a separate occasion, participants completed a 16-minute, progressive sub-maximal exercise 
test followed, after approximately 15 minutes, by a ramped maximal exercise test to determine 
V̇O2 peak and predict the treadmill speed to elicit 60 % of V̇O2 peak during experimental trials 
(see Sections 3.6 to 3.8 of General Methods for further detail).  
In the 48 h before main trials, participants refrained from strenuous physical activity, alcohol 
and caffeine, and standardised their dietary intake using weighed records. On the evening 
before main trials, participants were provided with a standardised meal (3138 kJ; 71% 
carbohydrate, 18% fat, 11% protein) to consume before 21:00, after which only water was 
permitted until the start of the trials.  
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4.3.3 Experimental trials 
Participants completed two experimental trials, control and exercise, in a counterbalanced order 
and separated by approximately one week. On the morning of each trial, participants arrived at 
the laboratory at 08:30, at which point an intravenous cannula (21 G; Venflon, Becton 
Dickinson, Sweden) was inserted into an antecubital vein. Trials were then initiated with a 
venous blood sample taken at ~09:00 (0 h) and additional samples were collected at 1, 1.5, 2.75, 
4 and 7 h (Figure 4.1). During exercise trials, participants completed a 60-min bout of 
moderate-intensity treadmill exercise (60% of V̇O2 peak) between 0 and 1 h, and then rested in 
the laboratory for the remainder of the trial (1-7 h). HR and RPE (Borg, 1970) were recorded 
every 15 min during exercise, and expired air was collected throughout for ongoing 
measurement of V̇O2 and V̇CO2. If necessary, treadmill speed was adjusted to maintain the 
desired exercise intensity. Participants rested for the entirety of control trials and samples of 
expired air were collected between 0 and 1 h to quantify resting energy expenditure; allowing 
the calculation of net energy expenditure elicited by exercise. Participants were provided with 
a standardised breakfast (2690 kJ; 72% carbohydrate, 18% fat, 10% protein) and lunch (3138 
kJ; 43% carbohydrate, 25% fat, 32% protein) at 1.5 and 4 h, respectively. 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Schematic representation of experimental trial days.  
Acute moderate-intensity exercise (exercise trials) or measurement of resting energy 
expenditure (control trials) 
 
Standardised meal consumed 
 
Venous cannula inserted 
 
Venous blood sample collected 
6 0 1 2 3 4 5 7 
Time (hours) 
~ 67 ~ 
 
4.3.4 Biochemical analyses 
Venous blood samples were collected into ice-cooled monovettes pre-treated with 
anticoagulant (Sarstedt, Leicester, UK) and plasma was isolated as outlined in General 
Methods (see Section 3.11). Plasma concentrations of FGF21, follistatin, fetuin-A, LECT2, 
insulin, glucagon and SeP were measured at each time point (see Section 3.12). The mean 
within-batch co-efficient of variation (CV) for these assays was ≤ 5.5%. Circulating 
concentrations of NEFA, glucose, TG, total cholesterol, AST, ALT and GGT were also 
measured (within batch CV ≤ 4.2%). All were measured at 0 h only with the exception of 
plasma NEFA, which was measured at each sample time point. Insulin resistance was assessed 
by HOMA-IR and Adipo-IR (see Section 3.14) (Matthews et al., 1985; Gastaldelli et al., 2007). 
Plasma volume was calculated in each whole blood sample using established equations (Dill 
and Costill, 1974) and circulating protein concentrations were corrected when plasma volume 
deviated significantly from baseline (see Section 3.13 for more details).  
4.3.5 Statistical analyses 
Two-tailed, independent samples t-tests were used to compare differences in participant 
characteristics, fasted plasma protein and metabolite concentrations, and characteristics of the 
exercise performed between normal weight and overweight/obese groups. When parametric 
assumptions were not met before or after log transformation, non-parametric Wilcoxon 
matched-pairs signed rank test was used. Relationships between fasted hepatokine 
concentrations and other participant characteristics were assessed using bivariate Pearson’s and 
Spearman’s correlation analyses as appropriate. Three-way, mixed-design analysis of variance 
(ANOVA), consisting of two within-participant factors (trial and sample time) and one 
between-participant factor (group), was used to assess hepatokine responses to exercise. After 
inspection of main effects, the three-way interaction between trial, time and group was used to 
assess whether hepatokine responses during and after exercise, when compared to the control 
trial, differed between normal weight and overweight/obese groups. When this was not 
significant, the two-way interaction between trial and time was used to investigate the 
hepatokine response to exercise in the two groups combined. Statistically significant two-way 
interactions were investigated further with two-tailed paired samples t-tests to identify the 
times at which circulating concentrations differed between control and exercise trials. Due to 
the sample size in this study, no correction for multiple comparisons was applied.  To help 
clarity in graphical presentation, total area under the concentration-time curve (AUC) was also 
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calculated for each experimental trial (see Section 3.15) and these data were analysed 
statistically using two-way mixed design ANOVA.   
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4.4  Results 
4.4.1 Participant characteristics 
Descriptive characteristics of the normal weight and overweight/obese groups can be found in 
Table 4.1. By design, the overweight/obese group had higher BMI, body mass, body fat 
percentage and waist circumference, but age was similar between groups. There was no 
difference in absolute cardiorespiratory fitness between groups but relative fitness was greater 
in the normal weight individuals due to their lower body mass. Fasted plasma glucose, insulin 
and HOMA-IR were similar between groups, but fasted plasma lipids were greater in the 
overweight/obese individuals, whilst Adipo-IR tended to be higher. There were no significant 
differences in AST, ALT or GGT between groups (all P ≥ 0.35; data not shown). 
4.4.2 Fasted plasma hepatokine concentrations and associations with metabolic variables 
The overweight/obese individuals had greater fasted plasma concentrations of LECT2 and 
FGF21, but fasted concentrations of follistatin, fetuin-A and SeP were similar between groups 
(Table 4.1). Fasted circulating LECT2 and FGF21 were positively correlated with each other 
(rho2 = 36.9%, P = 0.03), body mass, BMI, WC, BF%, NEFA, TG, Adipo-IR and glucagon (r2 
≥ 19.4%, P ≤ 0.02 or rho2 ≥ 17.6%, P ≤ 0.05), and negatively with relative V̇O2 peak (r2 ≥ 
27.0%, P ≤ 0.01). FGF21 was also marginally positively correlated with fasted plasma glucose 
(r2 = 18.1%, P = 0.048), whilst LECT2 was strongly positively correlated with HOMA-IR (rho2 
= 43.2%, P = 0.001). Significant negative correlations were found between fasted 
concentrations of follistatin and the AST:ALT ratio (r2 = 18.5%, P = 0.05), fetuin-A and age 
(rho2 = 25%, P = 0.02), and between fasted concentrations of SeP and ALT (r2 = 19.4%, P = 
0.04). Further details of all significant correlations can be found in Appendix VII. 
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Table 4.1 Participant characteristics 
a Heterogeneous variance between groups, non-parametric analyses performed and data 
presented as median (interquartile range). All other data presented as mean ± SD. Symbols 
indicate statistically significant differences between groups (* < 0.05; † ≤ 0.01; ‡ < 0.001). 
 Normal weight (n=11) 
Overweight/obese 
(n=11) 
Anthropometry       
BMI (kg·m-2) a 23.4 (1.6) 29.2 (4.5)‡ 
Age (years) 36 ± 15 45 ± 14 
Body weight (kg) 69.8 ± 1.5 92.3 ± 3.4‡ 
Body fat (%) 16.9 ± 3.6 26.4 ± 4.0‡ 
Waist circumference (cm) 81.6 ± 5.3 96.0 ± 7.8‡ 
Cardiorespiratory Fitness       
Absolute V̇O2 peak (L·min-1) 3.46 ± 0.74 3.21 ± 1.21 
Relative V̇O2 peak (mL·kg BW-1·min-1) 50.1 ± 11.9 38.5 ± 9.7† 
Circulating Metabolic Risk Factors       
Total cholesterol (mmol·L-1) 4.12 ± 0.73 4.91 ± 0.89* 
TG (mmol·L-1) 1.04 ± 0.15 1.82 ± 0.24† 
NEFA (mmol·L-1) 0.39 ± 0.18 0.58 ± 0.14† 
FPG (mmol·L-1) 4.9 ± 0.2 5.0 ± 0.3 
FPI (pmol·L-1) 30.0 ± 12.2 37.1 ± 19.3 
Insulin Sensitivity       
HOMA-IR 0.95 ± 0.39 1.21 ± 0.67 
Adipo-IR 12.57 ± 8.99 21.98 ± 13.01 
Hepatokines       
FGF21 (pg·mL-1) 83 ± 55 190 ± 74‡ 
Follistatin (pg·mL-1) 795 ± 257 670 ± 154 
LECT2 (ng·mL-1) 31 ± 10 48 ± 17† 
Fetuin-A (µg·mL-1) 541 ± 137 497 ± 99 
SeP (µg·mL-1) 3.01 ± 0.39 2.81 ± 0.30 
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4.4.3 Exercise characteristics 
Participants in the normal weight group exercised at a greater treadmill speed due to their 
higher relative cardiorespiratory fitness. However, the relative intensity of the exercise 
performed was similar between groups (Table 4.2). Consequently, given the higher energy cost 
of exercise in the overweight/obese group as a result of their higher body mass, the net energy 
expenditure during exercise trials was similar between groups (P = 0.98). During the exercise 
trials, there was a significant reduction in plasma volume immediately post-exercise 
irrespective of group (0 vs 1 h: 58.5 ± 0.7 vs. 53.7 ± 0.7%; P < 0.01), which returned to baseline 
by 1.5 h.  
 
Table 4.2 Exercise characteristics 
 Normal weight (n=11) 
Overweight/obese 
(n=11) 
Treadmill speed (km·h-1) 7.6 ± 1.0 6.8 ± 1.0* 
V̇O2 elicited (%V̇O2 peak) 59.3 ± 2.8 57.9 ± 2.3 
Net energy expenditure (kJ) 2211 ± 507 2217 ± 509 
Heart rate (beats·min-1) 141 ± 29 139 ± 19 
Rating of perceived exertion (6-20) 13 ± 1 12 ± 1 
Data presented as mean ± SD. *indicates a statistically significant difference between groups 
(P < 0.05). 
 
4.4.4 Circulating hepatokine responses to exercise 
Plasma FGF21 concentrations were higher in the overweight/obese group, irrespective of trial 
or time (Figure 4.2a; P = 0.003), but there was no interaction between trial, time and group (P 
= 0.19). With groups combined, there was a significant two-way interaction between trial and 
time for circulating FGF21 (Figure 4.3a; P < 0.001), and post-hoc analyses revealed that 
circulating concentrations were significantly higher at 1, 1.5 and 4 h in the exercise trial, 
compared with control (all P ≤ 0.005). Accordingly, the total AUC for FGF21 was significantly 
greater in the overweight/obese compared with the normal weight individuals (Figure 4.2b; P 
= 0.003), and in the exercise versus the control trials (Figure 4.3b; P = 0.003). However, there 
was no interaction between group and trial (P = 0.65).  
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Circulating follistatin was lower in the overweight/obese versus the normal weight group 
(Figure 4.2c; P = 0.05), but the interaction between trial, time and group was not significant (P 
= 0.94). In the whole study population, there was a significant two-way interaction between 
trial and time for plasma follistatin (Figure 4.3c; P = 0.001). Post-hoc analyses identified 
significantly higher concentrations at 2.75, 4 and 7 h in the exercise trial (P ≤ 0.02). Similarly, 
the total AUC for follistatin was significantly lower in the overweight/obese group (Figure 4.2d; 
P = 0.05) and greater in the exercise trials (Figure 4.3d; P < 0.01), but there was no interaction 
between group and trial (P = 0.41).  
Circulating LECT2 was higher in the overweight/obese group versus the normal weight group, 
(Figure 4.2e; P = 0.009), but there was no interaction between trial, time and group (P = 0.38). 
For plasma concentrations of LECT2, the two-way interaction between trial and time in the 
whole study population was also not significant (Figure 4.3e; P = 0.06). The total AUC 
analyses for LECT2 mirrored these results with a significantly greater AUC in the 
overweight/obese group (Figure 4.2f; P < 0.01), but no significant difference between the 
control and exercise trials (Figure 4.3f; P = 0.07) and no interaction between group and trial (P 
= 0.45). 
Circulating concentrations of fetuin-A and SeP were similar between groups (Figures 4.2g and 
4.2i; P ≥ 0.20) and there were no interactions between trial, time and group (P ≥ 0.07). 
Furthermore, with groups combined, there were no interactions between trial and time (Figures 
4.3g and 4.3i; P ≥ 0.11). In accordance, the total AUC for fetuin-A (Figures 4.2h and 4.3h) and 
SeP (Figures 4.2j and 4.3j) were similar between groups and between trials, and there were no 
significant interactions (all P ≥ 0.17).  
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 Figure 4.2 Hepatokine responses in normal weight and overweight/obese groups. Circulating 
plasma concentrations FGF21 (a-b), follistatin (c-d), LECT2 (e-f), fetuin-A (g-h) and SeP (i-j) during 
control and exercise trials in both normal weight and overweight/obese groups. Meals were provided at 
1.5 and 4 h. Exercise was performed between 0 and 1 h in the exercise trial only. Data presented as 
mean ± SEM. AUC represents the total area under the concentration-time curve for the given 
experimental day. P-values denote significant main effect of group irrespective or time or trial. 
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 Figure 4.3 Hepatokine exercise responses with groups combined to a single population. 
Circulating plasma concentrations FGF21 (a-b), follistatin (c-d), LECT2 (e-f), fetuin-A (g-h) and 
SeP (i-j) during control and exercise trials in the whole study population combined. Meals were 
provided at 1.5 and 4 h. Exercise was performed between 0 and 1 h in the exercise trial only. Data 
presented as mean ± SEM. AUC represents the total area under the concentration-time curve for 
the given experimental day. * indicates significant difference from control trial at the same time 
point (all P ≤ 0.02). P-values on AUC plots denote significant difference between control and 
exercise trials.  
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4.4.5 Circulating responses of NEFA, glucagon and insulin to exercise 
Despite differences in the fasted state, circulating concentrations of NEFA were similar 
between groups throughout experimental trials (P = 0.09), and there was no significant 
interaction between trial, time and group (P = 0.13). However, with groups combined there 
was a significant two-way interaction between trial and time (Figure 4.4a; P < 0.001) and post-
hoc analyses revealed significantly higher concentrations of NEFA in the exercise trial at 1, 
1.5, 2.75 and 7 h (P ≤ 0.04). 
Circulating concentrations of glucagon, insulin and glucagon to insulin ratio were also similar 
between groups (P ≥ 0.27), and the three-way interactions between trial, time and group were 
not significant for any of these outcomes (P ≥ 0.16). However, in the whole study population, 
there were significant two-way interactions between trial and time for all of glucagon, insulin 
and the glucagon to insulin ratio (Figure 4.4b-d; P ≤ 0.03). Post-hoc tests revealed the glucagon 
to insulin ratio was significantly greater at 1 and 1.5 h in the exercise trial when compared to 
the control trial (P ≤ 0.02). This was primarily driven by significantly higher concentrations of 
glucagon (P ≤ 0.01) and occurred despite significantly higher concentrations of insulin at 1.5 
h in the exercise trial (P = 0.02). Glucagon remained elevated in the exercise trial at 2.75 h (P 
= 0.03) but the consequential increase in the glucagon to insulin ratio was not statistically 
significant (P = 0.08). 
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Figure 4.4 Responses in NEFA, glucagon and insulin with groups combined to a single 
population. Circulating plasma concentrations (a) NEFA (b) glucagon (c) insulin and (d) the glucagon 
to insulin ratio during control and exercise trials in the whole study population combined. Meals were 
provided at 1.5 and 4 h. Exercise was performed between 0 and 1 h in the exercise trial only. Data 
presented as mean ± SEM. * indicates significant difference from control trial at the same time point 
(all P ≤ 0.04).  
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4.5  Discussion 
This study investigated the impact of adiposity and acute exercise on five candidate 
hepatokines which have been identified as novel circulating proteins linking the liver and 
peripheral metabolism. Our findings suggest that circulating levels of LECT2, FGF21 and 
follistatin are modulated by adiposity and are associated with various anthropometric 
measurements and biomarkers of metabolic health. Additionally, our findings show that 
circulating levels of FGF21 and follistatin are transiently elevated after a single bout of 
moderate-intensity exercise, and these responses are preserved in overweight/obese individuals. 
These responses may help mediate the favourable metabolic impact of exercise, but further 
research is needed to assess causality. 
Previous reports have shown increased LECT2 in obese individuals, with or without non-
alcoholic fatty liver disease (NAFLD), in two large Japanese cohorts (Okumura et al., 2013; 
Lan et al., 2014). The current study is the first, however, to show that LECT2 is elevated in 
European men that are overweight/obese and correlates with BMI in a population of normal 
weight, overweight and obese individuals. In mice, hepatic expression and circulating 
concentrations of LECT2 are negatively regulated by hepatic AMPK (Lan et al., 2014). 
Furthermore, eight weeks of high-fat overfeeding increased circulating concentrations of 
LECT2, alongside increases in body mass (Lan et al., 2014). As such, circulating LECT2 may 
be increased in overweight and obese individuals due to chronic reduction of hepatic AMPK 
activity resulting from sustained energy surplus. In agreement with previous studies (Okumura 
et al., 2013; Lan et al., 2014), we show significant associations between LECT2 and fasted 
plasma insulin and HOMA-IR, whilst we also report, for the first time, significant correlations 
between fasted concentrations of LECT2, NEFA and Adipo-IR. LECT2 has been shown to 
inhibit insulin signalling in C2C12 myotubes via activation of cJNK (Lan et al., 2014) but its 
effects on other peripheral tissues, including hepatic and adipose tissues, warrant further 
investigation.  
Previous reports have shown that fasted concentrations of FGF21 are elevated in obese 
individuals with normal or dysregulated glucose metabolism (Zhang et al., 2008; Chen et al., 
2011). Our findings are in agreement with these studies and show that FGF21 is also increased 
in individuals that are overweight/obese. Given the beneficial metabolic effects associated with 
FGF21, it may seem somewhat paradoxical that circulating concentrations are increased in 
individuals with overweight or obesity. However, it has been suggested that increased FGF21 
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may be part of an early adaptive response to chronic overnutrition, to aid subcutaneous adipose 
tissue expansion and thus attenuate lipid storage in ectopic sites (Li et al., 2018). This may 
explain why transient increases in circulating FGF21 to acute stimuli, such as exercise, may be 
apparent and considered beneficial, whilst concentrations are also elevated chronically in 
individuals with metabolic dysregulation. Hepatic expression and secretion of FGF21 is 
increased during periods of starvation via the activation of peroxisome proliferator-activated 
receptor alpha (PPAR-α) by circulating NEFA (Badman et al., 2007). However, plasma 
concentrations of NEFA are also increased with obesity (Boden, 2008), offering a potential 
mechanism to explain the increased FGF21 concentrations seen in the present and previous 
studies. In support of this, we report elevated fasted concentrations of NEFA in the 
overweight/obese group and a strong positive correlation between circulating concentrations 
of FGF21 and NEFA. Alternatively, a state of ‘FGF21 resistance’ may also result in elevated 
concentrations of FGF21 group (Potthoff, Kliewer and Mangelsdorf, 2012) but it was beyond 
the scope of this study to investigate this hypothesis. 
Despite no statistically significant difference in the fasted state, we showed lower 
concentrations of follistatin in the overweight/obese group throughout trial days. Our findings 
are consistent with previous data which identified lower follistatin levels in obese individuals 
with T2DM (Ueland et al., 2012), yet contrast those of Hansen et al. (Hansen et al., 2013) who 
identified higher follistatin in T2DM patients. The reasons for these discrepancies are not clear 
at this time and further work is therefore needed to more fully understand the metabolism of 
follistatin in health and disease.   
We report no differences between groups in concentrations of fetuin-A or SeP either in the 
fasted state or throughout trial days. This may suggest that the development of metabolic 
complications, and not adiposity per se, may be required to disrupt fetuin-A and SeP 
metabolism. Previous research has found no independent effect of obesity on fetuin-A 
concentrations (Obuchi et al., 2014), whilst studies reporting differences in SeP have recruited 
individuals with NAFLD or dysregulated glucose metabolism (Yang, Hwang, et al., 2011; H. 
Y. Choi et al., 2013).  
In the current study we demonstrate that circulating concentrations of FGF21 are increased 
immediately after an acute 60-min bout of moderate-intensity aerobic exercise, peaking 30 min 
after the cessation of exercise, and remaining elevated for up to 3 h. A similar, albeit delayed, 
increase in circulating follistatin also occurred. These findings support previous studies 
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showing that FGF21 and follistatin are increased with acute aerobic exercise (Slusher et al., 
2015; Hansen, Pedersen, et al., 2016; Hansen, Rutti, et al., 2016). FGF21 and follistatin 
production are positively regulated by the glucagon to insulin ratio (Hansen, Pedersen, et al., 
2016; Hansen, Rutti, et al., 2016), whilst FGF21 may also be increased via activation of PPAR-
α by circulating NEFA (K. H. Kim et al., 2013; Hansen, Pedersen, et al., 2016). The systemic 
glucagon to insulin ratio and circulating NEFA were both elevated in response to exercise in 
the present study. FGF21 improves glucose metabolism in skeletal muscle, adipose tissue and 
the liver, whilst follistatin may promote pancreatic beta cell survival, reduce circulating 
glucagon and preserve skeletal muscle mass (Camporez et al., 2013; Hansen, Rutti, et al., 2016). 
Transient increases in the circulating levels of these hepatokines may represent potential 
mechanisms which contribute to the short-term improvements in glycaemic control after acute 
exercise (Sylow et al., 2017) and, if occurring regularly with repeated bouts (i.e. training), the 
longer-term metabolic benefits associated with regular exercise. Notably, in Wistar rats 
undergoing a period of HFOF, FGF21 knockout abolished the beneficial effects of exercise 
training on hepatic steatosis and glucose tolerance (Loyd et al., 2016). 
In the current study the responses of circulating FGF21 and follistatin to exercise were similar 
in both normal weight and overweight/obese participants. It has been previously shown that 
the FGF21 and follistatin responses to acute exercise are blunted in individuals with T2DM, 
and this may be the result of differences in the exercise-induced changes in circulating NEFA 
and the glucagon to insulin ratio (Hansen, Pedersen, et al., 2016). Furthermore, the response 
of FGF21 to 30 min of exercise at 75% V̇O2 peak has been shown to be reduced in obese 
individuals compared with healthy, normal weight controls (Slusher et al., 2015). Notably, 
although the participants in the study by Slusher and colleagues (Slusher et al., 2015) were 
reportedly healthy, the obese group had a mean HOMA-IR of 4.36, which approaches the 5.13 
threshold previously used to distinguish insulin resistant individuals (Wildman et al., 2008). 
The participants in the current study were free from chronic disease and fasted plasma glucose, 
insulin and HOMA-IR suggested they were not insulin resistant. It could, therefore, be 
speculated that exercise-induced increases in circulating FGF21 and follistatin are maintained 
in overweight/obese individuals with preserved glycaemic control but not once a degree of 
insulin resistance has developed. Notably, the exercise-induced changes in NEFA and the 
glucagon to insulin ratio were no different between groups in the current study. This speculative 
hypothesis, however, should be tested further. 
~ 80 ~ 
 
The current study is the first to investigate the acute effects of aerobic exercise on fetuin-A, 
LECT2 and SeP, but these hepatokines were unaffected by exercise. Fetuin-A, LECT2 and SeP 
are all negatively regulated by hepatic AMPK (Jung, Choi, et al., 2013; Lan et al., 2014; 
Trepanowski, Mey and Varady, 2014) which is activated by exercise in an intensity-dependent 
manner (Camacho et al., 2006). It may be that higher intensity exercise is required to acutely 
modulate fetuin-A, LECT2 or SeP (Trepanowski, Mey and Varady, 2014), or that repeated 
bouts of exercise are required to elicit benefits; as shown previously for fetuin-A (Malin, Mulya, 
et al., 2013; Malin et al., 2014). 
This study is not without limitation. Most prominently, this trial was conducted using a 
relatively small sample of normal weight and overweight/obese men. Given the lack of prior 
evidence we were unable to determine a priori whether our sample size was sufficient for all 
of our outcomes. The novel data presented in this manuscript may, however, be utilised to 
inform power calculations for future studies, particularly those investigating the effects of acute 
exercise on LECT2, SeP and fetuin-A. Our results also cannot be generalised to individuals 
with chronic metabolic disease or women. Notably, we did not directly measure intrahepatic 
fat or insulin sensitivity in the current study. These are important considerations because the 
development of metabolic disease may influence hepatokine metabolism. Furthermore, the 
heightened propensity for fatty liver development in men, and the potential metabolic influence 
of sex hormones, underscores the necessity for additional research to be undertaken in women. 
It should also be noted that all analyses in this study were conducted using plasma isolated 
from systemic venous blood. Collection of systemic blood has been previously shown to be 
suitable to assess changes in FGF21 and follistatin after acute exercise (Hansen et al., 2011; 
Hansen, Pedersen, et al., 2016). However, the potential for changes in other circulating 
hepatokines (fetuin-A, LECT2 and SeP) to have been missed due to the location or timing of 
blood sampling cannot be dismissed. Isolation of the splanchnic circulation and the 
measurement of relevant protein expression in tissues of interest (e.g. hepatic, skeletal muscle 
and/or adipose tissues) would have been valuable and are necessary to explore this area further 
in future studies.   
In conclusion, this study has identified higher circulating concentrations of FGF21 and LECT2, 
and lower follistatin, in overweight/obese men when compared to normal weight individuals. 
Moreover, circulating FGF21 and follistatin are acutely increased after moderate-intensity 
aerobic exercise, and this beneficial shift in hepatokine profile is similar in both groups. Whilst 
each of these circulating proteins have been shown to exert beneficial effects of relevance to 
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metabolic health, the clinical impact of the changes seen with acute exercise in this study is not 
currently known. These data provide new information regarding the effect of adiposity on the 
metabolism of several novel hepatokines and supports evidence for a potential role of FGF21 
and follistatin in the metabolic benefits associated with exercise (both to a single bout and with 
regular training). However, additional work is needed to better understand the interaction 
between these novel proteins, obesity and chronic disease; as well as to better define their 
interaction with exercise and other metabolic perturbations. Studies exploring the clinical 
benefit of recurring changes in circulating hepatokines with regular exercise are also required.
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CHAPTER 5 
 
THE EFFECTS OF ACUTE MODERATE-INTENSITY 
CONTINUOUS EXERCISE OR LOW-VOLUME HIGH-
INTENSITY INTERVAL TRAINING ON CIRCULATING 
HEPATOKINE PROFILES IN INDIVIDUALS WITH 
IMPAIRED GLUCOSE REGULATION
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5.1  Abstract 
Background: Hepatokines represent a novel mechanism which may mediate the relationship 
between elevated IHTG and insulin resistance in peripheral tissues. This study presents 
preliminary findings exploring the effects of acute low-volume high-intensity interval training 
(LV-HIIT) or continuous moderate-intensity aerobic exercise (CME) on circulating 
concentrations of three hepatokines in overweight or obese individuals with impaired 
glycaemic control. 
Methods: Six men and six women (median (IQR) or mean ± SD; Age: 69 (67 – 70) years; BMI: 
28.8 (28.4 – 31.8) kg·m-2; HbA1c: 5.9 ± 0.2 %) performed three experimental trials (control, 
CME or LV-HIIT), each lasting 6 h, in a randomised, counterbalanced order. Participants 
performed LV-HIIT (25 min) or CME (35 min) during the respective exercise trials, both of 
which concluded at 2 h, and rested thereafter. Participants rested throughout control trials. 
Venous blood samples were collected at 0, 1, 2, 3, 4 and 6 h for the measurement of FGF21, 
follistatin, fetuin-A, insulin and NEFA. 
Results: Circulating follistatin concentrations were greater in the CME trial at 4 h and 6 h, 
compared to both LV-HIIT and control trials (P ≤ 0.03). However, there were no differences 
in circulating follistatin between LV-HIIT and control (all post hoc comparisons: P ≥ 0.15), 
whilst circulating FGF21 and fetuin-A concentrations were similar across the three trials days 
(time by trial interaction: P ≥ 0.14). 
Conclusions: These results suggest that, in individuals with impaired glycaemic control, a 
single bout of CME, but not LV-HIIT, increases circulating concentrations of follistatin, which 
may contribute to the improved glucose regulation associated with acute and chronic exercise. 
Conversely, FGF21 and fetuin-A are seemingly unaffected by either CME or LV-HIIT in 
dysglycaemic individuals. However, additional work is required to explore these preliminary 
findings further. 
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5.2  Introduction 
Elevated IHTG is the hallmark feature of NAFLD (Marchesini et al., 2016; Chalasani et al., 
2018) and is heavily implicated in the pathogenesis of T2DM (Taylor, 2008; Balkau et al., 
2010; Armstrong et al., 2014; Mantovani et al., 2018). IHTG correlates with insulin resistance 
not only in the liver but also in skeletal muscle and adipose tissues (Korenblat et al., 2008; Bril, 
Barb, et al., 2017). The mechanisms underlying these relationships between IHTG and 
peripheral tissues are not fully understood but liver-secreted ‘hepatokines’ may play a part in 
mediating inter-organ crosstalk (Stefan and Häring, 2013; Takamura, Misu and Kaneko, 2016; 
Meex and Watt, 2017).  
The accumulation of IHTG modulates the secretion of many hepatokines, including FGF21, 
follistatin and fetuin-A (Meex et al., 2015), each of which have been implicated in the 
regulation of glucose homeostasis by exerting endocrine effects in skeletal muscle, adipose 
tissue or the pancreas (Camporez et al., 2013; Malin, Mulya, et al., 2013; Stefan and Häring, 
2013; Hansen, Rutti, et al., 2016). Circulating concentrations of FGF21, follistatin and fetuin-
A are also higher in patients with T2DM compared to non-diabetic individuals, and correlate 
with markers of glycaemic control (Chavez et al., 2009; Ishibashi et al., 2010; Chen et al., 
2011; Hansen et al., 2013; Stefan et al., 2014). Furthermore, circulating hepatokine 
concentrations are altered by acute exercise (Hansen et al., 2011; K. H. Kim et al., 2013; 
Slusher et al., 2015; Hansen, Pedersen, et al., 2016; Hansen, Rutti, et al., 2016; Sargeant, Aithal, 
et al., 2018), leading to suggestions that they may be implicated in the metabolic benefits of 
regular exercise (Slusher et al., 2015). 
The study presented in Chapter 4 of this thesis demonstrated that circulating concentrations of 
FGF21 and follistatin are transiently elevated after a single bout of CME in lean and 
overweight/obese men (Sargeant, Aithal, et al., 2018), supporting previous research in 
individuals free from chronic metabolic disease (Hansen et al., 2011; K. H. Kim et al., 2013; 
Slusher et al., 2015; Hansen, Pedersen, et al., 2016; Hansen, Rutti, et al., 2016). However, it 
has been suggested that these responses may be blunted or even abolished in individuals with 
impaired glycaemic control or T2DM (Slusher et al., 2015; Hansen, Pedersen, et al., 2016). 
The study in Chapter 4 was also the first to investigate whether circulating concentrations of 
fetuin-A are modulated by acute exercise. However, despite evidence that circulating fetuin-A 
may be reduced by exercise training, (which was associated with improved insulin sensitivity) 
(Malin, Mulya, et al., 2013; Malin et al., 2014), a single bout of CME had no effect (Sargeant, 
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Aithal, et al., 2018). It is possible that the lack of response in fetuin-A may have been due to 
the fact that the population recruited were free from chronic disease and had normal glycaemic 
control. Accordingly, there were no differences in fasted fetuin-A concentrations between lean 
and overweight/obese groups (Sargeant, Aithal, et al., 2018). No study has explored the effects 
of acute exercise on circulating fetuin-A in individuals with impaired glucose regulation. 
In healthy individuals, the magnitude of increase in circulating FGF21 immediately after a 
single bout of exercise is dependent upon the intensity of the exercise performed (K. H. Kim 
et al., 2013). Similarly, fetuin-A expression is negatively regulated by hepatic AMPK activity 
(Jung, Youn, et al., 2013; Trepanowski, Mey and Varady, 2014), which itself may be activated 
in an intensity-dependent manner (Camacho et al., 2006). It has also been suggested that the 
circulating follistatin response to acute exercise may be regulated by exercise intensity (Hansen 
et al., 2011) but, at present, data from adequately controlled experimental studies are not 
available. Sustained, continuous high-intensity exercise may not be feasible for individuals 
with or at risk of chronic metabolic disease. However, LV-HIIT has been proposed as a 
practical exercise protocol allowing such populations to complete exercise of near-to-maximal 
intensity (Little et al., 2010, 2011). Whilst evidence remains limited, LV-HIIT has been 
suggested to improve markers of glycaemic control in overweight individuals with or without 
T2DM (Hood et al., 2011; Little et al., 2011, 2014; Gillen et al., 2012). However, the effects 
of LV-HIIT on circulating hepatokines have not been explored.  
This chapter presents preliminary analyses from an ongoing clinical trial (ISRCTN12337078) 
that explores the effects of a single bout of LV-HIIT or CME, on circulating hepatokines 
(FGF21, follistatin and fetuin-A) in individuals with impaired glycaemic control. It was 
hypothesised that, LV-HIIT would transiently increase plasma concentrations of FGF21 and 
follistatin and reduce circulating fetuin-A. Responses to CME would be of a lower magnitude 
or absent. 
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5.3  Materials and Methods 
5.3.1 Ethical approval and participant recruitment 
After receiving approval from the East Midlands NHS Research Ethics Committee (15-EM-
0259), 12 white European individuals (six men and six women) were recruited, giving written 
informed consent to participate (see Section 3.1). These participants represent half of the total 
sample that will be recruited to this study as recruitment of a south Asian group remains in 
progress. For consistency within this thesis, south Asian individuals recruited to date were not 
included in these preliminary analyses; all participants in Chapters 4 and 6 were of white 
European ethnicity.  
Participants were aged 50 to 74 years with a BMI > 27.5 kg·m-2. Participants were weight-
stable (defined as < 5 kg change in body weight in the previous six months) and free from overt 
chronic metabolic disease but had impaired glycaemic control as indicated by HbA1c between 
5.7 and 6.5 %. Participants that performed regular purposeful activity (≥ three or more sessions 
of vigorous-intensity exercise per week; ≥ 20 min per session) were excluded, as were those 
taking glucose-lowering medications or steroids. 
5.3.2 Preliminary visit 
Participants visited the Leicester Diabetes Centre having abstained from alcohol and strenuous 
exercise for 48 and 72 h, respectively. Height, weight, WC and BF% were measured as outlined 
in General Methods (see Section 3.3). Medical history was reviewed by a specialist cardiac 
nurse and a resting ECG was performed (Cardiofax GEM ECG, Nihon Nohden Corp., Tokyo, 
Japan). In the absence of established resting cardiac arrhythmias or other contraindications to 
participation in the study, participants completed a maximal exercise test to determine V̇O2  
peak, as outlined in General Methods (see Sections 3.6 to 3.8). ECG was monitored throughout 
and the test was aborted upon occurrence of any unexpected adverse events. 
After approximately 15 min (or until participants had sufficiently recovered), participants were 
familiarised with the LV-HIIT protocol used during experimental trials. LV-HIIT was 
performed as outlined in Table 5.1, except that only three intervals were completed. The 
preliminary visit concluded with a venous blood sample for the measurement of total 
cholesterol, HDL and HbA1c. 
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5.3.3 Experimental trials 
Participants completed three experimental trials (control, CME and LV-HIIT) in a randomised, 
counterbalanced order. Each trial was separated by approximately one week and, prior to each 
trial, participants refrained from strenuous activity and alcohol for 72 h and 48 h, respectively. 
Participants also recorded dietary intake, using weighed food records, for 48 h before their first 
trial day and were asked to replicate this prior to subsequent trials. They were instructed to 
consume all food and energy-containing beverages before 22:00 on the evening before 
experimental trials, after which only water was permitted. 
Participants arrived at the laboratory for experimental trials at approximately 08:00. Motorised 
transport was arranged and ambulatory activity was minimised throughout trial days. After 
ensuring compliance with standardisation instructions, experimental procedures were 
reiterated and willingness to continue was confirmed. An intravenous cannula (20/22G, Braun, 
Pennine Healthcare, Derby, UK) was inserted into an antecubital vein and, after a period of 
habituation (30 – 45 min), trials were initiated with the collection of a venous blood sample (0 
h). Further blood samples were drawn at 1, 2, 3, 4 and 6 h (Figure 5.1). Circulating FGF21, 
follistatin, fetuin-A, insulin and NEFA were measured at each timepoint. Standardised meals 
(8 kcal·kg-1; 51 % CHO, 35 % fat, 14 % protein) were provided at 0 and 3 h, and were consumed 
within 15 min. 
 
5 A 0 1 2 3 4 6 
Time (hours) 
\\ 
Figure 5.1 Schematic representation of experimental trial days 
   25 min LV-HIIT performed (LV-HIIT trials only) 
   35 min of continuous moderate-intensity aerobic exercise performed (CME trials only) 
   Standardised meal consumed  
   Participant arrival (approximately 60 min prior to first blood sample) 
   Venous cannula inserted (approximately 30 - 45 min prior to first blood sample) 
   Venous blood sample collected 
 
A 
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During exercise trials, participants performed a single bout of either CME or LV-HIIT. Each 
were performed on a motorised treadmill (Excite Med Technogym, Italy) and finished at 2 h. 
Therefore, to account for differences in exercise duration (35 vs. 25 min), the CME protocol 
commenced earlier than the LV-HIIT (Figure 5.1). Details of each exercise protocol, which are 
suggested to be closely matched for external work (Little et al., 2014), can be found in Table 
5.1. During exercise, HR and RPE (Borg, 1970) were recorded at regular intervals.  
 
Table 5.1 Details of exercise protocols employed in experimental trials 
 Continuous moderate-
intensity exercise 
Low-volume HIIT 
Total duration 35 min 25 min 
Warm-up 3.5 km·h-1 at 0% gradient (3 min) 
Exercise protocol Duration: 30 min 
 
Speed: Identical to that used in 
maximal exercise testing 
 
Gradient: That predicted to 
elicit 65 % of V̇O2 
peak. 
Duration: 20 min (10 x 60-s 
intervals, 10 x 60-s 
active recovery). 
 
Speed:  
Intervals: Identical to that used 
in maximal exercise 
testing. 
Recovery: 3.5 km·h-1 
 
Gradient: 
Intervals: 90 % of peak gradient 
achieved in maximal 
exercise testing. 
Recovery: 0 %. 
Cool-down 3.5 km·h-1 at 0% gradient (2 min) 
 
5.3.4 Biochemical analyses 
All biochemical analyses were conducted as outlined in General Methods (see Sections 3.11 
and 3.12). Briefly, plasma was isolated at each timepoint of experimental trials and stored at -
80 oC (see Section 3.11) for subsequent batch analysis of FGF21, fetuin-A, follistatin and 
insulin using commercially-available ELISA (see Section 3.12) (all CV ≤ 5.0%). Glucose, TG, 
total cholesterol, HDL and HbA1c were requested from the pathology laboratories of 
University Hospitals of Leicester NHS Trust, whilst NEFA analyses were conducted within 
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specialist laboratories at Nottingham University Hospitals NHS Trust. One participant was 
excluded from NEFA analysis as data were unavailable for an entire trial. Haemoglobin and 
haematocrit were also requested but missing data meant that plasma volume could only be 
calculated for 64% of all timepoints. Furthermore, complete data for all three experimental 
trials were only available for two participants. Therefore, no adjustments for plasma volume 
were made.  
5.3.5 Statistical analyses 
Data were analysed using an approach that was consistent with that of Chapter 4. Briefly, two-
way, repeated measures ANOVA (within-participant factors: trial and sample time) were used 
to assess hepatokine responses to exercise. Significant trial by time interactions were followed 
up post-hoc with paired samples t-tests between the three different trials at each sample time. 
Given the small sample size of this study, P-values were not corrected for multiple comparisons. 
Total AUC was also calculated for each hepatokine throughout each trial day (see Section 3.15) 
and differences between trials were investigated using one-way repeated measures ANOVA or 
Friedman’s test when the data were normally- or not normally-distributed, respectively. 
Significant main effects were followed up with paired samples t-tests or Wilcoxon matched 
pairs tests, as appropriate. 
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5.4  Results 
5.4.1 Participant and exercise characteristics 
Details of participant characteristics can be found in Table 5.2. As per study eligibility criteria, 
participants were older adults with overweight or obesity and with HbA1c indicative of 
impaired glycaemic control. Four of the twelve individuals also met diagnostic criteria for 
impaired fasting glucose (> 5.7 mmol·L-1) (American Diabetes Association, 2018). There were 
no differences in HR or RPE between the CME (mean ± SD; HR: 114 ± 17 beats·min-1, RPE: 
12 ± 2) or LV-HIIT (HR: 119 ± 12 beats·min-1, RPE: 13 ± 2) exercise (both P ≥ 0.27). 
Table 5.2 Participant characteristics 
Anthropometry    
Age (years) 69 (67 – 71) 
Body weight (kg) 82.1 ± 9.0 
BMI (kg·m-2) 28.8 (28.4 – 32.5) 
Waist circumference (cm) 101.7 ± 6.4 
Body fat (%) 35.7 ± 6.0 
Glycaemic Control and Insulin Sensitivity     
HbA1c (%) 5.9 ± 0.2 
Fasted plasma glucose (mmol·L-1) 5.4 ± 0.5 
Fasted plasma insulin (pmol·L-1) 72.1 ± 28.3 
HOMA-IR 2.9 ± 1.2 
Fasted plasma NEFA (mmol·L-1) 0.52 ± 0.16 
Adipo-IR 35.2 ± 12.5 
Other Metabolic Risk Factors    
Systolic blood pressure (mmHg) 135 ± 10 
Diastolic blood pressure (mmHg) 81 ± 6 
Total Cholesterol (mmol·L-1)* 5.2 ± 0.9 
HDL (mmol·L-1)* 1.6 ± 0.4 
LDL (mmol·L-1)* 2.6 (2.4 – 2.9) 
Fasted plasma TG (mmol·L-1) 1.36 (1.19 – 2.31) 
Cardiorespiratory Fitness    
Absolute V̇Ȯ2 peak (L·min-1) 2.19 ± 0.50 
Relative V̇Ȯ2 peak (mL·kg-1·min-1) 26.5 ± 4.6 
Fasted Hepatokines    
FGF21 (pg·mL-1) 143 (133 – 386) 
Fetuin-A (µg·mL-1) 682 ± 141 
Follistatin (pg·mL-1) 2077 ± 480 
Data presented as arithmetic mean ± SD or median (IQR). * n = 11.  
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5.4.2 Circulating hepatokines responses to exercise  
FGF21 concentrations were similar between trials (P = 0.79) and there was no interaction 
between trial and time (P = 0.23; Figure 5.2a). Similarly, there were no differences in the total 
AUC between trials (Figure 5.2b).  
The mean circulating follistatin concentrations were also similar between trials (P = 0.10), but 
there was a significant interaction between trial and time (P = 0.004; Figure 5.2c). Post-hoc 
tests revealed that, whilst there were no differences between control and LV-HIIT trials (all P 
≥ 0.15), circulating follistatin concentrations were significantly higher at 4 h (P ≤ 0.03) and 6 
h (P ≤ 0.002) in the CME trial. There was a significant main effect of trial when data were 
analysed as total AUC (P = 0.05; Figure 5.2d) and post-hoc tests revealed a significantly higher 
total AUC in the CME trial compared to the LV-HIIT trial (P = 0.03). The difference in total 
AUC between the CME and control trials approached statistical significance (P = 0.08). 
Circulating concentrations of fetuin-A were similar between trials (P = 0.67) and there was no 
interaction between trial and time (P = 0.14; Figure 5.2e). Total AUC was similar between 
trials (P = 0.50; Figure 5.2f). 
5.4.3 Circulating responses of NEFA and insulin to exercise 
The mean circulating concentrations of NEFA were similar between trials (P = 0.13) but there 
was a significant interaction between trial and time (P = 0.02; Figure 5.3a). Post-hoc tests 
revealed that circulating concentrations were higher in the CME trial compared to the control 
trial at 2 h (P = 0.02) and 3 h (P = 0.02), and higher than the LV-HIIT trial at 1h (P < 0.01) and 
2 h (P < 0.001). The total AUC was similar between trials (P = 0.23; Figure 5.3b). 
The interaction between trial and time for circulating concentrations of insulin approached 
statistical significance (P = 0.08; Figure 5.3c) and there was a main effect of trial when data 
were analysed either using raw concentrations (P = 0.045) or as total AUC (P = 0.02). Post-
hoc tests using AUC data suggested that the total AUC during the LV-HIIT trial was lower 
than that of both the control and CME trials (P < 0.01 and P = 0.03, respectively; Figure 5.3d).  
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Figure 5.2 Circulating hepatokine response during control, CME and LV-HIIT trials. 
Circulating plasma concentrations of FGF21 (a-b), follistatin (c-d) and fetuin-A (e-f) during 
control, CME and LV-HIIT trials. Meals were provided at 0 and 3 h. During CME and LV-
HIIT trials, participants performed 35 min of CME or 25 min of LV-HIIT, respectively. 
Exercise was co-ordinated such that each exercise bout finished at 2 h. Data presented as mean 
± SEM unless otherwise stated. # indicates data were not normally distributed and thus 
presented as median with IQR. AUC represents the total area under the concentration-time 
curve for the given experimental day. * indicates significant difference between CME and 
control trials (all P ≤ 0.03). ‡ indicates significant difference between CME and LV-HIIT trials 
(all P ≤ 0.01). 
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Figure 5.3 Circulating NEFA (a-b) and insulin (c-d) responses during control, CME and 
LV-HIIT trials. Data for NEFA analysis are n = 11. Meals were provided at 0 and 3 h. During 
CME and LV-HIIT trials, participants performed 35 min of CME or 25 min of LV-HIIT, 
respectively. Exercise was co-ordinated such that each exercise bout finished at 2 h. Data 
presented as mean ± SEM unless otherwise stated. # indicates data were not normally 
distributed and thus presented as median with IQR. AUC represents the total area under the 
concentration-time curve for the given experimental day. * indicates significant difference 
between CME and control trials (all P ≤ 0.02). ‡ indicates significant difference between CME 
and LV-HIIT trials (all P ≤ 0.02). † indicates significant difference between LV-HIIT and 
control trials (P = 0.02). 
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5.5  Discussion 
This chapter presents preliminary findings exploring the acute effects of CME or LV-HIIT on 
circulating concentrations of FGF21, follistatin and fetuin-A in individuals with overweight or 
obesity and impaired glycaemic control. These data suggest that circulating follistatin is 
increased 2 h after the cessation of CME and remains elevated for a minimum of 4 h post-
exercise. Conversely, a single bout of LV-HIIT appears to have no effect on circulating 
follistatin, whilst FGF21 and fetuin-A are unaffected by either exercise bout in this population. 
These results are consistent with previous research demonstrating a transient increase in 
circulating follistatin after a single bout of CME (Hansen et al., 2011; Hansen, Pedersen, et al., 
2016; Hansen, Rutti, et al., 2016; Sargeant, Aithal, et al., 2018). Notably, one of these studies 
also reported that this response is blunted in individuals with T2DM (Hansen, Pedersen, et al., 
2016). Whilst the reasons for this blunted response could not be determined conclusively, the 
authors speculated that it may be a result of hyperinsulinaemia in individuals with T2DM, 
leading to a smaller change in the circulating glucagon to insulin ratio during exercise (Hansen, 
Pedersen, et al., 2016). This ratio has previously been reported as an important mediator of the 
post-exercise response of circulating follistatin (Hansen, Pedersen, et al., 2016; Hansen, Rutti, 
et al., 2016). It is notable that in the dysglycaemic population recruited in this study, the mean 
fasted plasma insulin concentrations was approximately 2 to 2.5-fold greater than both the lean 
and overweight/obese normoglycaemic groups recruited in Chapter 4 (Sargeant, Aithal, et al., 
2018). However, comparisons between different populations are not possible at this time as the 
current study does not directly compare the magnitude of exercise-induced changes in 
circulating follistatin between individuals with different degrees of glycaemic control 
completing the same exercise protocol.  
Nonetheless, the data presented in this chapter do confirm the potential for acute exercise to 
modulate circulating follistatin concentrations in individuals with impaired glucose regulation. 
Follistatin promotes the synthesis of skeletal muscle, by inhibiting myostatin and activin 
(Gilson et al., 2009; Yaden et al., 2014), and increases pancreatic β-cell mass by promoting 
proliferation and reducing apoptosis (Zhao et al., 2015; Hansen, Rutti, et al., 2016). It may also 
reduce glucagon secretion from islet cells (Hansen, Rutti, et al., 2016). It is plausible, therefore, 
that regular transient elevations in follistatin after repeated bouts of exercise may play a part in 
the improvements in glycaemic control seen with exercise training. However, this hypothesis 
requires further investigation. 
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Previous reports have speculated that the response of circulating follistatin to acute exercise 
may be dependent on the intensity of exercise performed (Hansen et al., 2011). In the current 
analysis, however, LV-HIIT had no effect on circulating follistatin concentrations. Whilst 
contrary to the hypothesis of Hansen and colleagues, these results are consistent with a separate 
study recently conducted in our research group (Willis et al., 2018). This study demonstrated 
that, in healthy normal-weight individuals, the exercise-induced increase in circulating 
follistatin was no different after energy-matched bouts of aerobic exercise performed at either 
55% or 75% of V̇O2 peak (Willis et al., 2018). It is possible, therefore, that characteristics of 
acute exercise other than intensity may be more important in mediating the post-exercise 
increase in circulating follistatin. One such exercise characteristic may be exercise duration. In 
the study by Hansen and colleagues, the increase in circulating follistatin was greater after 3 h 
of moderate-intensity cycling than after 2 h of knee extensor exercise (Hansen et al., 2011). 
Similarly, in the current study the single bout of CME was approximately one-third longer than 
the LV-HIIT.  
An alternative explanation for the lack of change in circulating follistatin after LV-HIIT is that 
the LV-HIIT utilised in this study did not induce changes in the glucagon to insulin ratio 
sufficient to modulate hepatic follistatin secretion. As mentioned previously, the circulating 
follistatin response after acute exercise is regulated by changes in the glucagon to insulin ratio 
and when exercise is performed under the conditions of a pancreatic clamp (during which 
glucagon and insulin concentrations are fixed) the post-exercise increase in plasma follistatin 
is blunted (Hansen, Pedersen, et al., 2016; Hansen, Rutti, et al., 2016). Glucagon was not 
measured in the current analyses and, therefore, it cannot be determined at present whether the 
glucagon to insulin ratio differed between the CME and LV-HIIT trials.  It is noteworthy, 
however, that the mean circulating insulin concentration was lower during the LV-HIIT trial 
compared to the CME and control trials. This would, if anything, contribute to a greater 
glucagon to insulin ratio. Finally, the fact that the follistatin response to acute exercise is 
blunted but not abolished during pancreatic clamp suggests that additional mechanisms beyond 
the glucagon to insulin ratio may be responsible. Whilst, these alternative mechanisms are 
currently unclear it is possible that they may be differentially modulated by CME and LV-HIIT. 
In the current study, circulating concentrations of FGF21 were unaffected by CME in 
individuals with impaired glucose regulation but not overt T2DM. Furthermore, despite 
previous evidence that the post-exercise increase in circulating FGF21 may be intensity-
dependent in healthy individuals (K. H. Kim et al., 2013), a single bout of LV-HIIT in the 
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current study had no effect. These results are in accordance with previous research 
demonstrating that, compared to healthy normoglycaemic individuals, the increase in 
circulating FGF21 after exercise is blunted, or even abolished, in individuals with dysregulated 
glucose metabolism (Slusher et al., 2015; Hansen, Pedersen, et al., 2016). Notably, the 
individuals recruited by Slusher and colleagues were obese and had a baseline HOMA-IR that 
was indicative of insulin resistance, but were free from chronic metabolic disease (Wildman et 
al., 2008; Slusher et al., 2015); HbA1c was not assessed. Collectively, these results indicate 
that there may be a progressive decline in the FGF21 response to exercise as insulin resistance 
occurs and this may be fully suppressed before the development of overt T2DM. As such, 
changes in FGF21 may not be directly related to the acute improvement in insulin sensitivity 
seen after single bouts of exercise in individuals with dysglycaemia (Sylow et al., 2017). 
However, as mentioned previously when discussing the results for follistatin above, further 
studies directly comparing the response of FGF21 to identical bouts of acute exercise in 
matched groups of individuals with different degrees of insulin resistance are required to 
rigorously test this suggestion. 
The circulating FGF21 response to exercise is also regulated by the glucagon to insulin ratio 
(Hansen et al., 2015; Hansen, Pedersen, et al., 2016). However, unlike follistatin, this response 
is completely abolished when exercise is performed under conditions of the pancreatic clamp 
(Hansen, Pedersen, et al., 2016). It has been previously suggested that the blunted or abolished 
response of circulating FGF21 after acute exercise in individuals with impaired glycaemic 
control or overt T2DM may be due to elevated circulating insulin in these individuals leading 
to a lower change in the glucagon to insulin ratio with exercise (Hansen, Pedersen, et al., 2016). 
As mentioned previously, however, glucagon was not measured in the current study and, 
therefore, whilst fasted circulating insulin was greater in the current study population compared 
to the normoglycaemic individuals recruited in Chapter 4, potential differences in the glucagon 
to insulin ratio cannot be determined.  
The effects of acute exercise on circulating fetuin-A in individuals with impaired glucose 
regulation have not been explored previously. The preliminary findings presented in this 
chapter suggest that, in this population, plasma fetuin-A concentrations are unaffected by a 
single bout of either CME or LV-HIIT. These findings are similar to those previously reported 
in lean and overweight/obese individuals with normal glucose regulation, which also found no 
effect of acute CME on circulating fetuin-A (Sargeant, Aithal, et al., 2018; Chapter 4 of this 
thesis). It was hypothesised that the lack of fetuin-A response to acute exercise in individuals 
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free from chronic metabolic disease (Sargeant, Aithal, et al., 2018) may have been because 
fetuin-A concentrations were not elevated at baseline. In Chapter 4, there was no difference in 
circulating fetuin-A between the lean and overweight/obese normoglycaemic groups and this 
may have limited the potential for circulating fetuin-A to be reduced by acute exercise. 
Alternatively, fetuin-A expression is negatively regulated by hepatic AMPK (Jung, Youn, et 
al., 2013; Trepanowski, Mey and Varady, 2014) which, in rodents, is activated in a stepwise 
manner with exercise intensity (Camacho et al., 2006). Therefore, it may have been that the 
intensity of CME utilised in Chapter 4 was insufficient to modulate circulating fetuin-A. 
However, despite the mean fasted fetuin-A concentration in the current study being 26% to 37% 
higher than the groups recruited in Chapter 4 and a bout of high-intensity exercise being 
performed in the form of LV-HIIT, there was no effect of either CME or LV-HIIT on 
circulating fetuin-A. Therefore, the results of the current study in combination with those of 
Chapter 4 (Sargeant, Aithal, et al., 2018) suggest that, in humans, fetuin-A may not be sensitive 
to acute perturbations in metabolism, such as that caused by a single bout CME or LV-HIIT. 
Instead, it may be that more regular bouts of energy imbalance, such as those that occur with 
structured training, or prolonged energy deficit and weight loss may be required to elicit 
sustained reductions in circulating fetuin-A (Blüher et al., 2012; Malin, Mulya, et al., 2013; 
Malin et al., 2014). 
This study is the first to investigate the effects of a single bout of LV-HIIT or CME on 
circulating hepatokines in overweight/obese individuals with impaired glycaemic control but 
not overt T2DM. However, some important limitations should be considered. Most notably, 
this chapter presents preliminary analyses of an ongoing trial, with the current sample size 
constituting half of the final study population. As such, the current sample size may be 
insufficient to detect physiologically meaningful changes in some of the outcomes reported 
and null-findings may be the result of a lack of statistical power. Notably, based on the data 
contained in this chapter, where the largest standardised difference between trials for total AUC 
of FGF21 (between CON and CME) and fetuin-A (between CON and LV-HIIT) were -0.18 
and -0.20, respectively, and where the within-participant correlation was approximately 0.90 
for each, the current sample size (n = 12) only had 27.5% and 20.8% power to detect a 
significant main effect of trial, with an alpha error rate of 0.05. In turn, retrospective sample 
size calculations determined that 46 and 67 participants would be required to detect a 
significant main effect of trial for FGF21 and fetuin-A, respectively. Furthermore, additional 
research examining the impact of transient exercise-induced changes in FGF21 and fetuin-A 
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in clinical populations is required to determine what magnitude of difference in these 
hepatokines could be considered clinically meaningful. Accordingly, it is important to note that 
the potential explanations provided for the results of this chapter remain speculative and require 
rigorous investigation. Secondly, participants performed exercise approximately 60-90 min 
after consuming a breakfast meal. Whilst the content and timing of meals were standardised 
between conditions, and thus controlled within the context of this study, direct comparisons 
with previous studies (in which exercise was performed in the fasted state) should be made 
with caution. Finally, the CME and LV-HIIT protocols utilised in this study are suggested to 
be approximately matched for total external work (Little et al., 2014) and the mean HR and 
RPE during exercise was similar between trials. However, energy expenditure was not assessed 
directly (using indirect calorimetry, for example, as it was in Chapter 4) and therefore the 
possibility that differences in responses between CME and LV-HIIT may be due to differences 
in energy expenditure cannot be dismissed. Furthermore, it may be possible that the exercise 
protocols used in this chapter were insufficient to elicit changes in circulating hepatokines and 
that greater energy expenditure may be required to modulate circulating concentrations in this 
population. Further studies that rigorously examine the impact of exercise protocols differing 
in energy expenditure are required to test this hypothesis, and explore whether a minimum 
threshold of energy expenditure required to elicit changes in circulating hepatokines exists.  
In conclusion, this study demonstrates that circulating follistatin is transiently increased by a 
single bout of CME in individuals with overweight or obesity and impaired glycaemic control, 
which may contribute to the improved glucose regulation associated with regular exercise. 
Conversely, the data presented suggest that the increase in FGF21 previously reported after 
CME in a healthy (normoglycaemic) population is not apparent in individuals with glycaemic 
dysregulation. A single bout of LV-HIIT had no effect on follistatin or FGF21, whilst 
circulating concentrations of fetuin-A were unaffected by either exercise protocol. However, 
these analyses are preliminary in nature and additional work is required to explore these 
findings further. 
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CHAPTER 6 
  
EFFECTS OF SPRINT INTERVAL TRAINING ON 
ECTOPIC LIPIDS AND TISSUE-SPECIFIC INSULIN 
SENSITIVITY IN MEN WITH NON-ALCOHOLIC FATTY 
LIVER DISEASE 
 
 
 
 
 
 
 
 
The study presented in this chapter has been published and has the following citation: 
Sargeant JA, Bawden S, Aithal GP et al. (2018). European Journal of Applied Physiology. 
118(4): 817-828. 
This chapter presents the published manuscript but with some aspects of the methods section 
condensed or removed to avoid repetition within this thesis. When this occurs, readers are 
directed to the appropriate sections of the General Methods for more information. Conversely, 
further details of the participant recruitment process and hepatokines analyses, which were not 
submitted for publication, have been added to the results section of this chapter. 
~ 100 ~ 
 
6.1  Abstract 
Purpose: This study examined the feasibility of sprint interval exercise training (SIT) for men 
with non-alcoholic fatty liver disease (NAFLD) and its effects on intrahepatic triglyceride 
(IHTG), insulin sensitivity (hepatic and peripheral), visceral (VAT) and subcutaneous adipose 
tissue (ScAT). 
Methods: Nine men with NAFLD (age 41±8 years; BMI 31.7±3.1 kg·m-2; IHTG 15.6±8.3%) 
were assessed at: 1) baseline 2) after a control phase of no intervention (pre-training) and 3) 
after six weeks of SIT (4-6 maximal 30 s cycling intervals, three times per week). IHTG, VAT 
and ScAT were measured using magnetic resonance spectroscopy or imaging and insulin 
sensitivity was assessed via dual-step hyperinsulinaemic-euglycaemic clamp with [6,6-D2] 
glucose tracer.  
Results: Participants adhered to SIT, completing ≥96.7% of prescribed intervals. SIT increased 
peak oxygen uptake (V̇O2 peak: +13.6% [95% CI: 8.8 to 18.2%]) and elicited a relative 
reduction in IHTG (-12.4% [-31.6 to 6.7%]) and VAT (-16.9% [-24.4 to -9.4%]; n=8), with no 
change in body weight or ScAT. Peripheral insulin sensitivity increased throughout the study 
(n=8; significant main effect of phase) but changes from pre- to post-training were highly 
variable (range: -18.5 to +58.7%) and not significant (P=0.09), despite a moderate effect size 
(g*=0.63). Hepatic insulin sensitivity was not influenced by SIT. 
Conclusions: SIT is feasible for men with NAFLD in a controlled laboratory setting and is able 
to reduce IHTG and VAT in the absence of weight loss.  
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6.2  Introduction 
Non-alcoholic fatty liver disease (NAFLD) is a common complication of obesity that is 
integrated in the pathogenesis of extra-hepatic co-morbidities such as type 2 diabetes (T2DM) 
and cardiovascular disease (Byrne and Targher, 2015). Insulin resistance is a central 
pathophysiological feature of NAFLD with associations between intrahepatic triglyceride 
content (IHTG) and insulin action in skeletal muscle, adipose tissue and the liver (Bril, Barb, 
et al., 2017). The prominence of these metabolic defects within the development and 
progression of NAFLD makes them priority targets for intervention.  
Lifestyle interventions, incorporating diet and physical activity, remain the cornerstone of 
treatment for NAFLD (Marchesini et al., 2016) and the importance of structured exercise 
within such interventions is underscored by both hepatic and extra-hepatic benefits. Continuous 
moderate-to-vigorous intensity exercise interventions increase cardiorespiratory fitness, reduce 
adiposity, improve peripheral insulin sensitivity, enhance cardiovascular function and improve 
circulating markers of metabolic health (Pugh et al., 2014; Hallsworth et al., 2015; Keating et 
al., 2015; Cuthbertson et al., 2016; Zhang et al., 2016). 
Guidelines for the management of NAFLD suggest that individuals undertake 150-200 min of 
moderate-intensity aerobic or resistance exercise each week, spread over three to five sessions 
(Marchesini et al., 2016). Observational evidence (Kistler et al., 2011) and experimental data 
(Cho et al., 2015; Oh et al., 2017) suggest that high-intensity exercise may be more potent in 
attenuating IHTG accumulation and NAFLD progression than moderate-intensity exercise. 
This evidence is consistent with exercise intensity-dependent improvements in wider 
cardiometabolic outcomes, including indices of insulin sensitivity (Tjønna et al., 2008; Weston, 
Wisløff and Coombes, 2014). Moderate-intensity exercise improves peripheral insulin 
sensitivity in patients with NAFLD (Cuthbertson et al., 2016) but evidence of its impact on 
hepatic insulin sensitivity is unclear (Shojaee-Moradie et al., 2007; Cuthbertson et al., 2016). 
The effects of high-intensity exercise on hepatic and peripheral insulin sensitivity in individuals 
with NAFLD have not been assessed. A better understanding of these outcomes is important, 
given the link between IHTG, glycaemic control and metabolic disease (Byrne and Targher, 
2015; Marchesini et al., 2016; Bril, Barb, et al., 2017). 
High-intensity intermittent exercise training (HIIT), which is characterised by repeated 
intervals of high-intensity exercise interspersed with periods of rest or low-intensity active 
recovery, has emerged as a form of exercise capable of providing many health benefits for 
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individuals with, or at risk of, chronic disease (Gibala et al., 2012). Sprint interval training (SIT) 
is a version of HIIT consisting of brief bursts (30 s) of maximal-intensity exercise (Little et al., 
2011). SIT induces adaptations in skeletal muscle which improve oxidative metabolism (Gibala 
et al., 2012) and, in some studies, enhances whole-body insulin sensitivity and glycaemic 
control (Richards et al., 2010; Cocks et al., 2015). These adaptations are likely to be of benefit 
for individuals with NAFLD, but the influence of SIT on IHTG and tissue-specific (muscle, 
adipose tissue, liver) insulin sensitivity remains unknown. 
This study investigated the feasibility and efficacy of SIT as a therapeutic strategy in 
overweight or obese men with NAFLD. We sought to determine the effect of six weeks of SIT 
on IHTG, visceral (VAT) and subcutaneous adipose tissue (ScAT), as well as hepatic and 
peripheral (skeletal muscle and adipose tissue) insulin sensitivity. We hypothesised that SIT 
would reduce IHTG, VAT and ScAT, and increase insulin sensitivity. 
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6.3  Participant and Methods  
6.3.1 Ethical approval 
This study was approved by the research ethics committees of Loughborough University and 
the University of Nottingham and was conducted in accordance with the Declaration of 
Helsinki (World Health Organisation, 2013). 
6.3.2 Participants 
Nine white European men were recruited from the general population and gave informed, 
written consent to participate (see Section 3.1). Although no power calculation was performed 
for this study, this sample size was chosen based on studies reporting significant improvements 
in cardiorespiratory fitness and indices of glycaemic control with HIIT (Little et al., 2011; 
Cocks et al., 2015). Eligibility criteria included inactive but weight-stable individuals aged 25 
to 55 years with a body mass index (BMI) between 27 and 40 kg·m-2 and a waist circumference 
≥ 94 cm. Participants were considered inactive if they did not complete any form of regular 
structured exercise.  Participants were identified as exhibiting NAFLD in that they had IHTG 
≥ 5.56%, determined during screening using magnetic resonance (MR) spectroscopy (1H-
MRS), and did not report excessive alcohol consumption (>21 units·week-1; Appendix VIII) or 
other secondary causes of hepatic steatosis (Marchesini et al., 2016). Participants were 
excluded if they: a) had any form of diagnosed chronic metabolic disease, b) were taking 
prescribed medications for hypertension, dyslipidaemia or glucose regulation or c) had 
contraindications to exercise or MR procedures.    
6.3.3 Study design 
This study utilised a repeated measures longitudinal design in which, following screening, 
participants completed two consecutive six week phases (control and SIT). This study design 
was chosen over an RCT design to reduce the number of participants recruited and the number 
of measurement sessions required. Our within-measures design also meant that we avoided 
additional heterogeneity that would occur through the recruitment of different individuals into 
two separate groups. Notably, our control phase acted to monitor the variation in study 
outcomes over a similar period to that of the exercise intervention, but with participants 
maintaining their usual lifestyle. All participants completed the control phase followed by the 
exercise intervention, in order to avoid the confounding effects of detraining during the control 
phase. All study assessments were performed on consecutive days at baseline, pre-training and 
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post-training: day 1) IHTG, VAT and ScAT; day 2) hepatic and peripheral insulin sensitivity 
and systemic metabolic biomarkers; day 3) cardiorespiratory fitness. Post-training assessments 
began 48 h after the final SIT session to eliminate the confounding influence of the final 
exercise training session on insulin sensitivity (Sylow et al., 2017).  
Dietary intake was standardised for 24 h before metabolic assessments through provision of all 
food and energy-containing drinks. This diet provided a balanced macronutrient profile and 
was tailored to each participant’s estimated energy requirement (Mifflin et al., 1990) using a  
multiplication factor of 1.45 to account for the physical activity level of an inactive group (FAO, 
WHO and UNU, 2001). Participants were instructed and regularly reminded to maintain their 
usual lifestyle habits throughout both the control and SIT phases of the study. This included 
instructions to maintain dietary habits. Energy intake was not recorded due to concerns that 
monitoring may prompt dietary changes and given documented concerns regarding the 
accuracy of self-reported energy intake data (Dhurandhar et al., 2015). 
6.3.4 Imaging and metabolic assessments 
All metabolic assessments were performed after an overnight fast. MR measurements were 
performed on a Philips Achieva 3T system with 32 channel XL-Torso coil. IHTG was 
measured from a 20x20x20 mm voxel within the right lobe of the liver using 1H-MRS with 
Stimulated Echo Acquisition Mode (STEAM) localization (repetition time = 2046 ms) 
(Stephenson et al., 2013; Bawden, Scott and Aithal, 2017). VAT and ScAT were assessed using 
a two-point modified Dixon technique (Philips) (Nakai et al., 2010) and an in-house algorithm 
to generate fat boundaries of visceral and subcutaneous regions.  
Hepatic and peripheral insulin sensitivity were assessed using a modified version of the 
hyperinsulinaemic, euglycaemic clamp with two stages of insulin infusion, low- (20 mU·m-
2·min-1) and high-dose (50 mU·m-2·min-1), each lasting 120 min. A continuous infusion of [6,6-
D2] glucose tracer was initiated 120 min before the first hyperinsulinaemic stage and continued 
throughout for the quantification of endogenous glucose production (EGP) (Johnston et al., 
2013). Blood glucose was clamped at 4.5 mmol·L-1 (coefficient of variation: mean (± SD) = 
1.6 ± 0.9 and 2.7 ± 1.1 % at steady-state low- and high-dose insulin infusion, respectively). 
Further details of 1H-MRS, MRI and dual-step hyperinsulinaemic, euglycaemic clamp 
procedures can be found in the General Methods section of this thesis (see Sections 3.9 and 
3.10). 
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The hepatic insulin sensitivity index (HISI) (Matsuda and DeFronzo, 1999) and the percentage 
suppression of EGP by low-dose insulin infusion (%EGPsupp) were calculated as indices of 
hepatic insulin sensitivity in the fasted and insulin-stimulated states, respectively, as outlined 
in General Methods (see Section 3.14). Peripheral insulin sensitivity was assessed as whole-
body glucose uptake, which was assumed to be equal to the exogenous glucose infusion rate 
required to maintain euglycaemia at high-dose insulin infusion, during which EGP was 
negligible.  
6.3.5 Assessment of cardiorespiratory fitness and habitual physical activity 
V̇O2 peak and PPO were measured using a ramped (+16 Watt·min-1) cycling test on an 
electromagnetically-braked cycle ergometer (Excalibur Sport, Lode BV, The Netherlands) (see 
Sections 3.6 to 3.8 of General Methods for further details). V̇O2 peak and PPO are presented 
as both absolute units (L·min-1 and W) and relative to the participant’s body weight (mL·kg-
1·min-1 and W·kg-1). Participants were familiarised with this test one week before baseline 
assessments.  
To assess the impact of SIT on habitual physical activity levels, participants wore a tri-axial 
accelerometer (GT3x, Actigraph LLC, USA) for seven consecutive days before each 
assessment (baseline, pre-training and post-training). Data were analysed using computer 
software (Kinesoft 3.3.80, USA) (Troiano et al., 2008) and are presented as absolute minutes 
per day in each activity domain (sedentary time, light, moderate and vigorous physical activity) 
as well as percentages of accelerometer wear time. Further details of data collection and 
analysis can be found in Appendix VIII) 
6.3.6 Exercise training 
Participants completed a SIT program consisting of three exercise sessions per week for six 
weeks. Sessions consisted of a low-intensity warm-up (5 min cycling at 50W), followed by 30 
s intervals of maximal sprint cycling on a stationary ergometer (Ergomedic 894E, Monark 
Exercise AB, Sweden), which was separated by periods of active recovery (4.5 min of low 
intensity cycling at 50W). The braking resistance of the ergometer was increased during 
intervals through the application of a load equivalent to 6.5% of lean body mass, determined 
using bioelectrical impedance analysis (BC-418, TANITA Europe BV, Amsterdam, The 
Netherlands). Participants were instructed to cycle ‘all-out’ during intervals whilst members of 
the research team provided verbal encouragement (Whyte, Gill and Cathcart, 2010). Four 
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intervals were completed per session in the first two weeks with an additional interval added 
to each session every two weeks. Participants therefore completed 90 intervals over the six 
weeks of supervised training. 
6.3.7 Biochemical analyses 
Plasma glucose isotope enrichment (atoms percent excess) was quantified as the 
oxime/trimethylsilyl derivative via gas chromatography mass spectrometry (GC-MS; 7890B, 
MSD 5977A; Agilent Technologies, UK) using selected ion monitoring of the ions at m/z 319 
and 321 (CV = 6.4%). Fasted circulating concentrations of total cholesterol, HDL, LDL, TG 
and NEFA (All CV ≤ 1.5%), and FGF21, follistatin, fetuin-A and LECT2 (all CV ≤ 7.1%) were 
analysed from plasma aliquots, collected before the start of hyperinsulinaemic euglycaemic 
clamps (as outlined in General Methods, Sections 3.11 & 3.12) (All CV ≤ 1.5%). Serum insulin 
was quantified using radioimmunoassay (Millipore, USA) (CV = 7.3%), and HOMA-IR and 
Adipo-IR were calculated (see Section 3.14) (Matthews et al., 1985; Gastaldelli et al., 2007). 
6.3.8 Tracer calculations 
Rates of EGP in the basal state and at low-dose insulin infusion were calculated (Wolfe and 
Chinkes, 2005; Vella and Rizza, 2009), accounting for non-steady-state during low-dose 
insulin infusion and assuming a fractional volume of distribution of 160 mL·kg-1. Further 
details of glucose tracer calculations can be found in Appendix VIII. 
6.3.9 Statistical analyses 
Normally distributed data are presented as mean with standard deviation (SD) and one-way 
repeated measures ANOVA was used to assess changes in outcomes across assessment visits 
(main effect of phase). The homogeneity of variance between data collected at each visit was 
assessed and a Greenhouse-Geisser or Huynh-Feldt correction was applied, where appropriate. 
Statistically significant main effects were explored post-hoc using paired samples t-tests. Non-
normally distributed data are presented as the median with interquartile range (IQR) and 
Friedman tests were used to assess the main effect of phase. Wilcoxon matched pairs tests were 
used for post-hoc pairwise comparisons on non-normally distributed data. Probability (P-) 
values for post-hoc tests were adjusted using the Holm-Bonferroni correction (Holm, 1979) to 
account for multiple comparisons. In text, the changes from pre- to post-training are presented 
as relative percentage change along with 95% confidence interval [CI] and effect size (adjusted 
Hedges’ g*). Cohen’s descriptors were used to interpret the magnitude of effect (Cohen, 1988). 
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For clarity, the change in IHTG is presented as both the absolute and relative percentage change. 
The association between changes in IHTG and whole-body glucose uptake from pre- to post-
SIT was assessed using Pearson’s bivariate correlation analysis.   
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6.4  Results 
6.4.1 Participant recruitment 
One-hundred and thirty-five men expressed an interest to participate and underwent pre-
screening via face-to-face, telephone or email contact. Of these, 32 progressed to formal 
screening, nine of whom were eligible for inclusion in the study. A flowchart of study 
recruitment, along with reasons for exclusion, can be found in Figure 6.1. 
Excluded following pre-screen 
n=103 
Interest expressed and pre-screen completed 
n=135 
Informed, written 
consent received 
n=32 
Reasons for exclusion: 
• Age (n=8) 
• BMI < 27 kg·m-2 (n=18) 
• BMI > 40 kg·m-2 (n=6) 
• Medications (n=12) 
• Antihypertensives (n=4) 
• Statins (n=4) 
• Diabetic (n=2) 
• Other (n=2) 
• Declined having read and 
discussed participant information 
sheet (n=23) 
• Time (n=10) 
• Phobia of needles (n=2) 
• Other / Reason not stated 
(n=11) 
• Lost contact / no response (n=31) 
• Other (n=5) 
Entered full study testing 
n=9 
Reasons for Exclusion: 
• Liver fat < 5.56 % (n=5) 
• High blood pressure (n=6) 
• Abnormal ECG (n=3)  
• BMI < 27 kg·m-2 (n=2) 
• BMI > 40 kg·m-2 (n=1) 
• Failed medical (n=2) 
• Withdrew (n=4) 
• Claustrophobia (n=1) 
• Could no longer commit time (n=1) 
• Lost contact / moved away (n=2) 
Excluded during full screening 
n=23 
Figure 6.1 Study recruitment process 
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6.4.2 Participant characteristics and exercise training compliance 
All assessments made at baseline, pre- and post-training can be found in Table 6.1. The median 
self-reported alcohol intake of recruited participants was four units per week (range: 1 to 14). 
One participant was unable to attend hyperinsulinaemic, euglycaemic clamp assessments. 
Participant characteristics specific to these eight individuals can be found in Appendix IX. All 
participants completed exercise training and attended all 18 sessions. Due to fatigue, one 
participant failed to complete two intervals in their first session and one interval in session two, 
but completed all prescribed intervals thereafter (total intervals: 87 = 96.7%).  
There were no significant differences in any measured outcome between baseline and pre-
training assessments, determined as a non-significant main effect of phase or, where 
appropriate, post-hoc comparison. However, from baseline to pre-training assessments, there 
was a tendency for increased fasted serum insulin and HOMA-IR, and reduced relative V̇O2 
peak (uncorrected P = 0.06, 0.07 and 0.07, respectively; all other outcomes P ≥ 0.13). 
6.4.3 Effects of SIT on cardiorespiratory fitness and habitual physical activity 
Training improved absolute and relative V̇O2 peak by 11.2% [95% CI: 6.4 to 16.0%] (g* = 0.83) 
and 13.6% [8.8 to 18.2%] (g* = 0.78; Figure 6.2a), respectively (P ≤ 0.001). This was alongside 
improvements in absolute (14.7% [10.7 to 18.7%], g* = 0.75) and relative (16.2% [11.1 to 
21.2%], g* = 0.64; Figure 6.2b) peak power output (P ≤ 0.001). As outlined in Table 6.2, there 
were no differences in sedentary time or light, moderate or vigorous physical activity 
throughout the duration of the study when analysed either as minutes per day or as a percentage 
of accelerometer wear time (main effect of phase: P ≥ 0.24). 
~ 110 ~ 
 
Table 6.1 Participant characteristics and study outcomes (continued overleaf) 
 Baseline Pre-training Post-training 
P-value  
(main 
effect of 
phase) 
Effect size  
(Hedges’ g*) 
Baseline- 
Pre-
Training 
Pre- to 
Post-
Training 
Anthropometry             
Age (years) 41 ± 8          
BMI (kg·m-2) 31.7 ± 3.1          
Waist circumference (cm) 111.3 ± 7.5          
Body weight (kg) 102.5 ± 10.6 102.4 ± 10.1 101.2 ± 10.4 0.17 Trivial Trivial 
VAT (mL) (n=8) 1094 ± 238 1220 ± 395 995 ± 281 0.01 0.36 -0.62 
ScAT (mL) (n=8) 2801 ± 847 2800 ± 653 2658 ± 655 0.16 Trivial -0.21 
IHTG (%) 15.6 ± 8.4 14.4 ± 8.7 12.4 ± 8.2 0.001 Trivial -0.23 
Cardiorespiratory Fitness             
Absolute V̇Ȯ2 peak (L·min-1) 3.23 ± 0.41 3.18 ± 0.41 3.53 ± 0.45c <0.001 Trivial 0.83 
Relative V̇Ȯ2 peak (mL·kg-1·min-1) 31.8 ± 4.8 31.0 ± 4.7a 35.1 ± 5.4c <0.001 Trivial 0.78 
Absolute peak power output (W) 239 ± 42 237 ± 42 270 ± 43d <0.001 Trivial 0.75 
Relative peak power output (W·kg-1)  2.36 ± 0.49 2.34 ± 0.54 2.71 ± 0.57d <0.001 Trivial 0.64 
Insulin Sensitivity (n=8)             
Fasted serum insulin (mU·L-1) 17.6 ± 4.5 21.8 ± 8.1a 18.2 ± 6.0b 0.04 0.60 -0.48 
Fasted blood glucose (mmol·L-1) 4.7 ± 0.3 4.7 ± 0.4 4.5 ± 0.5 0.13 Trivial -0.32 
HOMA-IR 3.7 ± 1.0 4.5 ± 1.7a 3.7 ± 1.2b 0.03 0.59 -0.56 
Whole-body glucose uptake  
(mg·kg-1·min-1) 5.2 ± 1.1 5.4 ± 1.1 6.4 ± 1.8
e 0.02 Trivial 0.63 
Fasted plasma NEFA (mmol·L-1) 0.59 ± 0.15 0.55 ± 0.12 0.58 ± 0.19 0.83 -0.41 0.29 
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Adipo-IR* 52.7 (44.6 – 83.2)  69.3 (46.9 – 101.8)   55.4 (45.8 – 73.4) >0.99 0.38 -0.24 
Basal EGP (μmol·kg-1·min-1) 10.8 ± 1.5 10.7 ± 2.2 11.2 ± 2.1 0.70 Trivial 0.25 
HISI* (mg·m-2·min-1 per mU·L-1) 0.65 (0.54 – 0.76)   0.54 (0.50 – 0.62)   0.63 (0.49 – 0.74) 0.42 -0.47 0.34 
Low-dose EGP (μmol·kg-1·min-1) 4.39 ± 2.17 4.63 ± 1.31 5.34 ± 1.58 0.27 Trivial 0.46 
%EGPsupp (%) 59.9 ± 17.4 55.7 ± 11.3 51.6 ± 14.6 0.37 -0.28 -0.30 
Circulating Lipids             
Triacylglycerol (mmol·L-1) 2.2 ± 0.9 2.2 ± 0.7 1.9 ± 0.7 0.50 Trivial -0.35 
Total Cholesterol (mmol·L-1) 4.88 ± 0.59 4.80 ± 0.54 4.62 ± 0.75 0.19 Trivial -0.26 
HDL (mmol·L-1)* 0.90 (0.83 – 1.11)  0.88 (0.84 – 1.08)   0.95 (0.88 – 1.18)b 0.01 Trivial 0.44 
LDL (mmol·L-1) 2.85 ± 0.61 2.89 ± 0.54 2.77 ± 0.60 0.48 Trivial -0.21 
Hepatokines             
FGF21 (pg·mL-1) 176 (110 – 505) 210 (131 – 408) 182 (99 – 463) 0.55 Trivial Trivial 
Follistatin (pg·mL-1) 2310 (1534 – 3389) 2104 (1626 – 2683) 2143 (1557 – 2442) 0.37 -0.22 Trivial 
Fetuin-A (µg·mL-1) 608 ± 138 643 ± 176 614 ± 156 0.67 0.21 Trivial 
LECT2 (ng·mL-1) 40 ± 5 39 ± 5 39 ± 5 0.51 Trivial Trivial 
Data presented as mean ± SD and for n=9 unless otherwise stated. * indicates that data are not normally distributed and thus presented as median 
(IQR). a the difference between baseline and pre-training values approached statistical significance (uncorrected P-values; FPI P=0.06, HOMA-
IR P=0.07, Relative V̇Ȯ2 peak P=0.07), b significantly different from pre-training values (P<0.05), c significantly different from pre-training values 
(P<0.01), d significantly different from pre-training values (P<0.001), e the difference between pre-training and post-training values approached 
statistical significance (uncorrected P=0.09); Trivial effect sizes were considered those of magnitude < 0.2. To convert serum insulin from mU·L-
1 to pmol·L-1, multiply by 6. 
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Table 6.2 Habitual sedentary time and physical activity during baseline, pre- and post-training assessment periods 
 Baseline Pre-training Post-training 
P-value 
(main effect  
of phase) 
General           
Device wear time (minutes per day) 1027 ± 131 989 ± 119 1027 ± 166 0.68 
Counts per wear minute 293 ± 111 316 ± 156 294 ± 92 0.34 
Sedentary Behaviour           
Minutes per day 719 ± 92 693 ± 139 726 ± 155 0.77 
% of wear time# 70.3 (64.2 – 74.8) 74.9 (59.6 – 76.6) 66.5 (65.6 – 77.3) 0.37 
Light Activity           
Minutes per day 270 ± 74 256 ± 82 262 ± 59 0.60 
% of wear time 26.1 ± 5.5 26.0 ± 8.1 25.8 ± 5.5 0.93 
Moderate Activity           
Minutes per day# 23.0 (18.0 – 50.5) 31.0 (19.5 – 63.0) 30.0 (13.5 – 52.5) 0.89 
% of wear time# 2.4 (1.6 – 5.5) 2.7 (1.9 – 7.2) 2.5 (1.3 – 6.3) 0.24 
Vigorous Activity           
Minutes per day# 0.0 (0.0 – 2.0) 0.0 (0.0 – 1.5) 0.0 (0.0 – 1.5) 0.94 
% of wear time# 0.03 (0.00 – 0.18) 0.01 (0.00 – 0.13) 0.03 (0.00 – 0.13) 0.71 
Moderate-Vigorous Activity (MVPA)           
Minutes per day# 23.0 (18.5 – 55.0) 31.0 (19.5 – 67.0) 32.0 (13.5 – 59.0) 0.92 
% of wear time# 2.4 (1.7 – 6.1) 2.7 (1.9 – 7.8) 2.7 (1.3 – 7.1) 0.40 
Data presented as mean ± SD, unless otherwise stated. n=9. #indicates that data are not normally distributed and thus presented as median (IQR).  
P-values represent the main effect of phase. 
~ 113 ~ 
 
 
 
6.4.4 Effects of SIT on ectopic fat and systemic metabolic biomarkers  
Despite no change in body weight across study visits (main effect of phase: P = 0.17; Table 
6.1; Figure 6.3a), SIT elicited a reduction in IHTG (P = 0.03; Figure 6.3b). From pre- to post-
training, the mean absolute reduction was 2.1% [-3.4 to 0.8%], which equated to a relative 
reduction of 12.4% [-31.6 to 6.7%] (g* = -0.23). One MR-image was found to be corrupted at 
the point of analysis so changes in VAT and ScAT are presented for n=8 (characteristics 
specific to these individuals can be found in Appendix IX). These data do not correspond to 
the same eight individuals who completed the hyperinsulinaemic, euglycaemic clamp 
assessments. Training reduced VAT by 16.9% [-24.4 to -9.4%] (g* = -0.62, P = 0.02; Figure 
6.3c), but there were no changes in ScAT (main effect; P = 0.16; Figure 6.3d). Training 
increased circulating HDL by 8.4% [4.6 to 12.2%] (g* = 0.44, P = 0.02;) but total cholesterol, 
LDL, TG were unchanged throughout the study (P ≥ 0.19; Table 6.1). Likewise, circulating 
hepatokine concentrations were similar at baseline, pre- and post-training (≥ 0.37; Table 6.1). 
Figure 6.2 a) Peak oxygen uptake (V̇O2 peak) and b) peak power output measured at 
baseline, pre- and post-training. Data presented as mean ± SD (n=9). Outcomes presented 
relative to participant body weight. † indicates the difference between baseline and pre-training 
values approached statistical significance (unadjusted P = 0.07); * indicates significantly 
different from pre-training value (P ≤ 0.001). 
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6.4.5 Effects of SIT on peripheral and hepatic insulin sensitivity 
Figure 6.4 displays mean circulating insulin concentrations measured throughout dual-step 
hyperinsulinaemic, euglycaemic clamp assessments. There were no significant differences in 
the serum insulin concentrations reached at steady state low-dose (P = 0.55) or high-dose (P = 
0.64) insulin infusions between baseline, pre-training and post-training assessments.  
Figure 6.3 a) Body weight, b) intrahepatic triglyceride (IHTG), c) visceral adipose tissue 
(VAT) and d) subcutaneous abdominal adipose tissue (ScAT) measured at baseline, pre- 
and post-training. Data presented as mean ± SD. Data for body weight and IHTG are n=9. 
Data for VAT and ScAT are n=8. * indicates significantly different from pre-training value (P 
≤ 0.03). 
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There was a significant main effect of phase for the increase in whole-body glucose uptake, 
which is indicative of peripheral insulin sensitivity, across the three study visits (P = 0.02; 
Figure 6.5a). However, responses to SIT were highly variable between individuals (range: -
18.5% to +58.7%; Figure 6.5b) and, despite a medium effect size (g* = 0.63), the change from 
pre- to post-training (18.1% [-3.0 to 39.2%]) was not statistically significant (unadjusted P = 
0.09). There was an association between the change in IHTG and the change in whole-body 
glucose uptake from pre- to post-training (r = -0.83, P = 0.01). EGP in the basal state and 
during low-dose insulin infusion, HISI (Figure 6.5c) and %EGPsupp (Figure 6.5d), each markers 
of hepatic insulin sensitivity in the fasted or insulin-stimulated states respectively, did not differ 
across study visits (P ≥ 0.37; Table 6.1).  
Fasted blood glucose, plasma NEFA and Adipo-IR remained unchanged across the study visits 
(P ≥ 0.13; Table 6.1). From pre- to post-training, fasted serum insulin (-13.9% [-24.9 to -2.9%], 
g* = -0.48, P = 0.04) and HOMA-IR (-16.6% [-27.5 to -5.6%], g* = -0.56, P = 0.02) were 
reduced. However, these reductions were similar in magnitude to the increases from baseline 
to pre-training (unadjusted P = 0.06 and P = 0.07, respectively) such that post-training values 
were no different from those measured at baseline (P ≥ 0.68; Table 6.1). 
Figure 6.4 Serum insulin concentrations throughout dual-step hyperinsulinaemic, 
euglycaemic clamp assessments. Data presented as mean ± SD (n=8). 
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Figure 6.5 a-b) Peripheral and c) basal and d) insulin-stimulated hepatic insulin 
sensitivity measured at baseline, pre- and post-training. Data in ‘A’ and ‘D’ presented as 
mean ± SD (n=8). #Data in ‘C’ are not normally distributed and thus presented as median 
(IQR). Data in ‘B’ are % change from pre- to post-training measurements for each participant. 
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6.5  Discussion 
The principal findings of this study are that a six-week SIT intervention is feasible for 
individuals with NAFLD and is well adhered to in a controlled laboratory setting. Furthermore, 
six weeks of SIT reduces IHTG and VAT in the absence of body weight change and, whilst 
hepatic insulin sensitivity appears to be unaffected, changes in peripheral insulin sensitivity are 
highly variable between individuals.  
This study reports almost perfect adherence to a six-week SIT intervention in nine individuals. 
Specifically, every participant completed the exercise programme, attending all 18 training 
sessions. Eight participants completed all 90 of the prescribed intervals whilst the remaining 
participant completed 87 intervals, with the three missing intervals contained within the first 
two training sessions. The implication is that individuals with NAFLD are able and willing to 
perform exercise training sessions composed of bursts of maximal exercise. This is important 
because observational evidence (Kistler et al., 2011) and experimental data (Cho et al., 2015; 
Oh et al., 2017) suggest that high-intensity exercise may be more potent in attenuating IHTG 
accumulation and NAFLD progression than moderate-intensity exercise. This SIT intervention 
may, therefore, represent a model of exercise that facilitates the completion of more intense 
exercise in individuals with NAFLD. This intervention was performed in a tightly controlled 
laboratory setting, with specialist equipment and where participants were individually 
supported by the research team. The participants recruited to this study were also screened 
thoroughly to ensure the absence of advanced cardiometabolic disease and may, therefore, not 
be representative of the majority of individuals with NAFLD. Given that the risk of an acute 
cardiac event during exercise is elevated in previously inactive individuals with established 
cardiometabolic disease (Thompson et al., 2007), the implementation of SIT requires 
additional scrutiny. The necessity for medical clearance and acclimatisation to exercise must 
be considered in this context (Riebe et al., 2015).  
This study reports a mean absolute reduction in IHTG of 2.1% after six weeks of SIT in 
individuals with elevated IHTG (relative change from baseline: -12.4%). Previous studies 
employing aerobic and resistance exercise, combined or in isolation, report a reduction of 
similar magnitude (10 to 21%) in the absence of significant weight loss (Johnson et al., 2009; 
Hallsworth et al., 2011; Sullivan et al., 2012; Keating et al., 2015; Pugh et al., 2016; Houghton 
et al., 2017). However, greater reductions in IHTG (27 to 42%) have been reported when 
significant weight loss occurs as a result of exercise training (Hallsworth et al., 2015; Keating 
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et al., 2015; Cuthbertson et al., 2016; Zhang et al., 2016). Therefore, whilst the independent 
effects of exercise on IHTG are recognised (Brouwers et al., 2016), the greatest benefits occur 
when exercise contributes to a negative energy balance. 
It was beyond the scope of this study to examine the mechanisms through which SIT reduced 
IHTG. However, some speculative inferences can be made. There was a small reduction in 
mean body weight from pre- to post-SIT (mean 1.2 kg) which, whilst not statistically 
significant, may have impacted on the reduction in IHTG reported. Using the established, albeit 
simplified, rule of thumb that a 3500 kcal energy deficit corresponds to an approximate 1 lb 
loss of fat mass (Guth, 2014), and assuming that substantial changes in lean body mass over 
the 6 week SIT intervention are unlikely, the 1.2 kg (2.65 lbs) weight loss reported in this study 
corresponds to a total energy deficit of approximately 9275 kcal. Previous studies have reported 
that the energy expenditure of a single SIT session is approximately 143 kcal (Deighton et al., 
2013). Therefore, the total energy expenditure that can be attributed to our intervention (18 
sessions) is approximately 2574 kcal. Consequently, the intervention alone does not account 
for the weight loss reported in this study. Habitual physical activity was consistent across the 
duration of our study, but it may be that changes in energy intake or other components of daily 
energy balance (such basal metabolic rate) may have occurred. The exact nature of these 
potential changes is unclear at present, with the exiting literature reporting large heterogeneity 
in compensatory responses to SIT at both the individual and study level (Taylor et al., 2018; 
Schubert et al., 2017). 
In addition to the small degree of weight loss reported, metabolic factors may also underpin 
the reported change in IHTG (Brouwers et al., 2016). Neither fasted circulating NEFA nor 
Adipo-IR differed throughout the current study, suggesting that an improvement in adipose 
tissue insulin sensitivity in the fasted state is unlikely to be responsible for the reduction in 
IHTG with training. However, the possibility that changes in postprandial adipose tissue insulin 
sensitivity occurred cannot be dismissed (Brouwers et al., 2016). Circulating glucose 
stimulates hepatic de novo lipogenesis (Ameer et al., 2014) and, although fasted blood glucose 
was unchanged throughout the study, post-prandial glucose is likely to have been reduced in 
those with improved peripheral insulin sensitivity. Therefore, particularly in individuals who 
displayed improvements in whole-body glucose uptake, a reduction in hepatic de novo 
lipogenesis may have contributed to post-training reductions in IHTG (Linden et al., 2015). 
Lastly, altered very low-density lipoprotein metabolism is unlikely to be responsible for 
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exercise-induced reductions in IHTG (Sullivan et al., 2012) but enhanced capacity to oxidise 
hepatic lipid is possible (Linden et al., 2015).  
Peripheral insulin sensitivity increased throughout this study but individual changes from pre- 
to post-SIT were highly variable and, despite a mean relative increase of 18.1% and a moderate 
effect size, this change was not statistically significant. In obese but otherwise healthy men, 
four weeks (Cocks et al., 2015), but not two weeks (Whyte, Gill and Cathcart, 2010), of SIT 
increased peripheral insulin sensitivity. However, 15 to 20% of individuals may display 
minimal, or even adverse, responses after exercise training in outcomes related to glucose 
homeostasis (Stephens and Sparks, 2015) and insulin sensitivity improved in only 10 out of 12 
healthy individuals who completed a two-week SIT intervention, remaining unchanged in one 
and decreasing in another (Richards et al., 2010). This degree of variation in response to 
exercise is consistent with our findings where peripheral insulin sensitivity improved in 75% 
of participants after SIT, yet was reduced in 25%. Given this variation, a greater sample size 
may be required to detect significant differences in peripheral insulin sensitivity following SIT. 
A retrospective sample size calculation indicates that, with the current change in whole-body 
glucose uptake (mean ± SD = 0.99 ± 1.41 mg·kg-1·min-1; thus standardised difference = 0.70; 
within-person correlation = 0.63), 14 individuals would have been required to detect a 
statistically significant difference from pre- to post-training with 80% power and an alpha error 
rate of 0.05. A number of factors, including genetic polymorphisms, epigenetics and baseline 
participant characteristics, may impact on individual responses (Böhm et al., 2016). 
Neither basal nor insulin-stimulated hepatic insulin sensitivity are changed after six weeks of 
SIT. Our findings agree with data showing no change in hepatic insulin sensitivity after 12 
weeks of aerobic training in patients with NAFLD, despite significant reductions in body 
weight (Cuthbertson et al., 2016). EGP during low-dose insulin infusion is reduced after 
aerobic or combined aerobic-plus-resistance exercise training in sedentary, healthy individuals 
and in patients with T2DM (Shojaee-Moradie et al., 2007; Meex et al., 2010). However, neither 
of these studies report changes in basal EGP or HISI, and the change at low-dose insulin 
infusion reported by Meex et al. was no longer statistically significant when presented 
as %EGPsupp. EGP in both the basal state and during low-dose insulin infusion was reduced in 
overweight, older women after a 9-month moderate-intensity aerobic exercise intervention 
(DiPietro et al., 2006). However, this may have been due to notably higher rates of EGP in this 
group at baseline compared to both the control group, and a separate group completing a higher-
intensity exercise programme. The high-intensity exercise training had no effect on EGP in 
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either the basal or insulin-stimulated states (DiPietro et al., 2006). The lack of improvements 
in hepatic insulin sensitivity in the current study may be due to insufficient intervention 
duration or because IHTG at the end of the intervention remained elevated (Cuthbertson et al., 
2016). Hepatic insulin sensitivity, assessed as %EGPsupp, may be impaired with as little as 1.5% 
IHTG, with no further deterioration as IHTG increases (Bril, Barb, et al., 2017). Post-training 
IHTG values in the present study ranged from 4.3 to 25.9% (mean 12.4%).  
The favourable changes in IHTG, VAT, HDL and cardiorespiratory fitness in response to SIT 
are important for individuals with NAFLD. NAFLD is intricately related to the metabolic 
syndrome and associated with an elevated risk of T2DM, cardiovascular and renal disease 
(Byrne and Targher, 2015). Ectopic lipid and dyslipidaemia are components of the metabolic 
syndrome and improvements in these risk factors are important in the treatment of NAFLD. 
Additionally, cardiorespiratory fitness is a marker of metabolic health and inversely associated 
with all-cause and cardiovascular mortality (Blair et al., 1989; Kodama et al., 2009). The large 
increase following SIT most likely reflects metabolic adaptations within skeletal muscle 
(Gibala et al., 2012), which may provide benefit via improved substrate metabolism (Rabøl et 
al., 2011; Brouwers et al., 2016). Collectively, the present study demonstrates the potential of 
SIT to elicit relevant metabolic improvements in men with NAFLD, but it is notable that the 
magnitude of response over this intervention was insufficient to re-establish values in an 
optimal range. Furthermore, we report no effect of SIT on other cardiovascular risk factors, 
such as circulating TG, total cholesterol and LDL. Each of these have been previously shown 
to be reduced by exercise training (Garber et al., 2011). Whilst our null findings may be the 
result of a lack of statistical power, we report a small effect size from pre- to post-SIT for each 
of these outcomes (g* = -0.21 to -0.35). Alternatively, it may be that the intervention was 
insufficient in duration or that more traditional forms of exercise training, such as CME, which 
are associated with greater energy expenditure and weight loss, may be required to elicit potent 
benefits on these outcomes.  
It should also be noted that we saw no significant change in circulating hepatokines as a result 
of our SIT intervention and the effect size for each hepatokine measured was trivial. As stated 
previously, however, changes in body weight, IHTG and indices of metabolic health were also 
small in this study. It may be larger changes in metabolic parameters than those seen in the 
current study are required to modulate circulating hepatokine concentrations. 
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A strength of this study is the use of the most precise techniques available to assess key 
outcomes. Conversely, this study was conducted in a relatively small and homogenous sample 
of white European men with no other chronic metabolic disease. We may have lacked statistical 
power to detect differences in some of our outcomes following training and null-findings may 
be the result of type II error. The findings of this study may also not be generalisable to women, 
individuals of different ethnicity or those with metabolic co-morbidities. Furthermore, 
participants did not have a formal diagnosis of NAFLD so we have no information regarding 
disease severity. An RCT design would also have been preferred. However, the inclusion of a 
control phase within our within-measures study design was chosen to monitor variation in study 
outcomes over a period of no intervention, whilst avoiding the additional recruitment of a non-
exercise control group.  
In this study we have shown that men with NAFLD are compliant with SIT which, over six 
weeks, improves cardiorespiratory fitness and reduces IHTG and VAT, without altering body 
weight. Furthermore, changes in peripheral insulin sensitivity with training are highly variable 
between individuals, whilst hepatic insulin sensitivity remains unchanged. These results 
support the potential for interval-based, high-intensity exercise as an alternative to continuous 
moderate-intensity exercise in the management of NAFLD. However, larger RCTs are required 
to test the effectiveness of SIT in diverse populations, as well as its applicability in a clinical 
setting, sustainability over time and efficacy in individuals with advanced NAFLD. 
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CHAPTER 7 
  
 THE EFFECT OF EXERCISE TRAINING ON 
INTRAHEPATIC TRIGLYCERIDE AND HEPATIC INSULIN 
SENSITIVITY: A SYSTEMATIC REVIEW AND META-
ANALYSIS  
 
 
 
 
 
 
 
 
 
 
 
 
This study presented in this chapter has been published and has the following citation: 
Sargeant JA, Gray LJ, Bodicoat DH et al. (2018). Obesity Reviews. 19: 1446-1459. 
This chapter presents the published manuscript. 
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7.1  Abstract 
This systematic review and meta-analysis determined the impact of structured exercise training, 
and the influence of associated weight loss, on intrahepatic triglyceride (IHTG) in individuals 
with non-alcoholic fatty liver disease (NAFLD). It also examined its effect on hepatic insulin 
sensitivity in individuals with or at increased risk of NAFLD. Analyses were restricted to 
studies using magnetic resonance spectroscopy or liver biopsy for the measurement of IHTG 
and isotope-labelled glucose tracer for assessment of hepatic insulin sensitivity. Pooling data 
from 17 studies (373 exercising participants), exercise training for one to 24 weeks (mode: 12 
weeks) elicits an absolute reduction in IHTG of 3.31% (95% CI: -4.41 to -2.22%). Exercise 
reduces IHTG independent of significant weight change (-2.16 [-2.87 to -1.44]%), but benefits 
are substantially greater when weight loss occurs (-4.87 [-6.64 to -3.11]%). Furthermore, meta-
regression identified a positive association between percentage weight loss and absolute 
reduction in IHTG (β = 0.99 [0.62 to 1.36], P<0.001). Pooling of six studies (94 participants) 
suggests that exercise training also improves basal hepatic insulin sensitivity (mean change in 
hepatic insulin sensitivity index: 0.13 [0.05 to 0.21] mg·m-2·min-1 per μU·mL-1), but available 
evidence is limited and the impact of exercise on insulin-stimulated hepatic insulin sensitivity 
remains unclear.  
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7.2  Introduction 
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease 
worldwide (Younossi et al., 2016) and a prominent risk factor for cardiovascular disease, 
chronic kidney disease and type 2 diabetes mellitus (T2DM) (Byrne and Targher, 2015). Insulin 
resistance promotes hepatic lipid accumulation, which is most commonly assessed via the 
measurement of intrahepatic triglyceride (IHTG) (Samuel et al., 2004; Taylor, 2008; 
Kumashiro et al., 2011; Shulman, 2014). The associated accumulation of lipid intermediates, 
such as diacylglycerol (DAG), may in turn perpetuate insulin resistance (Samuel et al., 2004; 
Taylor, 2008; Kumashiro et al., 2011; Shulman, 2014); providing a mechanistic link between 
NAFLD and impaired metabolic regulation. As such, strong associations exist between excess 
IHTG and insulin resistance in multiple tissues, including the liver (Korenblat et al., 2008; 
Shulman, 2014; Bril, Barb, et al., 2017). Defects in hepatic insulin signalling contribute to 
elevated endogenous glucose production (EGP) which is integral to the pathophysiology of 
impaired glucose regulation and T2DM (Taylor, 2008; Rizza, 2010; Petersen, Vatner and 
Shulman, 2017). 
Prompted by reports that exercise training has the capacity to reduce IHTG in the absence of 
weight loss (Johnson et al., 2009; Sullivan et al., 2012), the independent effects of exercise in 
the treatment of NAFLD have been examined (Keating et al., 2012; Orci et al., 2016; Smart et 
al., 2016; Hashida et al., 2017; Katsagoni et al., 2017). These reviews confirm the ability of 
exercise to reduce IHTG without significant weight change; however, the importance of the 
exercise-related energy deficit and subsequent weight loss has not been investigated thoroughly. 
Acute and sustained energy restriction and weight loss potently reduces IHTG in individuals 
with NAFLD (Kirk et al., 2009; Hickman et al., 2013) and therefore logic dictates that weight 
loss associated with exercise training would be an important mediator of the IHTG response to 
exercise training. This issue has practical implications for the prescription of exercise in the 
management of NAFLD and thus deserves explicit attention.  
Previous reviews highlight a range of different methods to estimate IHTG, including non-
invasive imaging by ultrasound (US) or computed tomography (CT), proton magnetic 
resonance spectroscopy (1H-MRS) and invasive liver biopsy. The inclusion of multiple 
methods within these reviews has the benefit of broadening study eligibility and thus increasing 
pooled participant sample size. However, it also adds an additional source of heterogeneity. 
US and CT are also limited by a lack of sensitivity to detect mild-to-moderate accumulation of 
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IHTG and to quantify subtle changes resulting from experimental interventions (Festi et al., 
2013). 1H-MRS has much greater precision (Bawden, Scott and Aithal, 2017), making it a more 
suitable method for experimental research, whilst the necessity to characterise histological 
features beyond steatosis make liver biopsy the standard tool in clinical practice (Marchesini 
et al., 2016; Chalasani et al., 2018).  
The effect of exercise training on hepatic insulin sensitivity has not been reviewed. A number 
of indices exist which assess insulin resistance using simple circulating biomarkers (Matsuda 
and DeFronzo, 1999) but stable or radioactive isotope-labelled tracers are required to obtain 
the most accurate measurement of insulin sensitivity in individual tissues (Kim et al., 2016). 
Glucose tracers can be used to quantify EGP (primarily attributed to hepatic glucose production) 
(Petersen, Vatner and Shulman, 2017) to accurately assess hepatic insulin sensitivity in the 
basal (fasted) and insulin-stimulated (post-prandial) states; using the hepatic insulin sensitivity 
index (HISI) and percentage suppression of EGP (%EGPsupp) by low-dose insulin infusion, 
respectively (DeFronzo, Simonson and Ferrannini, 1982; Matsuda and DeFronzo, 1999). 
This systematic review and meta-analysis had two primary aims. First, we investigated the 
effects of structured exercise training on IHTG in individuals with NAFLD, with a particular 
focus on the impact of concurrent weight loss, whilst restricting analyses to studies using 1H-
MRS and liver biopsy. Second, we explored the effects of exercise training on basal and 
insulin-stimulated hepatic insulin sensitivity. 
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7.3  Methods 
The current systematic review and meta-analysis (PROSPERO ID: CRD42014007268) was 
conducted in accordance with the “Cochrane handbook for systematic reviews of interventions” 
and PRISMA guidelines (Moher et al., 2009; Higgins and Green, 2011). All aspects of the 
literature search, study selection and risk of bias assessment were completed by two researchers 
independently (Jack Sargeant and James King/Scott Willis). Data extraction and analysis were 
performed by a single researcher (Jack Sargeant) before being checked, independently, by 
another (extraction: James King; analysis: Danielle Bodicoat/Laura Gray). 
7.3.1 Primary outcomes 
This review had two outcome measures: 
• IHTG 
• Hepatic insulin sensitivity (basal and insulin-stimulated) 
Eligible studies were restricted to those using 1H-MRS or liver biopsy for the measurement of 
IHTG and using isotope-labelled glucose tracer to quantify EGP in the fasted state and 
following low-dose (≤ 20 mU·m-2·min-1 or ≤ 0.5 mU·kg-1·min-1) insulin infusion, for the 
calculation of HISI and %EGPsupp, respectively. 
7.3.2 Literature search 
Six electronic online databases (EMBASE, MEDLINE, PubMed, Scopus, Sport Discus and 
Web of Science) were searched from inception to July 2017 using the following terms related 
to exercise, IHTG and hepatic insulin sensitivity (all terms within brackets were combined 
using ‘OR’):  
(exercise, physical activity, training) AND [(liver fat, hepatic fat, intrahepatic triglyceride, 
IHTG, intrahepatocellular lipids, intrahepatic lipids, non-alcoholic fatty liver disease, 
NAFLD, non-alcoholic fatty liver, fatty liver, hepatic steatosis, non-alcoholic steatosis, liver 
steatosis, non-alcoholic steatohepatitis, NASH, hepatic steatohepatitis, liver steatohepatitis, 
liver function) OR (hepatic insulin sensitivity, hepatic insulin resistance, liver insulin 
sensitivity, liver insulin resistance, hepatic IR, liver IR, hepatic glucose production, liver 
glucose production, endogenous glucose production, glycolysis, gluconeogenesis)]. 
Reference lists of all included manuscripts were screened for further eligible studies.  
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7.3.3 Study selection 
Human experimental studies written in the English language were included. Conference 
abstracts were considered but underwent the same eligibility and risk of bias assessments as 
full articles. Eligible studies were those in which participants with overweight or obesity 
completed an exercise training programme of at least three exercise sessions. All types of study 
design were considered. Studies investigating changes in IHTG were only eligible if 
participants had diagnosed NAFLD or where baseline characteristics met diagnostic criteria 
(IHTG > 5% in the absence of secondary steatogenic sources, including excessive alcohol 
intake and viral infection) (Marchesini et al., 2016; Chalasani et al., 2018). NAFLD was not 
an inclusion criterion for studies investigating changes in hepatic insulin sensitivity as it 
became apparent that very few studies have examined this outcome exclusively in this patient 
group and several otherwise eligible studies did not measure IHTG. Studies investigating 
exercise in combination with dietary intervention were eligible only when data were available 
for matched, independent groups prescribed exercise training with or without diet. In studies 
measuring hepatic insulin sensitivity, it was essential that participants refrained from strenuous 
exercise for at least 48 hours before assessments (Sylow et al., 2017). 
7.3.4 Data extraction 
Descriptive information (first author and year of publication), details of study design, 
participant and intervention characteristics and outcome data were extracted from eligible 
manuscripts. Outcome data were extracted as mean change and standard deviation from pre- 
to post-intervention for all exercise groups, as well as for the control groups of randomised 
controlled trials (RCTs). Where possible, outcome data presented in alternative forms were 
converted as outlined in Appendix X. When data were presented in graphical form only, values 
were estimated using commercially available software (Digitizeit, Version 2.2, Bormann, I., 
Braunschweig, Germany). When incomplete or insufficient data were reported, the authors 
were contacted and if the required data were unavailable the study was removed. When 
characteristics of exercise interventions (such as the frequency, intensity or duration of exercise 
sessions) progressed over the course of a programme, a weighted mean was calculated. Further 
details of data extraction can be found in Appendix X. 
A number of variations of HISI exist, including the statistical inverse (the hepatic insulin 
resistance index; HIRI). Studies reporting these alternatives were included in qualitative review 
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but were only included in quantitative meta-analysis when raw data were available for the 
calculation of HISI as originally described (Matsuda and DeFronzo, 1999): 
1000 / (EGP [mg·m-2·min-1] x fasted plasma insulin [µU·mL-1]) 
Studies that reported EGP and fasted plasma insulin (FPI) separately were also considered, but 
were excluded from all analyses unless raw data were available for the calculation of HISI as 
above. Mean values of EGP and FPI were not combined. Similarly, when study design allowed 
the calculation of %EGPsupp but it was not reported, raw data were requested. 
7.3.5 Risk of bias assessment 
Studies were assessed for risk of bias using a modified Downs and Black scale (Downs and 
Black, 1998). This checklist includes 26 items divided into categories of (i) reporting, (ii) 
external validity, (iii) internal validity – bias, (iv) internal validity – confounding and (v) power. 
The Downs and Black scale was modified in two ways. Blinding participants and 
experimenters to group allocations is a difficult task in exercise trials. It is possible, however, 
to blind experimenters who are conducting data analysis. As such, item 14 of the original scale 
(concerning participant blinding) was removed, whilst item 15 (concerning experimenter 
blinding) was scored according to whether attempts were made to blind experimenters during 
data analysis. Item 27, concerning statistical power, was modified as follows: 
Formal power calculation performed based on detecting a significant change in IHTG = 
score of two awarded 
Formal power calculation performed based on detecting a significant difference in a relevant 
and related outcome but which was not IHTG = score of one awarded 
No formal power calculation performed = score of zero awarded. 
Consensus between the two independent assessors (Jack Sargeant/James King) was ensured. 
Publication bias was assessed using funnel plots. 
7.3.6 Meta-analyses 
Pooled characteristics of study participants are presented as weighted means, accounting for 
differences in sample size, along with the range. Quantitative analysis was conducted using 
commercially available software (Stata IC, Version 14.1, StataCorp LP, Texas, USA). Pooled 
mean differences with 95% confidence intervals (95% CI) were calculated for primary 
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outcomes using random effects models and heterogeneity was assessed quantitatively using the 
I2 statistic. 
Where possible, primary outcomes were analysed in two ways: 
• Within-group analysis: The change from pre- to post-intervention measurements in all 
exercise groups of all eligible studies. 
• Between-group analysis: The difference in the change from pre- to post-intervention 
between exercise and control groups in RCTs only. 
In RCTs with multiple intervention groups, the intervention groups were combined, where 
possible, using appropriate statistical formulae (Higgins and Green, 2011) and, for the purpose 
of exercise programme description, the exercise intensity, duration and frequency of the 
combined group were calculated as the weighted mean of the individual groups. When groups 
were not suitable to be combined (for example, aerobic and resistance exercise training groups), 
data from the aerobic intervention group was used. 
7.3.7 Subgroup analyses and meta-regression 
Subgroup analyses were performed to investigate whether the presence of significant weight 
loss (defined as a statistically significant reduction in body weight from pre- to post-
intervention) explained heterogeneity in the response of IHTG to exercise training. The 
influence of the exercise mode (aerobic, high-intensity interval (HIIT), resistance or combined 
aerobic/HIIT-plus-resistance training) was also investigated, as was the exercise intensity 
(moderate- or high-intensity) of aerobic and HIIT interventions. Exercise intensity was 
categorised according to published criteria (Garber et al., 2011), which are summarised in 
Table 7.1. One study (Meex et al., 2010) prescribed exercise relative to maximal workload. 
This study was categorised using the same percentage categories as those of V̇O2 peak. Meta-
regression was also performed to explore the effects of intervention duration and the magnitude 
of body weight change on changes in IHTG. All subgroup analyses and meta-regressions were 
performed using the mean change from pre- to post-training in all exercise groups of eligible 
studies. Secondary analyses of hepatic insulin sensitivity were not performed due to the limited 
number of studies identified. 
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Table 7.1 Categories of exercise intensity 
Adapted from (Garber et al., 2011); %HR max: percentage of maximal heart rate; %HRR: 
percentage of heart rate reserve; %V̇O2 peak: percentage of peak oxygen uptake; RPE: rating 
of perceived exertion (Borg, 1970). 
 RPE %HR max %HRR  %V̇O2 peak 
Moderate-intensity 12 – 13 64 – 76 40 – 59 46 – 63 
High-intensity 14 – 17 77 – 95 60 – 89 64 – 90 
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7.4  Results 
7.4.1 Literature search 
Figure 7.1 presents a flowchart of the literature search and study selection processes. To 
summarise, 20,055 records were returned by the six online databases, along with five from 
reference lists of eligible manuscripts. Of these, 111 manuscripts underwent full assessment 
and 21 were eligible for inclusion (20 for meta-analyses). Twenty were complete articles and 
one was a conference abstract, although the latter has since been published in full (Sargeant, 
Bawden, et al., 2018). Table 7.2 presents an overview of all eligible studies and readers are 
directed to Appendix XI for more detailed description of participant and intervention 
characteristics for each study. 
 
Figure 7.1 Flowchart of literature search process 
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Table 7.2 Overview of included studies (continued overleaf) 
First Author 
(Year of 
Publication) 
Study  
Design 
Sample Size  
(M/F) 
Exercise 
Mode 
Intervention 
Duration 
Session 
Frequency 
Exercise 
Intensity 
(Category) 
Technique 
used for 
Assessment 
of IHTG 
Index of 
Basal 
Hepatic IS 
Originally 
Reported 
Details of Low-
Dose Insulin 
Infusion 
Weight 
Change with 
Exercise 
Training 
(mean % 
change from 
baseline) 
Cassidy  
(2016) RCT 
Ex: 12 (10/2) 
Con: 11 (8/3) 
HIIT 12 weeks 3 times per week High 
1H-MRS - - -1.1 β 
Cuthbertson 
(2016) RCT 
Ex: 30 (23/7) 
[12 (8/3/1 NR)] 
Con: 20 (16/4) 
[7 (3/4)] 
Aerobic 16 weeks 3 – 5 times per week Moderate 
1H-MRS HIRI 0.3 mU•kg
-1•min-1 
for 120 min -2.5 
α, β 
Hallsworth  
(2011) RCT 
Ex: 11 (NR) 
Con: 8 (NR) 
Resistance 8 weeks 3 times per week N/A 
1H-MRS - - 0.0 
Hallsworth  
(2015) RCT 
Ex: 12 (6/6) 
Con: 11 (10/1) 
HIIT 12 weeks 3 times per week High 
1H-MRS - - -1.6 α, β 
Haus  
(2013) 
Uncontrolled 
Intervention Ex: 17 (NR) Aerobic 1 week 
7 times per 
week High 
1H-MRS - - 0.2 
Hickman  
(2013) RCT
* 
Ex: 9 (7/2) 
[13 (9/4)] 
Resistance 24 weeks 3 times per week N/A Biopsy
† HIRI - -2.6 
Houghton  
(2017) RCT 
Ex: 12 (7/5) 
Con: 12 (7/5) 
Combined 
(HIIT + 
Resistance) 
12 weeks 3 times per week High 
1H-MRS - - 1.1 
Johnson  
(2009) RCT 
Ex: 12 (NR) 
Con: 7 (NR) 
Aerobic 4 weeks 3 times per week Moderate 
1H-MRS - - -0.3 
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Keating  
(2015) RCT 
Ex1: 12 (6/6) 
Ex2: 11 (5/6) 
Con: 12 (3/9) 
Aerobic 8 weeks 
Ex1: 3 
sessions per 
week 
Ex2: 4 
sessions per 
week 
Ex1: High 
Ex2: Moderate 
1H-MRS - - 
Ex1: -1.2 α, β 
Ex2: -1.5 α, β 
Langleite  
(2016) 
Uncontrolled 
Intervention Ex: 11 (11/0) 
Combined 
(Aerobic + 
HIIT + 
Resistance) 
12 weeks 
4 times per 
week 
(1 aerobic,  
1 HIIT, 2 
resistance) 
High 1H-MRS - - -1.2 
Lee  
(2013) RCT 
Ex1: [16 (0/16)] 
Ex2: [16 (0/16)] 
Con: [12 (0/12)] 
Ex1: 
Aerobic 
Ex2: 
Resistance 
12 weeks 3 times per week High - HISI
† - 
Ex1: -1.3 
Ex2: -0.3 
Malin  
(2013) 
Uncontrolled 
Intervention Ex: 13 (6/7) Aerobic 1 week 
7 times per 
week High 
1H-MRS - - 0.6 
Meex  
(2010) 
Uncontrolled 
Intervention 
Ex1: [20 (20/0)] 
Ex2: [17 (17/0)] 
Combined 
(Aerobic + 
Resistance) 
12 weeks 
3 times per 
week  
(2 aerobic, 1 
resistance)  
Moderate - HISI# - 
Ex1: -1.1 
Ex2: -1.0 
Oh  
(2014) 
Uncontrolled 
Intervention Ex: 18 (4/14) 
Vibration / 
Acceleration 6 weeks 
3 times per 
week N/A 
1H-MRS - - -0.4 α 
Pugh  
(2014) RCT 
Ex: 13 (7/6) 
Con: 8 (4/4) 
Aerobic 16 weeks 3 – 5 times per week Moderate 
1H-MRS - - -2.4 
Sargeant  
(2018) 
Controlled 
Longitudinal 
Intervention 
Ex: 9 (9/0) 
[8 (8/0)] 
HIIT 6 weeks 3 times per week High 
1H-MRS HISI 20 mU•m
-2•min-1 
for 120 min -1.2 
Shojaee-
Moradie  
(2007) 
RCT 
Ex: [10 (10/0)] 
Con: [7 (7/0)] 
Aerobic 6 weeks 3 times per week High - HISI
# 0.3 mU•kg
-1•min-1 
for 120 min -0.8 
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Sullivan  
(2012) RCT 
Ex: 12 (4/8) 
Con: 6 (1/5) 
Aerobic 16 weeks 5 times per week Moderate 
1H-MRS - - -0.2 α 
van der 
Heijden  
(2010a)‡ 
Uncontrolled 
Intervention 
Ex: 15 (7/8) 
[15 (7/8)] 
Aerobic 12 weeks 4 times per week High 
1H-MRS HISI - -0.5 
van der 
Heijden  
(2010b) 
Uncontrolled 
Intervention 
Ex: 7 (NR) 
[12 (6/6)] 
Resistance 12 weeks 2 times per week N/A 
1H-MRS HISI - 2.6 α 
Zhang  
(2016) RCT 
Ex1: 73 (22/51) 
Ex2: 73 (21/52) 
Con: 74 (28/46) 
Aerobic 24 weeks 5 times per week 
Ex1: Moderate 
Ex2: High 
1H-MRS - - 
Ex1: -2.8 α, β 
Ex2: -6.0 α β 
Sample sizes in squared brackets represent the number of participants included in hepatic insulin sensitivity outcomes; Mean changes in body 
weight with exercise are as reported in the original manuscript (α indicates significantly different from baseline, β indicates significantly different 
from non-exercise control group); Exercise intensity is categorised according to published criteria (Garber et al., 2011), which are summarised in 
Table 7.1; *Study did not include a ‘standard care’ or ‘no intervention’ group, exercise was compared with hypocaloric diet; †Study was excluded 
from one or more meta-analyses - Hickman et al (2013) was removed from meta-analyses of changes in hepatic steatosis to reduce heterogeneity 
as it was the only study using liver biopsy to assess IHTG. Lee et al (2013) was removed from meta-analysis of changes in basal hepatic insulin 
sensitivity because raw data were not available to allow re-calculation of HISI as outlined by Matsuda and DeFronzo (1999); #Published manuscript 
contained no index of hepatic insulin sensitivity. HISI was calculated after authors provided raw data; ‡Manuscript refers to the same study as van 
der Heijden et al (2009); Con: Control group; Ex1/2: Exercise group 1/2; N/A: not applicable; NR: not reported.
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7.4.2 Risk of bias assessment 
Full results of the risk of bias assessment can be found in Table 7.3. Studies scored highly on 
items related to reporting, with the exception of reporting adverse events, and internal validity. 
Seven studies (Johnson et al., 2009; Hallsworth et al., 2011; Hickman et al., 2013; Cassidy et 
al., 2016; Cuthbertson et al., 2016; Langleite et al., 2016; Zhang et al., 2016) blinded the 
investigators performing assessments of IHTG, but allocation concealment was only performed 
in three out of 10 RCTs (Cassidy et al., 2016; Langleite et al., 2016; Zhang et al., 2016). 
Conversely, studies scored poorly in relation to external validity, primarily due to an inability 
to determine whether recruited participants were representative of the entire population or of 
those who were approached to participate. One study (Keating et al., 2015) performed a power 
calculation on IHTG to detect change between groups indicating that 116 participants were 
required per group. However, due to limited data to inform this power calculation and the 
difficulties in performing a study of that design in such large numbers they did not recruit to 
this extent. Given that 1) the purpose of this meta-analysis was not to determine differences 
between groups, 2) they had attempted to perform an appropriate calculation and 3) the 
numbers they did recruit were similar to those of other suitably powered studies, a score of two 
was awarded for item 27 (statistical power). Funnel plots suggested minimal evidence of 
publication bias (Figure 7.2a-c), although the plot of all intervention groups investigating IHTG 
(Figure 7.2a) suggested a small bias towards studies reporting small effects. This would, if 
anything, result in an attenuated pooled effect.  
Seven studies recorded energy intake using self-reported food diaries (Johnson et al., 2009; 
Haus et al., 2013; Oh et al., 2014; Pugh et al., 2014; Keating et al., 2015; Cuthbertson et al., 
2016) or a validated food frequency questionnaire (Langleite et al., 2016). All of these reported 
no change in energy intake from pre- to post-intervention, although one (Keating et al., 2015) 
reported a small increase in carbohydrate intake in participants completing a high-intensity, 
low-volume exercise programme. One study (Lee et al., 2013) prescribed a weight 
maintenance diet to participants. A further 10 studies instructed participants to maintain their 
dietary habits throughout the duration of study involvement without formally monitoring diet 
(Shojaee-Moradie et al., 2007; van der Heijden, Wang, Chu, Sauer, et al., 2010; van der 
Heijden, Wang, Chu, Toffolo, et al., 2010; Hickman et al., 2013; Malin, Mulya, et al., 2013; 
Hallsworth et al., 2015; Cassidy et al., 2016; Zhang et al., 2016; Houghton et al., 2017; 
Sargeant, Bawden, et al., 2018), whilst three manuscripts make no reference to the control of 
dietary intake (Meex et al., 2010; Hallsworth et al., 2011; Sullivan et al., 2012). 
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Table 7.3 Risk of bias assessment for all studies (legend overleaf) 
First Author  
(Publication Year) 
 
Item Category / Number 
Reporting External Validity Internal Validity: Bias* Internal Validity: Confounding Power 
1 2 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 21 22 23 24 25 26 27 
Cassidy (2016) 1 1 1 1 2 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 1 1 1 0 1 1 
Cuthbertson (2016) 1 1 1 1 2 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 1 0 0 1 2 
Hallsworth (2011) 1 1 1 1 2 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 1 0 0 1 2 
Hallsworth (2015) 1 1 1 1 2 1 1 0 1 1 0 0 1 0 1 1 1 1 1 1 1 1 0 0 1 2 
Haus (2013) 1 1 1 1 2 1 1 0 1 1 0 0 1 0 1 1 1 1 1 1 0 0 0 0 1 0 
Hickman (2013) 1 1 1 1 2 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 1 1 0 0 1 2 
Houghton (2017) 1 1 1 1 2 1 1 1 1 1 0 0 1 0 1 1 1 1 1 1 0 1 0 0 1 2 
Johnson (2009) 1 1 1 1 2 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 1 0 1 1 0 
Keating (2015) 1 1 1 1 2 1 1 0 1 1 0 0 1 0 1 1 1 1 1 1 1 0 0 0 1 2 
Langleite (2016) 1 1 1 1 2 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 1 1 1 1 0 
Lee (2013) 0 1 1 1 2 1 1 0 1 1 0 0 1 0 0 1 1 1 1 1 1 1 0 1 1 0 
Malin (2013) 1 1 1 1 2 1 1 0 1 1 0 0 1 0 1 1 1 1 1 1 1 0 0 0 1 0 
Meex (2010) 0 1 1 1 2 1 1 0 1 1 0 0 1 0 1 1 1 1 1 1 1 0 0 1 1 0 
Oh (2014) 1 1 1 1 2 1 1 0 1 1 0 0 1 0 1 1 1 0 1 1 1 0 0 0 1 0 
Pugh (2014) 1 1 1 1 2 1 1 0 1 1 0 0 1 0 1 1 1 1 1 1 0 1 0 0 1 1 
Sargeant (2018) 1 1 1 1 2 1 1 0 1 1 0 0 1 0 1 1 1 1 1 1 1 0 0 0 1 0 
Shojaee-Moradie (2007) 0 1 1 1 2 1 1 0 1 1 0 0 1 0 1 1 1 1 1 1 1 1 0 0 1 0 
Sullivan (2012) 1 1 1 1 2 1 1 1 1 1 0 0 1 0 1 1 1 1 1 1 0 1 0 0 1 2 
van der Heijden 
(2009 & 2010a)‡ 1 1 1 1 2 1 1 0 1 1 0 0 1 0 1 1 1 1 1 1 1 0 0 0 1 0 
van der Heijden (2010b) 1 1 1 1 2 1 1 0 1 0 0 0 1 0 0 1 1 1 1 1 0 0 0 1 1 2 
Zhang (2016) 1 1 1 1 2 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 1 1 1 0 1 2 
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Full marking criteria can be found in the appendix of the original article by Downs and Black (Downs and Black, 1998). * Item 14 of the Downs 
and Black scale (concerning participant blinding) was not scored in this meta-analysis as blinding participants to group allocation in exercise 
studies is very difficult and uncommon. Item 27 (concerning power) was amended as outlined above. A higher number represents a more positive 
score. ‡ Two manuscripts reporting separate outcomes of the same study.
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Figure 7.2 Funnel plots for assessment of publication bias in studies included in the 
following analyses: a) within-group change in IHTG, b) difference between groups in 
change in IHTG, and c) within-group change in HISI 
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7.4.3 The effects of exercise training on IHTG 
Eighteen studies reported the effects of exercise training on IHTG (Johnson et al., 2009; van 
der Heijden, Wang, Chu, Sauer, et al., 2010; van der Heijden, Wang, Chu, Toffolo, et al., 2010; 
Hallsworth et al., 2011, 2015; Sullivan et al., 2012; Malin, Mulya, et al., 2013; Haus et al., 
2013; Hickman et al., 2013; Oh et al., 2014; Pugh et al., 2014; Keating et al., 2015; Cassidy et 
al., 2016; Cuthbertson et al., 2016; Langleite et al., 2016; Houghton et al., 2017; Sargeant, 
Bawden, et al., 2018) (Table 7.2). Only one of these used paired liver biopsy (Hickman et al., 
2013), reporting no significant effect of 6-months resistance exercise on the percentage of 
hepatocytes affected by steatosis in individuals with NAFLD. The remaining 17 studies used 
1H-MRS to measure IHTG so, to reduce heterogeneity, only these studies were included in 
subsequent meta-analyses. These studies contained 19 exercise groups and a combined total of 
373 participants (male: 151 [40.5%]; female: 182 [48.8%]; data not reported: 40 [10.7%]). 
Participants had a weighted mean age of 50 [range 15.5 to 60] years and were overweight or 
obese (body mass index: 30.6 [27.8 to 37.1] kg·m-2; body fat percentage: 35.6 [28.7 to 43.7] %; 
waist circumference: 101.2 [95.2 to 111.9] cm). Participants were reported as sedentary and/or 
inactive and had low aerobic capacity (peak oxygen uptake: 25.2 [21.8 to 38.7] ml·kg-1·min-1). 
Two studies actively recruited individuals with T2DM (Cassidy et al., 2016) or dysregulated 
glucose metabolism (Langleite et al., 2016), whilst the mean baseline characteristics of seven 
other studies (Johnson et al., 2009; Hallsworth et al., 2011, 2015; Haus et al., 2013; Malin, 
Mulya, et al., 2013; Zhang et al., 2016; Houghton et al., 2017) met diagnostic criteria for 
impaired fasted glucose (weighted mean fasted glucose: 5.61 [4.09 to 6.80] mmol·L-1) 
(American Diabetes Association, 2018). The weighted mean IHTG at baseline was 15.8 [6.9 
to 23.1] %.  
Interventions included aerobic (n = 11), HIIT (n = 3), resistance (n = 2), combined 
aerobic/HIIT-plus-resistance (n = 2) and acceleration/vibration (n = 1) exercise training, 
ranging from seven days to 24 weeks (mode: 12 weeks). Session frequency ranged from two 
to seven times per week (mode: three times per week) for 30 to 60 minutes. Six aerobic 
interventions used moderate-intensity exercise whilst the remaining five, along with all of the 
HIIT interventions, were categorised as high-intensity.  
Ten of the included studies were RCTs, containing a combined 283 and 169 participants in 
exercise and control groups, respectively (Table 7.2). Pooled participant and intervention 
characteristics of RCTs only can be found in Tables 7.4 and 7.5. There were no significant 
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differences between the pooled characteristics of RCTs and those of all eligible studies (P ≥ 
0.13). Participants in RCT control groups were instructed to maintain standard care (n = 5) or 
habitual lifestyle activities (n = 1), prescribed a low-intensity stretching programme (n = 2) or 
attended sessions providing education on the health benefits of exercise (n = 2). 
 
Table 7.4 Pooled participant characteristics of RCTs included in meta-analysis of the 
effects of exercise training on IHTG (n = 10 studies) 
 Exercise Groups Control Groups 
Total participant number 283 169 
Male/Female/NR 111/149/23 77/77/15 
Age (years) 52 (45 to 61) 52 (39 to 62) 
Body weight (kg) 82.7 (71.4 to 103.0) 84.0 (72.1 to 113.7) 
BMI (kg·m-2) 30.2 (28.0 to 37.1) 30.2 (28.0 to 40.0) 
Body fat (%) 34.4 (30.4 to 38.9) 34.8 (31.0 to 42.5) 
Waist circumference (cm) 99.9 (95.5 to 110.0) 99.2 (93.7 to 109.0) 
Fasted glucose (mmol·L-1) 5.63 (4.30 to 6.80) 5.67 (4.00 to 7.00) 
V̇O2 peak (ml·kg-1·min-1) 23.6 (21.8 to 26.4) 22.3 (18.5 to 27.0) 
IHTG (%) 16.2 (6.9 to 21.3) 14.5 (7.1 to 21.4) 
Data presented as weighted mean with range. 
 
Table 7.5 Pooled intervention characteristics of RCTs included in meta-analysis of the 
effects of exercise training on IHTG (n = 10 studies) 
 Mode Range 
Intervention duration (weeks) 12 4 to 24 
Session frequency (times per week) 3 3 to 5 
Session duration (min) - 30 to 53 
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Fourteen of the 17 studies reported a statistically significant benefit of exercise on IHTG either 
within-group (van der Heijden, Wang, Chu, Sauer, et al., 2010; Oh et al., 2014; Pugh et al., 
2014; Langleite et al., 2016; Sargeant, Bawden, et al., 2018), between-group (Johnson et al., 
2009; Sullivan et al., 2012), or both (Hallsworth et al., 2011, 2015; Keating et al., 2015; 
Cassidy et al., 2016; Cuthbertson et al., 2016; Zhang et al., 2016; Houghton et al., 2017). In 
the two studies with multiple exercise groups, exercise elicited a significant reduction in both 
groups (Keating et al., 2015; Zhang et al., 2016). One RCT reported a significant reduction 
from baseline, but this was not significant when compared to the change in the control group 
(Pugh et al., 2014). Of the three studies that reported no benefit of exercise, two were short 
interventions (performing exercise on seven consecutive days) (Haus et al., 2013; Malin, 
Mulya, et al., 2013), whilst the other was a resistance exercise programme in obese adolescents 
(van der Heijden, Wang, Chu, Toffolo, et al., 2010). 
When data from pre- to post-exercise in all interventions were pooled, a statistically significant 
benefit of exercise training was found (Figure 7.3), but high heterogeneity was also apparent. 
In a sensitivity analysis of RCTs only, the significant benefit of exercise was strengthened 
(mean difference in change between groups [95% CI]: -3.61 [-4.68 to -2.54] %; Figure 7.4), 
and results were highly homogeneous (I2 < 0.1%, P = 0.84). Therefore, to allow the inclusion 
of maximum data, subgroup analyses and meta-regressions were performed using the within-
group change in all interventions. 
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Figure 7.3 Meta-analysis of the pooled effect of exercise training on IHTG from pre- to 
post-training in all exercise groups of all eligible studies. Studies are grouped by exercise 
mode. 
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Figure 7.4 Meta-analysis of the pooled effect of exercise training on IHTG using eligible 
RCTs only 
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Exercise training significantly reduced IHTG in the absence of weight loss. However, when 
significant weight loss occurred, the pooled effect was substantially greater (Figure 7.5). 
Furthermore, meta-regression displayed a significant positive relationship between the change 
in body weight (relative to baseline) and the absolute change in IHTG (β = 0.99 [95% CI: 0.62 
to 1.36], P < 0.001; Figure 7.6).  A significant relationship was also apparent between 
intervention duration and change in IHTG (β = -0.27 [95% CI: -0.35 to -0.19], P < 0.001; 
Figure 7.7), suggesting that as the duration of intervention increases, so does the magnitude of 
reduction in IHTG. The duration of interventions that elicited significant weight loss versus 
those that did not were similar (median [range]: 12 [8 to 24] vs. 12 [1 to 16] weeks), but 
bivariate Pearson’s correlation analysis showed a significant positive relationship between the 
duration of intervention and magnitude of weight loss elicited (r2 = 36%, P < 0.01). 
 
Figure 7.5 Meta-analysis of the pooled effect of exercise training on IHTG from pre- to 
post-training in all exercise groups of all eligible studies when studies are grouped into 
those that elicited weight loss versus those that did not.
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Figure 7.6 Meta-regression between the magnitude of weight loss, relative to baseline, 
elicited by exercise intervention and the absolute change in IHTG. Each circle represents 
a study, with larger circles indicating greater weight within the meta-regression analysis. 
Figure 7.7 Meta-regression between duration of exercise intervention in weeks and the 
absolute change in IHTG from baseline elicited in all eligible studies. Each circle represents 
a study, with larger circles indicating greater weight within the meta-regression analysis. 
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Figure 7.3 displays the mean change from baseline in IHTG for all interventions categorised 
by exercise type. The pooled effect on IHTG for aerobic exercise interventions was greater 
than that for each other mode of exercise, as well as the pooled mean for all interventions. 
However, the high prevalence of aerobic interventions in comparison to other types of 
intervention should be noted. When interventions were grouped according to exercise intensity, 
the pooled effect for moderate-intensity interventions was greater than that of the high-intensity 
exercise programmes (-4.82 [-7.00 to -2.65] %, I2 = 75.5%, P = 0.001 vs. -2.89 [-4.25 to -
1.53] %, I2 = 73.2%, P < 0.001). The intervention duration of the moderate and high-intensity 
interventions were similar (median [range]: 14 [4 to 24] vs. 12 [1 to 24] weeks). 
7.4.4 Overview of studies investigating the effects of exercise on hepatic insulin sensitivity 
Eight studies, containing a total of 10 exercise groups, reported the effects of exercise training 
on hepatic insulin sensitivity (Shojaee-Moradie et al., 2007; van der Heijden et al., 2009; Meex 
et al., 2010; van der Heijden, Wang, Chu, Toffolo, et al., 2010; Hickman et al., 2013; Lee et 
al., 2013; Cuthbertson et al., 2016; Sargeant, Bawden, et al., 2018) (Table 7.2). Four studies 
reported HISI (van der Heijden, Wang, Chu, Sauer, et al., 2010; van der Heijden, Wang, Chu, 
Toffolo, et al., 2010; Lee et al., 2013; Sargeant, Bawden, et al., 2018), although three presented 
EGP (and thus HISI) in different units to those outlined above. Two studies reported HIRI 
(Hickman et al., 2013; Cuthbertson et al., 2016). Four studies were able to provide raw data 
for the re-calculation of HISI (van der Heijden, Wang, Chu, Sauer, et al., 2010; van der Heijden, 
Wang, Chu, Toffolo, et al., 2010; Hickman et al., 2013; Cuthbertson et al., 2016), along with 
two that reported EGP and FPI separately (Shojaee-Moradie et al., 2007; Meex et al., 2010). 
As such, seven studies (eight exercise groups) were included in meta-analysis of changes in 
HISI with exercise training. Only two of these (Shojaee-Moradie et al., 2007; Cuthbertson et 
al., 2016) were RCTs with a non-intervention/standard care control group (containing a 
combined 22 and 14 participants in exercise and control groups, respectively) so only within-
group analysis was conducted. Three studies also reported %EGPsupp with low-dose insulin 
infusion (Shojaee-Moradie et al., 2007; Cuthbertson et al., 2016; Sargeant, Bawden, et al., 
2018) but, due to this limited number, meta-analysis was not performed. Seven further studies 
were found that utilised a study design allowing the calculation of at least one of HISI 
or %EGPsupp, but neither were reported (DeFronzo, Sherwin and Kraemer, 1987; Segal et al., 
1991; Hughes et al., 1993; Coker et al., 2006, 2009; DiPietro et al., 2006; Kirk, Sullivan and 
Klein, 2010). Whilst the authors of five of these studies kindly replied to requests for raw data, 
none were able to provide it. 
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7.4.5 The effects of exercise training on basal hepatic insulin sensitivity  
The study that was excluded from meta-analysis of changes in HISI reported a tendency for a 
reduction in HIRI in obese adolescent girls following 12 weeks of resistance exercise training, 
but not after 12 weeks of moderate- to high-intensity aerobic exercise (Lee et al., 2013). The 
remaining eight exercise groups were pooled and had a combined total of 105 participants 
(male: 84 (80%); female: 20 (19%); data not available: 1 (1%)). Participants had a weighted 
mean age of 43 [range 15.5 to 59] years and, as per study selection criteria, were overweight 
or obese (body mass index: 31.3 [27.6 to 35.3] kg·m-2; body fat percentage: 34.0 [25.5 to 
40.8] %). Participants were reported as sedentary and/or inactive and had low aerobic capacity 
(maximal or peak oxygen uptake: 24.7 [21.6 to 32.0] ml·kg-1·min-1). Five studies (five exercise 
groups) were conducted in individuals with diagnosed NAFLD or in those with baseline 
characteristics that met diagnostic criteria as outlined above (van der Heijden et al., 2009; van 
der Heijden, Wang, Chu, Toffolo, et al., 2010; Hickman et al., 2013; Cuthbertson et al., 2016; 
Sargeant, Bawden, et al., 2018). One study included separate groups of patients with impaired 
fasted glucose and T2DM (Meex et al., 2010) but, according to mean baseline characteristics, 
all other studies recruited individuals with normal fasted glycaemia (weighted mean fasted 
glucose for all studies was 5.36 [4.70 to 9.00] mmol·L-1) (American Diabetes Association, 
2018). The weighted mean HISI at baseline was 0.99 [0.58 to 2.09] mg·m-2·min-1 per μU·mL-
1.  
Studies included aerobic (n = 3), HIIT (n = 1), resistance (n = 2) and combined (n = 2) exercise 
interventions for six (n = 2), 12 (n = 5) or 24 (n = 1) weeks. Participants exercised on two to 
four days per week with sessions ranging from 20 to 60 minutes. One aerobic intervention, and 
the aerobic component of the combined exercise programmes, utilised moderate-intensity 
exercise, whilst the remaining aerobic interventions and the HIIT intervention were categorised 
as high-intensity.  
Two of the eight exercise groups displayed a statistically significant improvement in HISI with 
exercise, both of which were in adolescents (van der Heijden et al., 2009; van der Heijden, 
Wang, Chu, Toffolo, et al., 2010). One study reported a tendency for reduced HIRI after 
exercise training, but this effect was statistically significant when HISI was re-calculated as 
above. Neither RCT reported a significant difference between exercise and control groups 
(Shojaee-Moradie et al., 2007; Cuthbertson et al., 2016). However, when data were pooled, a 
statistically significant benefit of exercise was found (Figure 7.8). Based on the weighted mean 
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HISI at baseline, this pooled effect represents a relative improvement of approximately 13%. 
Two studies in obese adolescents reported a reduction in basal EGP after aerobic or resistance 
exercise training (van der Heijden et al., 2009; van der Heijden, Wang, Chu, Toffolo, et al., 
2010), but EGP was unaffected in all other studies. In contrast, FPI was significantly reduced 
in five of the exercise groups (van der Heijden et al., 2009; Meex et al., 2010; Cuthbertson et 
al., 2016; Sargeant, Bawden, et al., 2018), whilst the mean reduction in another (Hickman et 
al., 2013) approached statistical significance. One study (Cuthbertson et al., 2016) reported a 
statistically significant reduction in body weight from pre- to post-exercise training (2.5%) but 
this was not associated with an improvement in HISI. Another study (Hickman et al., 2013) 
reported a mean reduction in body weight of similar magnitude (2.6%) which, although not 
statistically significant, was associated with a significant improvement in HISI. 
 
Figure 7.8 Meta-analysis of the pooled effect of exercise training on HISI from pre- to 
post-training in all exercise groups of all eligible studies 
 
7.4.6 The effects of exercise training on insulin-stimulated hepatic insulin sensitivity 
Participant and intervention characteristics for the three studies examining the effects of 
exercise on %EGPsupp can be found in supplementary materials (Appendix XI). The two RCTs 
that reported HISI also reported %EGPsupp. One RCT reported a significant improvement 
in %EGPsupp, compared to the control group, after six weeks of aerobic exercise training, 
despite no change in total body weight or IHTG (Shojaee-Moradie et al., 2007). In 
contrast, %EGPsupp was reportedly unaffected by either twelve weeks of aerobic training 
(Cuthbertson et al., 2016) or six weeks of HIIT (Sargeant, Bawden, et al., 2018).  
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7.5  Discussion 
The prominent findings of this review are that structured exercise training, independent of 
dietary intervention, reduces IHTG in individuals with NAFLD. Importantly, whilst this effect 
is apparent without weight loss, the magnitude of reduction increases in direct proportion to 
the amount of weight loss induced by the intervention. Furthermore, our analyses indicate that 
exercise training for six to 24 weeks may also improve basal hepatic insulin sensitivity by 
approximately 13%. 
Previous reviews report that exercise training significantly reduces IHTG with a moderate to 
large pooled effect size (Keating et al., 2012; Orci et al., 2016; Katsagoni et al., 2017). The 
restriction of the current meta-analysis to a single technique (1H-MRS) allowed us to report 
this pooled effect as the absolute mean difference and our findings suggest that exercise 
training for between one and 24 weeks (mode 12 weeks) elicits an absolute reduction in IHTG 
of approximately 2.2 to 4.7% (mean ~3.5%); re-enforcing the meaningful therapeutic role of 
exercise for individuals with NAFLD. An important finding to emerge from this meta-analysis 
is the impact of weight loss as a mediator of the reduction in IHTG associated with exercise 
training interventions. This outcome is consistent with previous reviews (Brouwers et al., 2016; 
Golabi et al., 2016), which have highlighted the more potent impact of weight loss per se 
(primarily through dietary energy restriction) than the independent effect of exercise in the 
absence of body weight reduction. Specifically, our data show that whilst IHTG is significantly 
reduced in the absence of exercise-induced weight loss, the magnitude of effect is more than 
two-fold greater when weight loss occurs (-2.16 vs. -4.87%). Meta-regression suggests that 
each 1% relative reduction in body weight is associated with approximately 1% absolute 
reduction in IHTG. Interestingly, an almost identical relationship can be seen in studies that 
have examined IHTG responses to short-, medium- and long-term dietary energy restriction 
interventions (Browning et al., 2011; Wong et al., 2013; Patel et al., 2015). These data 
therefore illustrate that relative changes in IHTG are several-fold greater than associated 
alterations in body weight regardless of physiological stimulus. This overriding influence of 
weight loss may also explain why previous reviews have not found additive benefits of exercise 
when combined with dietary intervention (Keating et al., 2012; Smart et al., 2016). In these 
scenarios, large energy deficits created by dietary modification may dilute the much smaller 
contribution of exercise (Ross, Freeman and Janssen, 2000). Consequently, whilst exercise 
alone may be effective at reducing IHTG, the greatest therapeutic benefits will be realised when 
exercise interventions contribute to weight loss in combination with dietary energy restriction.  
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These findings have direct implications for exercise prescription in NAFLD. Firstly, given that 
weight loss appears to be the dominant factor mediating changes in IHTG (as demonstrated in 
our meta-regression analyses), and the capacity of dietary energy restriction to induce large 
amounts of weight loss is greater than that of exercise training (Browning et al., 2011; Wong 
et al., 2013; Patel et al., 2015), structured exercise training should be seen as a valuable addition, 
rather than an alternative, to dietary energy restriction in the majority of individuals. That said, 
whilst the magnitude of effects may be comparatively smaller, there is evidence to suggest 
weight-independent effects of exercise training on IHTG, including beneficial changes in 
skeletal muscle and hepatic substrate metabolism (Brouwers et al., 2016). Therefore, the 
benefits of exercise on IHTG should not be completely dismissed and structured exercise 
training may be an effective alternative for individuals where prolonged energy restriction has 
proved ineffective. No studies to date have directly compared the impact of the diet- versus 
exercise-induced weight loss, matched for magnitude, on IHTG. Notably, the wider benefits of 
exercise training on metabolic health beyond IHTG should also not be forgotten (Garber et al., 
2011). 
When recommending exercise training for individuals with NAFLD, the greatest impact of 
exercise training on IHTG is likely to occur with exercise that is associated with the greatest 
weight loss (Smart et al., 2016). Evidence suggests that aerobic exercise interventions typically 
evoke a higher amount of weight loss than anaerobic exercise modalities (Yumuk et al., 2015). 
The superiority of aerobic exercise interventions for reducing IHTG in individuals with 
NAFLD is supported by the present results and those of a previous meta-analysis (Orci et al., 
2016). Consequently, although resistance exercise training and HIIT promote a reduction in 
IHTG in patients with NAFLD, greater benefits will likely be achieved through continuous 
aerobic exercise protocols such as running, swimming and cycling. 
Exercise volume may also be an important variable which helps to explain why our analyses 
documented a larger reduction in IHTG with moderate- compared to high-intensity exercise 
interventions. Specifically, compared with shorter intense bouts of exercise, continuous 
moderate-intensity protocols commonly exhibit a greater total exercise volume and, 
consequently, energy expenditure. This higher level of energy expenditure may elicit a greater 
impact on metabolism, energy balance and IHTG. It is, however, important to consider that 
exercise-related energy expenditure may not necessarily translate into greater total daily energy 
expenditure (Pontzer et al., 2016; Melanson, 2017). Furthermore, given the inability to 
accurately calculate exercise-related energy expenditure in our review, further research is 
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needed to investigate the precise relationship between exercise-related energy expenditure and 
IHTG. 
Our analyses also demonstrate a significant relationship between the duration of exercise 
interventions and the change in IHTG, and a positive relationship between the duration of 
exercise training and the magnitude of weight loss. Each week of exercise training is associated 
with a reduction in IHTG of approximately 0.27%. Collectively, our findings highlight the 
importance of developing sustainable exercise interventions, which, in combination with 
dietary strategies, may elicit the greatest benefits on IHTG in individuals with NAFLD. 
The second part of this review examined the influence of exercise training on hepatic insulin 
sensitivity. Hepatic insulin resistance, which is strongly correlated with elevated IHTG 
(Korenblat et al., 2008; Shulman, 2014; Bril, Barb, et al., 2017), contributes to impaired 
glycaemic control in the pathogenesis of T2DM (Taylor, 2008; Rizza, 2010; Petersen, Vatner 
and Shulman, 2017). We assessed the impact of exercise interventions on HISI and %EGPsupp, 
which are measures of hepatic insulin sensitivity in the basal and insulin-stimulated states, 
respectively. The paucity of studies examining these effects meant that our analyses were 
conducted using any study that recruited individuals with overweight or obesity, who are thus 
at increased risk of NAFLD, in addition to studies exclusively in patients with NAFLD. 
In total, we identified eight studies (two of which had two exercise groups) which assessed the 
impact of exercise on basal hepatic insulin sensitivity (Shojaee-Moradie et al., 2007; van der 
Heijden et al., 2009; Meex et al., 2010; van der Heijden, Wang, Chu, Toffolo, et al., 2010; 
Hickman et al., 2013; Lee et al., 2013; Cuthbertson et al., 2016; Sargeant, Bawden, et al., 
2018). Seven studies had sufficient data for inclusion in our meta-analysis but only two of 
which were RCTs. Therefore, our analysis was restricted to within-group changes in eight 
exercise groups. Interestingly, despite only three exercise groups displaying significant 
improvements in HISI from pre- to post- intervention (van der Heijden et al., 2009; van der 
Heijden, Wang, Chu, Toffolo, et al., 2010; Hickman et al., 2013), our pooled analysis identified 
a statistically significant increase of approximately 13%. In adults, basal rates of EGP were 
unaffected by exercise, but this improvement in basal hepatic insulin sensitivity may be 
reflected by a reduction of FPI. The clinical relevance of this magnitude of improvement in 
basal hepatic insulin sensitivity for individuals that are overweight and obese is not 
immediately clear. However, this novel finding suggests that exercise training favourably 
modifies this important parameter in individuals at risk of NAFLD and T2DM.  
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Three studies reported the effects of exercise on %EGPsupp (Shojaee-Moradie et al., 2007; 
Cuthbertson et al., 2016; Sargeant, Bawden, et al., 2018), two of which were RCTs employing 
aerobic exercise interventions of six and 12 weeks (Shojaee-Moradie et al., 2007; Cuthbertson 
et al., 2016). While one study reported significant improvement in %EGPsupp, no change was 
reported in the other. Therefore, we cannot draw firm conclusions on the impact of exercise 
training on insulin-stimulated hepatic insulin sensitivity at this time.  
It is notable that we identified a further seven studies whose methods permitted the calculation 
of HISI or %EGPsupp but data were not presented or available. Furthermore, when hepatic 
insulin sensitivity was reported, the precise details of the experimental methods employed, 
units used for presentation of outcomes and calculation of indices of hepatic insulin sensitivity, 
varied between studies. This review, therefore, highlights the need for greater methodological 
and reporting consistency when assessing hepatic insulin resistance (e.g. standardisation of 
low-dose insulin infusion when undertaking dual-stepped hyperinsulinaemic-euglycaemic 
clamps and consistent use of units). 
Our meta-analysis of the effects of exercise training on IHTG in individuals with NAFLD, and 
the mediating influence of weight loss, is the most precise quantitative synthesis to date. 
Furthermore, this is the first systematic review and meta-analysis assessing the impact of 
exercise interventions on hepatic insulin sensitivity. However, a few important considerations 
are noteworthy. A range of exercise interventions are identified and our analyses of the effects 
of exercise on IHTG display significant heterogeneity. Whilst we explore potential sources of 
this heterogeneity, it is assumed that these studies are suitable for data pooling. Secondly, 
although most included studies attempt to control habitual diet, this is notoriously difficult 
(Dhurandhar et al., 2015) and the potential for dietary changes to influence study outcomes 
must, therefore, be recognised. Additionally, our subgroup analyses investigating the influence 
of weight loss on IHTG were performed with studies categorised according to statistical, rather 
than clinical, significance. This has the potential to exclude studies from the weight loss group 
that demonstrate physiologically relevant, but not statistically significant, weight loss. Notably, 
however, this is unlikely in our analyses because, in the ‘no weight loss’ studies, the largest 
mean relative reduction in body weight after exercise training was 1.2%. Furthermore, it is 
assumed that weight loss resulting from exercise training is primarily reflective of a reduction 
in fat mass but some exercise regimens may promote the synthesis of skeletal muscle; 
attenuating any reduction in total body weight. It should also be noted that while a reduction in 
IHTG may be indicative of improved metabolic health, these may be mediated by a reduction 
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in hepatic lipid intermediates rather than IHTG per se (Samuel et al., 2004; Kumashiro et al., 
2011; Shulman, 2014). Finally, the limited number of studies investigating hepatic insulin 
sensitivity means that our findings should be taken with caution. Large RCTs are required to 
further investigate the effects of exercise training on hepatic insulin sensitivity, particularly in 
individuals with NAFLD and T2DM.  
In conclusion, this systematic review and meta-analysis has shown that exercise training 
reduces IHTG in individuals with NAFLD and, whilst benefits can be realised in the absence 
of weight loss, reductions in IHTG are proportionally related to the magnitude of weight loss 
induced. Furthermore, exercise training may improve basal hepatic insulin sensitivity in 
individuals that are overweight or obese, which may have beneficial implications for the 
management of NAFLD and T2DM. 
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CHAPTER 8 
GENERAL DISCUSSION 
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8.1  Principal findings and chapter overview 
Collectively, the body of work presented in this thesis had three primary aims:  
1. To examine the effects of acute exercise on several circulating hepatokines, and their 
associations with anthropometric and circulating clinical biomarkers in individuals of 
different weight status and glycaemic control. 
2. To test the feasibility and efficacy of SIT as a novel intervention for patients with 
NAFLD, particularly exploring its effects on IHTG and tissue-specific (hepatic and 
peripheral) insulin sensitivity. 
3. To collate the existing literature and summarise the effects of exercise training on IHTG 
and hepatic insulin sensitivity, exploring the mediating influence of weight loss. 
The principal findings of this thesis are that:  
1. In volunteers free from chronic metabolic disease and with normal glucose regulation, 
circulating FGF21 and LECT2 are higher in individuals with overweight or obesity 
compared to normal weight healthy controls (Chapter 4).  
2. In all these individuals, a single bout of CME elicits a transient increase in circulating 
FGF21 and follistatin (Chapter 4), but whilst the follistatin response is maintained in 
individuals with dysglycaemia, the response of FGF21 is abolished (Chapter 5).  
3. In a controlled, supervised environment, SIT is feasible for individuals with NAFLD and 
reduces IHTG without significant reduction in body weight. However, hepatic insulin 
sensitivity is unaffected by SIT and the response of peripheral insulin sensitivity is highly 
variable (Chapter 6).  
4. Whilst exercise training has the potential to reduce IHTG in the absence of weight loss, 
the greatest benefits are apparent when training is associated with significant reductions 
in body weight (Chapter 7). 
5. However, there is limited evidence examining the effects of exercise training on hepatic 
insulin sensitivity. The effects in the insulin-stimulated state (%EGPsupp) are particularly 
unclear, but exercise training may improve basal hepatic insulin sensitivity, as assessed 
using HISI (Chapter 7).  
This chapter discusses these findings collectively and, where appropriate, their impact on 
clinical practice. Some additional analyses are also presented, pooling hepatokine data from 
Chapters 4, 5 and 6, before potential directions for future investigations are highlighted. 
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8.2  Intrahepatic triglyceride 
The studies in Chapters 6 and 7 of this thesis demonstrate that supervised exercise training 
alone has the capacity to reduce IHTG in individuals with NAFLD. Importantly, whilst this 
may occur in the absence of significant weight loss, the magnitude of reduction in IHTG 
increases in direct proportion with the magnitude of weight loss elicited. It is important to note, 
however, that the reduction in IHTG with exercise training is modest, even when weight loss 
occurs.  
The systematic review and meta-analysis presented in Chapter 7 collated studies examining the 
effects of exercise training on IHTG in patients with NAFLD, restricting eligible studies to 
those using 1H-MRS. This restrictive inclusion criteria was a strength of the study in Chapter 
7 because 1H-MRS has much greater precision than alternative methods of assessment, such as 
US or CT, to assess small changes in IHTG. Furthermore, the use of a single common technique 
allowed estimates of the pooled effect to be presented in absolute units (% change in IHTG), 
rather than a standardised effect size. Of the studies identified in Chapter 7, the greatest 
reduction with exercise training was reported by Cuthbertson and colleagues, where 16 weeks 
of aerobic exercise training elicited a median absolute reduction in IHTG of 9.3% (Cuthbertson 
et al., 2016). However, when data from all eligible studies were pooled (total 373 patients with 
NAFLD), the mean reduction in IHTG over 1 to 24 weeks of exercise training was 
approximately two-thirds lower (3.3%). This pooled effect was increased in a subgroup 
analysis of studies reporting associated weight loss, but remained less than 5%. Moreover, the 
largest (n = 220) and longest study identified in Chapter 7 randomised individuals to one of 
two 12-month aerobic exercise interventions or a standard-care control (6-month data were 
used for quantitative data pooling; see Appendix X for justification) (Zhang et al., 2016). This 
study reported approximately 6.5 to 7% absolute reduction in IHTG at 12 months in both 
exercise groups (Zhang et al., 2016). 
The pooled mean baseline IHTG in Chapter 7 was approximately 16%, which was similar to 
that reported in the studies by Cuthbertson et al (17%) and Zhang et al (19%) (Cuthbertson et 
al., 2016; Zhang et al., 2016). Consequently, the magnitude of reduction in IHTG with exercise 
training alone (as outlined above) would be insufficient to bring the typical NAFLD patient 
below diagnostic criteria (5.56%) (Marchesini et al., 2016; Chalasani et al., 2018), at least 
within 12 months of training. Furthermore, many of the studies identified in Chapter 7 recruited 
individuals with relatively low disease severity and IHTG may be even higher in individuals 
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with advanced NAFLD. Accordingly, only one study in Chapter 7 reported a mean IHTG post-
training below 5.56% (Cassidy et al., 2016). The baseline IHTG of individuals in this study 
was comparatively lower (6.9%) than many of the other eligible studies in Chapter 7. 
Furthermore, in Chapter 6 of this thesis, only two of the nine participants reduced IHTG below 
5.56% after six weeks of SIT, and these individuals had pre-intervention IHTG of 5.8% and 
8.6%, respectively, which was much lower than the group mean of 14.4%. These data suggest 
that the independent effect of exercise training alone on IHTG is modest and unlikely to be 
sufficient to bring the majority of patients with NAFLD below clinical diagnostic criteria. 
The modest effect of exercise training on IHTG could be explained, at least in part, by the fact 
that the weight loss associated with exercise training alone is also low. For example, in the 
studies by Cuthbertson et al and Zhang et al, the mean relative reduction in body weight from 
pre- to post-training was 2.5% and 4%, respectively (Cuthbertson et al., 2016; Zhang et al., 
2016). In contrast, dietary energy restriction has the capacity to impart a much greater influence 
on daily energy balance and is thus associated with much greater reductions in body weight 
(Ross, Freeman and Janssen, 2000). Accordingly, dietary energy restriction in patients with 
NAFLD elicits much greater reductions in IHTG than that of exercise training (Petersen et al., 
2005; Villareal et al., 2011; Hickman et al., 2013; Washburn et al., 2014). For example, in 
patients with NASH, approximately 10% weight loss through dietary energy restriction reduces 
the number of hepatocytes affected by steatosis, determined by histological assessment of liver 
biopsy tissue, (from 73% to 23%; P = 0.04; n = 5) and this reduction is much greater than that 
of a matched group undergoing resistance exercise training without weight loss (71% to 54%, 
P = 0.12; n = 9) (Hickman et al., 2013). Furthermore, in patients with T2DM (mean baseline 
IHTG of 12%), daily energy restriction (total energy intake 1200 kcal per day) elicits 8% 
weight loss in just seven weeks and this is associated with an approximate 10% absolute 
reduction in IHTG (Petersen et al., 2005).  
Importantly, in Chapter 7, meta-regression analyses suggest that each 1% relative reduction in 
body weight through exercise training alone is associated with approximately 1% absolute 
reduction in IHTG. This relationship is similar to that shown previously with dietary 
restriction-induced weight loss (Petersen et al., 2005; Browning et al., 2011; Wong et al., 2013; 
Patel et al., 2015). Therefore, whilst the absolute independent effect of exercise training on 
IHTG may be modest, exercise-associated weight loss may contribute towards substantial 
reductions in IHTG, when combined with dietary energy restriction. The role of exercise type 
in modulating reductions in IHTG is discussed in more detail below (see Section 8.5). 
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8.3  Effects of exercise training beyond IHTG 
Given the dominance of energy restriction compared to exercise training in its potential to 
mediate energy balance and reduce IHTG, it is understandable that some individuals may 
consider the promotion of structured exercise as a lesser priority in patients with NAFLD. 
However, whilst weight loss remains a core component in the management of NAFLD (and 
many other chronic metabolic diseases), the importance of exercise should not be readily 
dismissed. Firstly, dietary approaches may not be tolerated or sustained by all individuals so, 
whilst less than optimal, exercise training may constitute the primary treatment approach for 
these patients (alongside pharmacological treatment of other associated co-morbidities). 
Secondly, exercise has several important benefits beyond its impact on body weight and IHTG, 
many of which are clinically relevant for patients with NAFLD (Garber et al., 2011; Fiuza-
Luces et al., 2013; Keating, George and Johnson, 2015).  
Exercise training elicits several beneficial effects on cardiovascular risk factors, such as 
improved endothelial function, reduced blood pressure and a more favourable circulating lipid 
profile (Garber et al., 2011; Pugh et al., 2014; Zhang et al., 2016). Whilst some of these benefits 
may not impact directly on the clinical severity of NAFLD per se, CVD remains the leading 
cause of death in patients with NAFLD, so reduction in cardiovascular risk is an important 
clinical outcome (Targher, Day and Bonora, 2010; Targher et al., 2016). In Chapter 6, 
circulating HDL was improved after six weeks of SIT in patients with NAFLD. There were no 
other statistically significant changes in circulating cardiovascular risk factors, but this may 
have been a result of the small sample size recruited. Exercise training has also been shown to 
improve cardiorespiratory fitness and physical function (Garber et al., 2011; Fiuza-Luces et al., 
2013; Keating, George and Johnson, 2015). Both of these benefits may mediate improvements 
in health-related quality of life (Gillison et al., 2009; Awick et al., 2015), whilst 
cardiorespiratory fitness remains a leading predictor of both cardiovascular and all-cause 
mortality (Blair et al., 1989; Kodama et al., 2009). This list is not exhaustive and an active 
lifestyle has several other benefits that are beyond the scope of discussion in this thesis. Notably, 
however, the potential psychosocial benefits of engaging in regular exercise and a physically 
active lifestyle should not be forgotten (Castellani et al., 2003; Cadmus-Bertram et al., 2014).   
Exercise training also improves glycaemic control and much of this benefit may be mediated 
by improvements in insulin sensitivity (Garber et al., 2011; Umpierre et al., 2011; Fiuza-Luces 
et al., 2013; Keating, George and Johnson, 2015). Insulin resistance is heavily implicated in 
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the pathogenesis of NAFLD, with consequential hyperglycaemia, hyperinsulinaemia and 
hyperlipidaemia all factors contributing to the development of hepatic steatosis (Fabbrini, 
Sullivan and Klein, 2010; Birkenfeld and Shulman, 2014; Brouwers et al., 2016). However, 
insulin resistance is equally implicated in several other obesity-associated metabolic co-
morbidities, including T2DM, which are common in patients with NAFLD (Armstrong et al., 
2014; Byrne and Targher, 2015). As such, improved insulin sensitivity and glycaemic control 
are clinically important outcomes for patients with NAFLD. The effects of exercise training on 
tissue-specific insulin sensitivity in patients with or at risk of NAFLD were explored in 
Chapters 6 and 7 of this thesis. 
8.4  Insulin sensitivity 
The study presented in Chapter 6 examined the effects of a 6-week SIT intervention on 
peripheral and hepatic insulin sensitivity in patients with NAFLD. Hepatic insulin sensitivity 
in both the basal and insulin-stimulated states was unaffected by SIT, but there was a tendency 
for improved peripheral insulin sensitivity. The latter is assumed to be primarily reflective of 
improved insulin sensitivity in skeletal muscle. Chapter 7 collated existing published literature 
exploring the effects of exercise training on HISI and %EGPsupp in patients with or at high risk 
of NAFLD. This included the data reported in Chapter 6. Despite limited evidence however, 
particularly with regards to the effects of training on %EGPsupp, data pooling suggested that 
exercise training may improve HISI. 
In Chapter 6, the response of peripheral insulin sensitivity to training was highly variable and 
ranged from a 59% increase in one individual to an 18% reduction in another (mean 18% 
improvement). Six individuals demonstrated an improvement (minimum 11%), whilst the 
remaining two showed a decline (11% and 18%, respectively). Several reasons may be 
responsible for this variability, including genetic factors and baseline characteristics (Böhm et 
al., 2016). Furthermore, whilst (a) adherence to the training intervention was over 99%, (b) 
participants were instructed to make no changes to dietary habits and (c) no change in habitual 
physical activity was identified using hip-worn accelerometry, it cannot be discounted that 
variable responses may result from differences in participant motivation during training or 
compliance outside of the controlled environment. It should also be noted that the lack of 
response in some individuals may have been due to the short intervention duration and 
individuals showing no improvements after six weeks may have displayed an increase in 
peripheral insulin sensitivity had a longer intervention been utilised.  
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Improvements in peripheral insulin sensitivity will contribute to improved glucose tolerance 
and consequently lower postprandial hyperglycaemia and hyperinsulinaemia. In turn, lower 
circulating glucose and insulin may contribute to reductions in IHTG by reducing activation of 
ChREBP and SREBP-1c, respectively, thus lowering hepatic DNL (Yamashita et al., 2001; 
Ameer et al., 2014). Improved insulin sensitivity would also be of clinical benefit for many of 
the 22% of patients who have NAFLD and diabetes (particularly those with T2DM) (Younossi 
et al., 2016) and may also reduce the risk of T2DM incidence in those without (Balkau et al., 
2010; Sung, Wild and Byrne, 2013; Mantovani et al., 2018). 
As mentioned previously, very few studies (n = 3) have investigated the effect of exercise 
training on hepatic insulin sensitivity in the insulin-stimulated state. Furthermore, this evidence 
remains contradictory. One study reported an improvement in %EGPsupp after six weeks of 
aerobic exercise training (Shojaee-Moradie et al., 2007). However, it is notable that many of 
these individuals did not have NAFLD (median IHTG approximately 4%). The remaining two 
studies showed no effect of aerobic exercise or SIT on %EGPsupp (Cuthbertson et al. 2016; 
Sargeant et al. 2018; Chapter 6). The lack of studies exploring the effects of exercise 
on %EGPsupp may be the result, at least in part, of the technical expertise required to perform 
dual-step hyperinsulinaemic euglycaemic clamps with labelled glucose tracer, and the high 
financial cost. However, the results of the study in Chapter 6 and that of Cuthbertson et al 
(Cuthbertson et al., 2016) are in accordance with existing evidence demonstrating 
that %EGPsupp may become substantially impaired at a very low level of IHTG; possibly as 
low as 1.5% (Bril, Barb, et al., 2017). As such, in patients with NAFLD, a large reduction in 
IHTG, likely in association with substantial weight loss (see above), may be required to elicit 
improvements in insulin-stimulated hepatic insulin sensitivity. 
Whilst the number of studies investigating the effects of exercise training on HISI is also 
limited, there was sufficient data to perform a small meta-analysis. This analysis demonstrated 
that, when data were pooled, exercise training elicits approximately 13% improvement in basal 
hepatic insulin sensitivity. This was despite very few studies reporting a statistically significant 
benefit within individual manuscripts. Notably, the HISI index is made up of two components, 
EGP and circulating insulin, and improvements with exercise training may be realised by 
reductions in the latter. Very few studies reported a reduction in basal rates of EGP after 
exercise training. This might be expected, however, given that in most of the studies 
participants were not hyperglycaemic. As such, improvements in basal hepatic insulin 
sensitivity may not result in lower rates of EGP because, in many individuals, these were 
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already normal. However, the concentration of circulating insulin required to maintain these 
rates, and thus fasted euglycaemia, may be reduced. These findings are supported by previous 
literature demonstrating that, in contrast to the relationship with %EGPsupp, the relationship 
between IHTG and HISI may be linear (Korenblat et al., 2008). Thus, any reduction in IHTG 
(such as the small reductions seen with exercise) may elicit improvements in basal hepatic 
insulin sensitivity. 
8.5  Implementation of exercise training in the management of NAFLD 
The findings of Chapters 6 and 7 demonstrate that exercise training has an important role in 
the management of NAFLD but its implementation alongside dietary energy restriction, with 
the aim of reducing total body weight, may be required to elicit the greatest benefits. Given 
that weight loss appears to be a critical modulator of change in IHTG, and dietary energy 
restriction has a greater capacity to induce large amounts of weight loss than exercise alone 
(Browning et al., 2011; Wong et al., 2013; Patel et al., 2015), exercise training should not be 
considered a complete replacement to energy restriction for the majority of individuals. 
However, this does not mean that exercise training should be readily dismissed. Whilst the 
absolute effects may be smaller in comparison to energy restriction, the evidence from Chapters 
6 and 7 of this thesis suggests that exercise training may contribute to reductions in IHTG. 
Identifying the precise mechanisms underlying these benefits was beyond the scope of this 
thesis but existing evidence suggests that both weight-dependent and independent effects may 
play a role (Brouwers et al., 2016). It is also important to remember that exercise training 
provides a wide array of benefits to individuals with NAFLD beyond effects on IHTG (Garber 
et al., 2011). Some of these benefits, which include improved glycaemic control and other 
components of cardiovascular disease risk, are discussed in more detail below.  
Whilst the data presented in this thesis are novel, the promotion of a combined lifestyle 
intervention approach is not. In fact, the findings of this thesis support current guidelines for 
the management of NAFLD from the European Associations for the study of Liver (EASL), 
Diabetes (EASD) and Obesity (EASO), and the American Association for the Study of Liver 
Diseases (AASLD) (Marchesini et al., 2016; Chalasani et al., 2018). These guidelines endorse 
the promotion of structured exercise in conjunction with dietary energy restriction with the aim 
of reducing body weight by a minimum of 7-10%. Underpinning these guidelines is evidence 
that weight loss of at least 7% may be required to improve histological outcomes of NASH, in 
addition to reductions in IHTG (Promrat et al., 2010; Vilar-Gomez et al., 2015).  
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It is important to remember that, in similarity to pharmacological and surgical treatments, many 
forms of structured exercise exist and no ‘one size fits all’. Consequently, there is the need to 
develop a variety of sustainable, evidence-based exercise interventions in order to provide 
health care professionals with a range of safe, effective options when formulating a treatment 
plan for a given individual. Importantly, with the ever-increasing focus on personalised 
medicine and prominence of patient preferences at the centre of treatment plans, having 
multiple potential exercise interventions also gives patients the chance to explore several 
different approaches throughout the ongoing management of their chronic condition. Data from 
Chapter 7, demonstrating that greater reductions in IHTG are elicited with interventions of 
longer duration, support the need to identify effective, sustainable exercise interventions. 
The systematic review presented in Chapter 7 identified that aerobic and resistance exercise 
training, and several forms of HIIT (as well as combinations of two or more), have all been 
examined in individuals with NAFLD. Whilst the subgroup analysis performed in Chapter 7 is 
limited by the number of available studies, aerobic, HIIT and combined exercise training were 
each found to effectively reduce IHTG. These studies also include data presented in Chapter 6, 
where individuals with NAFLD were compliant with a SIT intervention involving repeated 
maximal exercise. However, the results of Chapter 7, along with previous reviews (Orci et al., 
2016), indicate that the greatest benefits on IHTG may be realised with aerobic exercise 
training and this may be mediated by a greater energy expenditure and subsequently greater 
potential for weight loss (Keating et al., 2012; Yumuk et al., 2015; Smart et al., 2016). 
Other studies (which did not utilise 1H-MRS and therefore were not eligible for the review in 
Chapter 7) have shown that resistance exercise training may also reduce IHTG in patients with 
NAFLD (Bacchi et al., 2013; Zelber-Sagi et al., 2014). A recent review suggested that 
resistance exercise training may, in fact, be an important option for individuals with low 
cardiorespiratory fitness, as it may elicit a reduction in hepatic steatosis at a lower energy 
consumption (Hashida et al., 2017). However, evidence for the direct benefits of resistance 
exercise training on hepatic outcomes in NAFLD remain inconclusive (Slentz et al., 2011; 
Hickman et al., 2013; Keating, George and Johnson, 2015). As previously discussed, however, 
patients with NAFLD will gain clinical benefits from factors beyond simply IHTG and 
resistance exercise may elicit many of these (Garber et al., 2011; Fiuza-Luces et al., 2013). 
Furthermore, evidence suggests that approximately one-third of weight loss may be attributed 
to the loss of metabolically and functionally important lean tissue mass (Heymsfield et al., 
2014; Weiss et al., 2017). Resistance exercise training may attenuate this loss of lean mass and 
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help achieve a more favourable composition of weight loss (Weiss et al., 2007; Villareal et al., 
2017). Resistance exercise has also been shown to elicit improvements in insulin sensitivity 
and glycaemic control (Garber et al., 2011; Hallsworth et al., 2011; Umpierre et al., 2011; 
Strasser et al., 2013). 
Collectively, the findings in Chapters 6 and 7 of this thesis demonstrate that, where possible, 
the greatest benefits for individuals with NAFLD may be realised when structured exercise 
training is combined with dietary energy restriction with the aim of reducing body weight by 
at least 7%. However, studies directly comparing dietary energy restriction alone with 
combined diet and exercise training on IHTG, insulin sensitivity and other outcomes of clinical 
relevance in NAFLD would be valuable. Aerobic exercise is strongly endorsed as part of a 
structured exercise intervention to contribute to weight loss and improve cardiorespiratory 
fitness, whilst a resistance exercise component is firmly advised to induce wider metabolic 
benefits, promote the preservation of lean mass and improve physical function. Importantly, 
however, treatment approaches should be configured around patient preferences, motivations 
and individual circumstances to encourage sustainable changes in lifestyle behaviours. 
Furthermore, clinically relevant outcomes in NAFLD beyond IHTG and insulin sensitivity 
should also be considered. 
8.6  Hepatokines 
As mentioned previously, IHTG and insulin resistance are highly associated and the magnitude 
of IHTG is strongly predictive of insulin resistance not only in the liver, but also in skeletal 
muscle and adipose tissues (Korenblat et al., 2008; Bril, Barb, et al., 2017). Insulin resistance 
is heavily implicated in the pathogenesis of both NAFLD and T2DM and it is therefore 
unsurprising that these conditions commonly co-exist (Williamson et al., 2011; Portillo 
Sanchez et al., 2015; Cusi et al., 2017). Individuals with both NAFLD and T2DM also have 
poorer prognosis (Vernon, Baranova and Younossi, 2011; Loomba et al., 2012; Lomonaco et 
al., 2016). In experimental rodent models, however, hepatic steatosis precedes the development 
of systemic insulin resistance during periods of high-fat overfeeding (Kraegen et al., 1991; 
Davis et al., 2010; Turner et al., 2013) and in humans the presence of NAFLD is an independent 
predictor of T2DM incidence (Balkau et al., 2010; Armstrong et al., 2014; Mantovani et al., 
2018). This evidence suggests that the relationships between NAFLD and glucose regulation 
in peripheral tissues may not be simply associational, but changes in liver metabolism with the 
development of hepatic steatosis may act to modulate metabolic processes in the periphery 
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(Meex and Watt, 2017). Consequently, there is increasing interest into the potential 
mechanisms that may mediate cross-talk between the liver and peripheral tissues with the 
secretion of  hepatokines proposed as one such mechanism (Stefan and Häring, 2013; 
Takamura, Misu and Kaneko, 2016; Meex and Watt, 2017). 
Many hepatokines exist (Meex et al., 2015), but five (FGF21, follistatin, fetuin-A, LECT2 and 
SeP) have been investigated in this thesis due to their reported influence on several aspects of 
glycaemic control (Misu et al., 2010; Camporez et al., 2013; Malin, Mulya, et al., 2013; Lan 
et al., 2014; Hansen, Rutti, et al., 2016). Specifically, FGF21 and follistatin have positive 
actions by augmenting insulin signalling, increasing pancreatic β-cell proliferation or 
promoting the synthesis of skeletal muscle (Gilson et al., 2009; Yaden et al., 2014; Zhao et al., 
2015; Hansen, Rutti, et al., 2016), whilst fetuin-A, LECT2 and SeP have deleterious effects on 
insulin signalling (Auberger et al., 1989; Srinivas et al., 1993; Misu et al., 2012; Lan et al., 
2014).  
Observational evidence in humans suggests that fasted concentrations of each of these 
hepatokines correlate with markers of insulin resistance, whilst all except follistatin correlate 
with adiposity (Chavez et al., 2009; Brix et al., 2010; Ishibashi et al., 2010; Misu et al., 2010; 
Yang, Hwang, et al., 2011; Mashili et al., 2011; Wu et al., 2012; Ismail et al., 2012; Ou, Yang, 
et al., 2012; Hansen et al., 2013; Okumura et al., 2013; Lan et al., 2014). Data presented in 
Chapter 4 of this thesis support these findings in part, with circulating concentrations of FGF21 
and LECT2 reportedly higher in individuals with overweight or obesity (but normal glycaemic 
control), compared to normoglycaemic normal weight individuals. Furthermore, circulating 
FGF21 and LECT2 were positively correlated with markers of adiposity and insulin resistance, 
and negatively with cardiorespiratory fitness (V̇O2 peak). 
The studies presented in this thesis recruited individuals with a range of adiposity and 
glycaemic control. In addition to the normal weight, overweight and obese normoglycaemic 
individuals recruited in Chapter 4, the studies in Chapters 5 and 6 recruited overweight or obese 
individuals with dysglycaemia (HbA1c 5.7 to 6.5%) and NAFLD (who were also moderately 
insulin resistant), respectively. By pooling data from each these chapters, there is the 
opportunity to explore further the relationships between circulating hepatokine concentrations 
and markers of adiposity or insulin resistance in a more diverse population than that of any 
single chapter. Details of pooled data analysis can be found in Appendix XII.  
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The results of these pooled analyses support previous evidence, including that from Chapter 4, 
demonstrating that circulating concentrations of FGF21, follistatin and fetuin-A are elevated 
in association with increased adiposity and/or insulin resistance, as well as other markers of 
chronic metabolic disease. Interestingly, all of these hepatokines are upregulated in states of 
excess lipid storage or impaired glycaemic control. Given that FGF21 and follistatin have been 
shown to exert beneficial effects on glucose and lipid metabolism (Camporez et al., 2013; 
Hansen, Rutti, et al., 2016), these increased concentrations may represent adaptive responses 
in attempts to attenuate the decline in metabolic regulation. Conversely, fetuin-A has been 
shown to impair insulin signalling and may, therefore, be implicated in disease pathogenesis. 
Pooled analyses also suggest that, despite correlating with indices of insulin resistance, fasted 
circulating concentrations of FGF21 may be influenced more by adiposity than glycaemic 
control. No differences were identified between overweight/obese individuals with 
normoglycaemia, dysglycaemia or NAFLD, but each of these groups had higher fasted plasma 
FGF21 than the normal weight individuals. This finding is supported by previous evidence 
demonstrating that, whilst FGF21 is elevated in individuals with T2DM, this may be the result 
of increased adiposity rather than impaired glycaemic control per se (Chavez et al., 2009; Mraz 
et al., 2009; Chen et al., 2011; Mashili et al., 2011). In contrast, follistatin and fetuin-A may 
only be elevated once a degree of metabolic dysregulation occurs as no differences were found 
between groups of normoglycaemic individuals irrespective of weight status. No previous 
study has identified independent relationships between markers of adiposity and circulating 
follistatin or fetuin-A. In fact, a study by Obuchi and colleagues found no difference in BMI 
between quartiles of fetuin-A in over 650 individuals (Obuchi et al., 2014). 
The primary aim of the studies in Chapters 4 and 5 of this thesis was to explore the effects of 
acute exercise on circulating hepatokine concentrations. These studies demonstrated that 
circulating concentrations of FGF21 and follistatin (but not LECT2, fetuin-A or SeP) are 
transiently elevated by a single bout of CME in both normal and overweight/obese individuals 
with normal glycaemic control (Chapter 4). However, only the follistatin response was 
maintained in individuals with dysglycaemia (Chapter 5), and a single bout of LV-HIIT did not 
affect circulating concentrations of any hepatokine measured in this thesis. Evidence suggests 
that the exercise response of FGF21 and follistatin to exercise may be mediated by changes in 
the glucagon to insulin ratio (Hansen et al., 2015; Hansen, Pedersen, et al., 2016; Hansen, Rutti, 
et al., 2016) and this is supported by data in Chapter 4. This mechanism may also explain 
differential responses between different groups of individuals, such as those with normal or 
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impaired glycaemic control. Unfortunately, glucagon was not measured in Chapter 5 and, 
therefore, the glucagon to insulin ratio could not be determined. Other mechanisms have also 
been implicated in the regulation of hepatokines, such as hepatic AMPK (Okumura et al., 2013; 
Lan et al., 2014) and circulating NEFA (Badman et al., 2007). In Chapter 4, circulating NEFA 
in the fasted state was higher in overweight/obese individuals, in accordance with higher 
FGF21 and LECT2. The response of circulating NEFA to acute exercise also mirrored that of 
FGF21. However, changes in systemic venous blood does not imply causality and more 
mechanistic studies containing the collection of hepatic and peripheral tissue samples and with 
isolation of the splanchnic circulation are required to directly investigate hepatokine regulation 
in humans. 
Circulating concentrations of FGF21, follistatin, fetuin-A and LECT2 were also analysed 
before and after individuals with NAFLD completed a 6-week SIT intervention, but no changes 
were identified (Chapter 6). These findings, as well as the null findings in Chapters 4 and 5, 
may have been the results of a lack of statistical power (discussed in more detail below). 
However, it should also be noted that this is a novel area of research, particularly with regards 
to the effects of acute and/or chronic exercise on fetuin-A, LECT2 and SeP. No studies have 
previously investigated the effects of acute exercise on fetuin-A or SeP, whilst the single study 
investigating LECT2 was conducted in mice and utilised a particularly large volume of exercise 
(three hours of forced treadmill running) (Lan et al., 2014). It could be, therefore, that 
hepatokine regulation differs between humans and rodent models or that the single bouts of 
exercise employed in Chapters 4 and 5 were simply insufficient to elicit a response. 
Collectively, the data presented in this thesis support suggestions that circulating hepatokines 
may be altered with the development of chronic metabolic diseases such as NAFLD and T2DM, 
which are both associated with increased adiposity and an insulin-resistant state (Stefan and 
Häring, 2013; Takamura, Misu and Kaneko, 2016; Meex and Watt, 2017). Furthermore, some 
of these hepatokines (FGF21 and follistatin) may be modulated transiently by perturbations in 
energy metabolism such as a single bout of exercise. These hepatokines may, therefore, have a 
role in metabolic regulation, being secreted from the liver as a signal of metabolic stress 
(Hansen and Plomgaard, 2016). Given that FGF21 and follistatin also elicit favourable 
metabolic effects in peripheral tissues, repeated increases in these hepatokines with regular 
exercise may be implicated in mediating the metabolic benefits of an active lifestyle. However, 
further studies exploring the associations between hepatokines and chronic metabolic disease 
in clinical populations are required. Specifically, longitudinal studies examining changes in 
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circulating hepatokines over time with the development (or reversal) of metabolic dysfunction 
would be of interest. Furthermore, of specific relevance to the work conducted in this thesis, it 
would be interesting to explore whether the acute hepatokine response to a single bout of 
exercise changes with repeated bouts over an extended period (i.e. exercise training), and 
whether any changes in this response, or in fasted concentrations, are associated with 
improvements in metabolic parameters such as IHTG or insulin sensitivity.  
It is important to acknowledge some limitations of the studies contained in this thesis. Firstly, 
the cross-sectional analyses presented in this thesis are exploratory and, as such, inferences 
remain speculative. Importantly, whilst the inclusion criteria for each experimental chapter of 
this thesis were varied in terms of weight status and glycaemic control, the pooled sample size 
remains small (n = 43) and most of these individuals were men (86%; n = 37). Moreover, all 
individuals recruited in this thesis were adults of white European ethnicity. Therefore, null 
findings may be the result of insufficient statistical power and these findings may not be 
generalizable to women, adolescents or children and different ethnic groups. Furthermore, the 
cross-sectional and correlational analyses presented in Chapter 4 and this General Discussion 
cannot be used to assess causality. Simple bivariate correlations were performed and many of 
the independent variables explored are strongly associated with one another. These analyses 
do not account for this shared variance and therefore the independent effects of the examined 
variables cannot be determined. Secondly, all hepatokine analyses conducted throughout this 
thesis were performed on plasma isolated from systemic venous blood. Cannulation of an 
antecubital vein is not optimal to assess changes in hepatokine secretion from the liver. 
Collection of systemic blood has been previously shown to be suitable to assess changes in 
FGF21 and follistatin after acute exercise (Hansen et al., 2011; Hansen, Pedersen, et al., 2016). 
However, the potential for changes in other circulating hepatokines (fetuin-A, LECT2 and SeP) 
to have been missed due to the location or timing of blood sampling cannot be dismissed. 
Finally, the hepatokine analyses presented may be limited by statistical power given that none 
of the studies reported in this thesis were formally powered to assess hepatokine outcomes. 
This may be particularly relevant for the data presented in Chapter 6. At the time of designing 
the studies in this thesis, there was very limited data available which investigated changes in 
circulating hepatokines with exercise. However, the data collected in this thesis may be used 
to inform future power calculations for larger studies in which changes in circulating 
hepatokines constitute the primary outcome. 
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Another interesting topic for discussion is that of adjusting for changes in plasma volume. In 
Chapter 4 of this thesis, the concentrations of all of our circulating biomarker outcomes 
(including hepatokines) were adjusted for changes in plasma volume; this was also the intention 
in Chapter 5 but large amounts of missing data for haematocrit and haemoglobin prevented this 
approach. The rationale for plasma volume adjustment during exercise studies comes from an 
observed haemoconcentration with exercise (Kargotich et al., 1998). As a result, changes in 
circulating concentrations of any given biomarker of interest may be due to changes in the 
plasma volume, rather than any change in biomarker production and secretion or clearance. 
This issue is, however, a widely debated one, with no definitive consensus currently apparent. 
One reasonable argument underlying the rationale not to adjust circulating biomarker 
concentrations, is that many homeostatic mechanisms appear to be based on the regulation of 
plasma biomarker concentration per se, regardless of any reason for change. For example, in 
individuals with normal glycaemic control, circulating glucose is regulated to a target 
concentration of approximately 4.5 mmol·L-1. 
It is interesting to note that repeating statistical analyses using unadjusted data from the study 
in Chapter 4 has no impact on the results for FGF21, follistatin or fetuin-A. However, when 
using unadjusted data, significant interactions between trial and time are apparent for LECT2 
(P = 0.002) and SeP (P < 0.001). In post-hoc tests LECT2 is significantly higher in the exercise 
trial at 1, 1.5 and 4 h (all P ≤ 0.03), whilst SeP is significantly greater in the exercise trial at 1 
h (P< 0.001) (Figure 8.1). Given that LECT2 and SeP are each associated with negative 
metabolic effects (Lan et al., 2014; Misu et al., 2010), an increase in these hepatokines after 
exercise is in contrast to that hypothesised in Chapter 4, and the physiological relevance or 
impact of these increased concentrations is currently unclear. The discrepancies between 
analyses performed on adjusted or unadjusted data do, however, highlight the important nature 
of this issue and the decision of which approach to take. In reality, the best approach may differ 
depending on any given biomarker of interest. When making this decision in future studies, 
researchers should consult the available literature to explore whether one approach or the other 
is more suitable in any given instance. If neither are, they may wish to present both adjusted 
and unadjusted data, or should at least be aware of the implications of the approach that they 
take. 
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Figure 8.1 Circulating concentrations of LECT2 and SeP during control and exercise 
trials in the combined population of Chapter 4, using data adjusted (a & c) or unadjusted 
(b & d) for changes in plasma volume. Meals were provided at 1.5 and 4 h. Exercise was 
performed between 0 and 1 h in the exercise trial only. Data presented as mean ± SEM. * 
indicates significant difference from control trial at the same time point (all P ≤ 0.03). 
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8.7  Future investigations  
Whilst accepting their limitations, the findings in Chapters 4 and 5 provide sufficient rationale 
to explore the interaction between exercise (acute and chronic) and circulating hepatokines 
further. Investigating responses in different populations is warranted and it would be interesting 
to explore the relationship between changes in circulating hepatokines and changes in IHTG in 
patients with NAFLD. Furthermore, in addition to the long-term modulation of circulating 
hepatokines with the development or treatment of chronic metabolic disease, there is growing 
interest into their acute and short-term (days to weeks) regulation. Extending the findings 
presented in Chapter 4, the effect of exercise intensity on acute hepatokine responses is 
currently being explored within our research group (Willis et al., 2018), as are the effects of 
other metabolic perturbations, such as short periods (1-7 d) of high-fat overfeeding (an abstract 
containing preliminary data has been submitted to BASES Conference 2018). 
Whilst the findings of Chapters 6 and 7 are interesting, analyses are limited to the effects of 
exercise training on IHTG and hepatic or peripheral insulin sensitivity. The impact of exercise 
on other clinical outcomes relevant to the development and management of NAFLD (as well 
as associated metabolic co-morbidities) would also be welcomed. Specifically, studies 
exploring the effects of exercise training on hepatic inflammation and fibrosis would be 
particularly valuable (Keating and Adams, 2016), as the development of these hepatic 
complications (i.e. advanced NAFLD) is associated with poorer clinical prognosis (Ekstedt et 
al., 2006; Söderberg et al., 2010; D. Kim et al., 2013; Younossi et al., 2016). It is also possible 
to quantify indices of hepatic lipid quality (saturated vs unsaturated) using magnetic resonance 
procedures, which may be linked to a greater likelihood of developing hepatic insulin resistance 
(Johnson et al., 2008). Furthermore, adipose tissue insulin sensitivity is heavily implicated in 
NAFLD, yet few studies have investigated the effects of exercise training on this outcome 
(Fabbrini et al., 2008; Korenblat et al., 2008; Lomonaco et al., 2012; Bril, Barb, et al., 2017).  
Multiple studies, including that presented in Chapter 6, have demonstrated that individuals with 
NAFLD are able to complete various HIIT protocols in a controlled laboratory environment 
and these are associated with significant reductions in IHTG. This is particularly encouraging 
given that high-intensity exercise may be important in protecting individuals from the advanced 
NAFLD (Kistler et al., 2011; Cho et al., 2015). However, the development of high-intensity 
exercise interventions that are implementable in a clinical setting is essential if HIIT is to have 
any long-term clinical application in NAFLD.  
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10.7  Appendix VII: Supplementary results for Chapter 4 
Table 10.1 Associations between fasted hepatokine concentrations and metabolic biomarkers. 
Corr: correlation coefficient (r or rho for Pearson’s and Spearman’s analysis, respectively; Data are analysed using parametric Pearson’s correlation 
analysis unless otherwise stated. * indicates non-parametric Spearman Rank correlation analysis used. # indicates data were log transformed prior 
to analysis. 
  Age Body mass  BMI BF%  WC 
Relative 
V̇O2 peak  
TG NEFA FPI  
Fasted 
plasma 
glucagon 
HOMA
-IR 
Adipo-
IR AST ALT 
AST: 
ALT FGF21 
FGF21 
Corr.   0.74 0.71 0.68 0.76 -0.52 0.72 0.79  0.44#  0.70#     
P-
value  <0.001 <0.001 0.001 <0.001 0.01 <0.001 <0.001  0.04  <0.001     
LECT2 
Corr.  0.47* 0.49 0.60* 0.42* -0.53 0.55# 0.52* 0.64# 0.49# 0.66# 0.70# 0.44#   0.61* 
P-
value  0.03 0.02 <0.01 0.05 0.01 <0.01 0.01 0.001 0.02 0.001 <0.001 0.04   <0.01 
Follistatin 
Corr.    
 
          -0.43#  
P-
value    
 
          0.05  
Fetuin-A 
Corr. -0.50*   
 
            
P-
value 0.02   
 
            
SeP 
Corr.    
 
         -0.44#   
P-
value    
 
         0.04   
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10.8  Appendix VIII: Supplementary methods for Chapter 6 
10.8.1 Self-report alcohol intake questionnaire 
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10.8.2 Further details of accelerometry data collection and analysis 
To assess the impact of SIT on habitual physical activity levels, participants wore a tri-axial 
accelerometer (GT3x, Actigraph LLC, USA) for seven consecutive days in the week before 
study assessments. Participants were encouraged to wear the device at all times, with the 
exception of showering/bathing or other water-based activities such as swimming. Participants 
were provided with a diary (see below) to note any points at which they removed the device, 
waking and sleeping times, physical activity performed and whether days were work or non-
work days. Participants were free to remove the device overnight, but were asked to note this 
on the diary and to remove the device as late as possible and put it back on as soon as they 
woke up. Data processing methods have been described in-depth previously (Troiano et al., 
2008) and were facilitated using computer software (Kinesoft 3.3.80, USA). A period of 
monitoring was considered valid for analysis when data was available for at least 600 minutes 
of wear time on at least three days of the week. In all but one period of monitoring, data 
included at least one weekend day. Non-wear time was considered 60 minutes of consecutive 
zero counts, allowing for two minutes of interruption. The cut-points in counts per minute 
(CPM) that were used to determine different categories of activity are presented in Table 10.2. 
 
Table 10.2 Troiano cut-points for categories of physical activity in counts per minute 
using tri-axial accelerometry analysis 
 Sedentary Behaviour 
Light Physical 
Activity 
Moderate 
Physical 
Activity 
Vigorous 
Physical 
Activity 
Counts per 
minute < 100 100 to 2019 2020 to 5999 > 5999 
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10.8.3 Full tracer calculations used in Chapter 6 
10.8.3.1 Basal EGP 
EGP was calculated using the following equations at both -20 and 0 min. The mean of the two 
values was then calculated and reported as basal EGP. 
APE = (TTRmeasured - TTRbaseline) / [1 + (TTRmeasured - TTRbaseline)] x 100 
Where APE = atoms percent excess, TTRmeasured = tracer to tracee ratio at timepoint of interest 
(-20 and 0 min samples) and TTRbaseline = tracer to tracee ratio at baseline (prior to tracer 
infusion). 
EGP (μmol·kg-1·min-1) = Ra = F / APE x 100 
Where F = the continuous tracer infusion rate (μmol·kg-1·min-1). 
 
10.8.3.2 EGP at low-dose insulin infusion: 
The following calculations were used to calculate EGP during low-dose insulin infusion: 
Tracer Racontinuous = {F – pV x [(C1 + C2) / 2] x [(APE2 – APE1) / (t2 – t1)]} 
[(APE1 + APE2) / 2] 
Where Racontinuous is the Ra contribution from the continuous tracer infusion (μmol·kg-1·min-1), 
pV is the fractional pool of distribution (a constant of 160mL·kg-1 was used in this study), C1, 
C2, APE1, APE2, t1 and t2 are glucose concentrations (mmol·L-1), enrichment (APE) and time 
(min) at consecutive timepoints of interest. 
Tracer Ravariable = TTRbag x GIR2 / [(TTR1 + TTR2) / 2] 
Where Ravariable is the Ra contribution from the tracer-spiked variable dextrose infusion 
(μmol·kg-1·min-1), TTRbag is the assumed TTR within the dextrose bags, GIR2 is the variable 
infusion rate at t2 (μmol·kg-1·min-1), and TTR1 and TTR2 are the TTR and t1 and t2 respectively. 
EGP (μmol·kg-1·min-1) = Racontinuous + Ravariable – GIR2 
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10.9  Appendix IX: Supplementary results for Chapter 6 
Table 10.3 Participant characteristics specific to those completing hyperinsulinaemic, 
euglycaemic clamps 
Anthropometry    
Age (years) 40 ± 7 
Body mass (kg) 102.1 ± 11.2 
BMI (kg.m-2) 31.5 ± 3.3 
Waist circumference (cm) 110.9 ± 8.0 
Body fat (%) 28.1 ± 2.5 
IHTG (%) 16.0 ± 8.8 
Metabolic Risk Factors    
Alcohol Intake (units.week-1)# 4 (3 – 10) 
Total Cholesterol (mmol.L-1) 4.74 ± 0.44 
HDL (mmol.L-1) 0.98 ± 0.23 
LDL (mmol.L-1) 2.70 ± 0.43 
Cardiorespiratory Fitness    
Absolute V̇Ȯ2 peak (L.min-1) 3.24 ± 0.44 
Relative V̇Ȯ2 peak (mL.kg-1.min-1) 32.0 ± 5.1 
Absolute PPO (W) 243 ± 44 
Relative PPO (W.kg-1)  2.40 ± 0.52 
Data presented as mean ± SD for n=8. #Data not normally distributed and thus presented as 
median (IQR). 
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Table 10.4 Participant characteristics specific to those for which full VAT and ScAT data 
are available 
Anthropometry    
Age (years) 42 ± 7 
Body mass (kg) 99.9 ± 7.7 
BMI (kg.m-2) 31.0 ± 2.5 
Waist circumference (cm) 110.0 ± 6.3 
Body fat (%) 28.4 ± 3.0 
IHTG (%) 14.2 ± 7.7 
Metabolic Risk Factors    
Alcohol Intake (units.week-1)# 4 (3 – 10) 
Total Cholesterol (mmol.L-1) 4.88 ± 0.63 
HDL (mmol.L-1) 0.98 ± 0.26 
LDL (mmol.L-1) 2.83 ± 0.65 
Cardiorespiratory Fitness    
Absolute V̇Ȯ2 peak (L.min-1) 3.24 ± 0.46 
Relative V̇Ȯ2 peak (mL.kg-1.min-1) 32.5 ± 4.6 
Absolute PPO (W) 241 ± 45 
Relative PPO (W.kg-1)  2.42 ± 0.48 
Data presented as mean ± SD for n=8. #Data not normally distributed and thus presented as 
median (IQR). 
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10.10  Appendix X: Supplementary methods for Chapter 7 
10.10.1 Data extraction 
10.10.1.1 Imputation of the mean and standard deviation (SD) during data extraction 
When the variation of change from pre- to post-intervention was reported as standard error or 
confidence intervals, established statistical equations were used to convert these to SD. When 
only pre- and post-intervention data were available, the mean change and SD were imputed as 
previously reported (Higgins and Green, 2011), assuming a correlation coefficient for change 
in IHTG of 0.80 (Pugh et al., 2014; Hallsworth et al., 2015; Houghton et al., 2017). 
10.10.1.2 Data presented as median and interquartile range 
When original data were reported as median and interquartile range, the median change was 
extracted and used in place of the mean, whilst the IQR was divided by 1.35 as an estimate SD 
(Higgins and Green, 2011). A sensitivity analysis removing these studies suggested that using 
data in this manner had no substantial impact on the results reported. 
10.10.1.3 Converting data to a consistent unit of measurement 
Data presented in this meta-analysis are, as much as possible, presented in a consistent format 
using similar units of measurement. When IHTG was reported as the ratio between intracellular 
lipid and water (lipid:water), this was converted to liver fat fraction using the following 
calculation: 
(lipid:water) / [1+(lipid:water)] x 100 
In some cases, data were converted during extraction using conversion factors as follows: 
Insulin: 1 mU = 6 pmol 
Glucose: 1 mmol·L-1 = 18 mg·dL-1 
EGP: 1 µmol·kg-1·min-1 = 0.18 mg·kg-1·min-1 
When data were also normalised, such as when presenting aerobic capacity in ml·kg-1·min-1 
rather than L·min-1, the mean value for the whole study group at baseline was used. 
~ 254 ~ 
 
10.10.1.4 Inclusion of subsets of participants 
When a paper reported one of the primary outcomes of this review in a subset of individuals 
(or when only a subset of individuals met the inclusion criteria), only these individuals were 
included. If descriptive data specific to this subset were available, they were extracted. If not, 
the sample size was adjusted to represent the subset of individuals but the mean descriptive 
data for the whole study population was used. This applies to the following studies: 
Cuthbertson et al., 2016 (Cuthbertson et al., 2016): only 19 individuals (ex: 12; con: 7) 
underwent hyperinsulinaemic, euglycaemic clamp and were thus included in HISI and 
percentage suppression of EGP analyses. 
Hickman et al., 2013 (Hickman et al., 2013): only nine of the 13 patients in the exercise 
group underwent post-training liver biopsy and were thus included in IHTG analyses. 
Furthermore, complete data to allow calculation of HISI were only available for 11 patients. 
Keating et al., 2015 (Keating et al., 2015): three separate exercise groups completing 
different exercise interventions were included in this study. One of these groups was 
ineligible as the mean baseline IHTG was < 5.56%. 
Langleite et al., 2016 (Langleite et al., 2016): only the dysglycaemic individuals had IHTG > 
5.56% at baseline. 
Meex et al., 2010 (Meex et al., 2010): Raw data was collected for the calculation of HISI. 
One participant was removed from analysis because no basal EGP data was available. 
Sargeant et al., 2018 (Sargeant, Bawden, et al., 2018): only eight of the nine participants 
completed hyperinsulinaemic, euglycaemic clamps and so only these participants were 
included in HISI and percentage suppression of EGP analyses. 
van der Heijden et al., 2010 (van der Heijden, Wang, Chu, Toffolo, et al., 2010): only seven 
individuals had NAFLD (defined as liver fat > 5.6%) and so only this subset was included 
in the hepatic steatosis analysis. All participants were included in the HISI analysis as 
NAFLD diagnosis was not an inclusion criterion for this outcome. 
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10.10.1.5 Inclusion of studies with multiple follow-up measurements 
One manuscript (Zhang et al., 2016) reported data after six months and 12 months of 
intervention  in two separate exercise groups. The interventions differed only during the first 
six months and, therefore, these data were extracted and used. 
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10.11  Appendix XI: Supplementary results for Chapter 7 
Table 10.5 Participant characteristics and outcome measures of studies assessing changes in IHTG (continued overleaf) 
Ref. 
 
Study Design 
Intervention 
Overview 
Participant Characteristics at Baseline Relative 
Change in 
Body Weight 
(%) 
Comments N  
(M/F) 
Age 
(years) 
BMI  
(kg•m-2) 
Body Fat 
(%) 
Aerobic 
Capacity 
(ml•kg-1•min-1) 
Baseline 
IHTG (%) Clinical Conditions 
Cassidy et al. 
(2016) 
 
RCT 
HIIT  
3 times per 
week for 12 
weeks. 
Ex: 12 (10/2) 
Con: 11 (8/3) 
61 ± 9 
59 ± 9 
31 ± 5 
32 ± 6 
35.4 (est.) 
39.6 (est.) 
21.8 ± 5.4 
20.3 ± 6.1 
6.9 ± 6.9 
7.1 ± 6.8 
Hepatic steatosis according 
to mean baseline measures. 
Diagnosed T2DM with stable 
control for ≥ 6 months. 
-1.1# 
1.1 
Reported medications: 
Metformin (Ex: n=7, Con: n=7) 
Statins (Ex: n=7, Con: n=6) 
Antihypertensives (Ex: n=3, Con: n=5) 
Cuthbertson 
et al. (2016) 
 
RCT 
Aerobic 
3 – 5 times 
per week for 
12 weeks. 
Ex: 30  
(23/7) 
Con: 20 
(16/4) 
50 
(46–58) 
52 
(46–59) 
30.6 
(29.0–32.9) 
29.7 
(28.0–33.0) 
30.4 
(25.9-32.1) 
31.0 
(26.5-37.7) 
23.7 
(21.7–27.8) 
32.2 
(20.9–25.6) 
19.4 
(14.6–36.1) 
16.0 
(9.6–32.5) 
Diagnosed NAFLD 
-2.5 
(-3.5 – -1.4)α,# 
0.2 
(-0.8–1.1) 
Notable exclusion criteria: 
T2DM and IHD 
Excessive weight loss during the course of the 
study 
Hallsworth et 
al. (2011) 
 
RCT 
Resistance 
3 times per 
weeks for 8 
weeks. 
Ex: 11 (NR) 
Con: 8 (NR) 
52 ± 13 
62 ± 7 
32.3 ± 4.9 
32.3 ± 4.8 
37 ± 8 
41 ± 6 
21.8 ± 3.8 
18.5 ± 5.2 
14.0 ± 9.1 
11.2 ± 8.4 
Clinically defined but non-
advanced NAFLD (defined 
as IHTG > 5% with NAFLD 
fibrosis score < -1.445). 
T2DM accepted provided 
diet and metformin 
prescription were stable for ≥ 
6 months. 
0.0 
0.6 
Notable exclusion criteria: 
Exogenous insulin therapy. 
IHD 
Weight loss > 2.5% during the study. 
Other: 
Exercise group were significantly younger than 
control (p < 0.05). 
Hallsworth et 
al. (2015) 
 
RCT 
HIIT 
3 times per 
week for 12 
weeks. 
Ex: 12 
(6/6) 
Con: 11 
(10/1) 
54 ± 10 
52 ± 12 
31.0 ± 4.0 
31.0 ± 5.0 
38.4 ± 6.4 
34.5 ± 7.0 
21.9 ± 6.2 
24.6 ± 5.7 
10.6 ± 4.9 
10.3 ± 4.4 
Clinically defined but non-
advanced NAFLD (defined 
as IHTG > 5% with NAFLD 
fibrosis score    < -1.445). 
Metformin accepted but 
participants with any other 
medication for T2DM were 
excluded. 
-1.6α,# 
0.0 
None 
Haus et al. 
(2013) 
 
Uncontrolled 
Intervention 
Aerobic 
Daily for 1 
week. 
Ex: 17 (NR) 54 ± 2 34.4 ± 1.0 NR 24.3 ± 1.5 19.4 ± 3.3 Diagnosed NAFLD. 0.2 
Notable exclusion criteria: 
T1DM,T2DM and CVD 
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Hickman et 
al. (2013) 
 
RCT* 
Resistance 
3 times per 
week for 24 
weeks. 
Ex: 9 (7/2) 48 ± 9 33.6 ± 5.8 38.8 ± 7.6 21.6 ± 7.3 71 ± 32† 
Diagnosed NAFLD. 
85% met diagnostic criteria 
for NASH. 
-2.6 ± 4.65 
Notable exclusion criteria: 
Diabetes 
Alcohol consumption > 40 and 20 g•day-1 for 
men and women respectively. 
Houghton et 
al. (2017) 
 
RCT 
Combined 
(HIIT + 
Resistance) 
3 times per 
week for 12 
weeks. 
Ex: 12 (7/5) 
Con: 12 (7/5) 
54 ± 12 
51 ± 16 
33.0 ± 7.0 
33.0 ± 5.0 
NR 
25.0 ± 8.0 
21.0 ± 5.0 
12.0 ± 9.0 
10.0 ± 5.0 
Histologically characterised 
NASH with NAFLD activity 
score ≥ 5. 
1.1 
1.1 
Notable exclusion criteria: 
≥60 minutes moderate-vigorous physical 
activity per week 
Insulin sensitising treatments 
Cardiac or renal diseases. 
Johnson et al. 
(2009) 
 
RCT 
Aerobic 
3 times per 
week for 4 
weeks. 
Ex: 12 (NR) 
Con: 7 (NR) 
49 ± 8 
47 ± 10 
32.2 ± 2.8 
31.1 ± 2.9 
NR 
25.9 ± 4.8 
25.0 ± 4.2 
8.6 ± 8.6 
9.2 ± 10.1 
Hepatic steatosis according 
to mean baseline measures. 
Hypertension allowed. 
-0.3 
-0.2 
Notable exclusion criteria: 
Lipid lowering medications 
FPG ≥ 7.0 mmol•L-1   
Reported medications: 
Anti-hypertensive medications (n=5) 
Note – medications were unaltered for the 
duration of the study except when participants 
refrained for 72 hours prior to study 
assessments. 
Keating et al. 
(2015) 
 
RCT 
Aerobic 
3-4 times per 
week for 8 
weeks. 
Ex1(HI:LO): 
12 (6/6) 
Ex2(LO:HI): 
11 (5/6) 
Con: 12 (3/9) 
44 ± 10 
45 ± 9 
39 ± 10 
36.3 ± 5.9 
34.0 ± 3.1 
32.2 ± 4.8 
NR 
21.9 ± 4.8 
24.5 ± 3.0 
21.7 ± 6.2 
8.4 ± 5.2 
9.4 ± 6.6 
7.7 ± 9.0 
Hepatic steatosis according 
to mean baseline measures. 
-1.2α,# 
-1.5α,# 
0.9a 
Notable exclusion criteria: 
Reported exercise on >3 days per week. 
Lipid-lowering or insulin-sensitizing 
medications. 
Langleite et 
al. (2016) 
 
Uncontrolled 
Intervention 
Combined 
(Aerobic + 
HIIT + 
Resistance) 
4 times per 
week for 12 
weeks 
Ex: 11 (11/0) 53 (10) 27.8 (5.3) NR 38.7 (8.1) 11.0 (11.9) 
Hepatic steatosis according 
to mean baseline measures 
Dysglycaemic according to 
OGTT performed during 
screening. 
-1.2 
Notable exclusion criteria: 
Structured exercise performed > once per week 
Hypertension, other liver or kidney diseases, 
chronic inflammatory disease or medications 
known to affect glucose metabolism. 
Malin et al. 
(2013) 
 
Uncontrolled 
Intervention 
Aerobic 
Daily for 1 
week. 
Ex: 13 (6/7) 51 ± 12 33.3 ± 3.2 NR 24.9 ± 5.4 23.1 ± 14.8 
Hepatic steatosis confirmed 
during baseline measures 
(defined as > 5% IHTG). 
0.6 None 
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Oh et al. 
(2014) 
 
Uncontrolled 
Intervention 
Acceleration / 
Vibration 
3 times per 
week for 6 
weeks. 
Ex: 18 (4/14) NR 
28.2 
(25.5–33.2) 
NR NR 
12.2 
(5.4–20.6) 
Diagnosed NAFLD by 
medical history, serum ALT 
and ultrasound. Confirmed 
by baseline IHTG > 5%. 
-0.4α None 
Pugh et al. 
(2014) 
 
RCT 
Aerobic 
3 – 5 times 
per week for 
16 weeks. 
Ex: 13 (7/6) 
Con: 8 (4/4) 
50 ± 3 
47 ± 5 
30.0 ± 0.8 
30.0 ± 2.0 
NR 
26.4 ± 2.3 
27.0 ± 2.8 
21.3 ± 12.8 
19.2 ± 6.1 
Clinically diagnosed NAFLD 
defined as IHTG ≥ 5.5%  
Individuals taking anti-
hypertensive medications 
were allowed. 
-2.4 ± 2.0 
-1.1 ± 2.0 
Notable exclusion criteria: 
Any form of structured exercise or > 2 hours of 
low-intensity physical activity per week. 
T2DM, IHD, habitual smokers. 
Reported medications: 
Anti-hypertensive medications (Ex: n=9)  
Note - medications were unaltered throughout 
the duration of the study. 
Sargeant et 
al. (2018) 
 
Controlled 
Longitudinal 
Intervention 
HIIT 
3 times per 
week for 6 
weeks. 
Ex: 9 (9/0) 41 ± 8 31.7 ± 3.1 28.7 ± 3.0 31.8 ± 4.8 15.6 ± 8.3 
NAFLD defined as IHTG ≥ 
5.56 percent in the absence 
of reported secondary causes 
as determined during 
participant screening. 
-1.2 
Participants were weight stable 
Notable exclusion criteria: 
Any form of diagnosed metabolic disease or 
taking medication known to influence lipid 
metabolism or glycaemic control. 
Sullivan et al. 
(2012) 
 
RCT 
Aerobic 
5 times per 
week for 16 
weeks. 
Ex: 12 (4/8) 
Con: 6 (1/5) 
49 ± 8 
48 ± 8 
37.1 ± 3.8 
40.0 ± 5.4 
38.9 ± 2.1 
42.5 ± 3.6 
22.8 ± 4.5 
18.5 ± 7.1 
20.2 ± 14.6 
21.4 ± 21.6 
NAFLD defined as IHTG > 
10%. 
-0.2a 
0.2a 
Notable exclusion criteria: 
T2DM or plasma TG > 400mg•dL-1. 
Not weight-stable (> 3kg weight change in 
previous three months). 
Self-reported exercise > 1 hour per week. 
van der 
Heijden et al. 
(2010a)‡ 
 
Uncontrolled 
Intervention 
Aerobic 
4 times per 
week for 12 
weeks. 
Ex: 15 (7/8) 16 ± 2 33.7 ± 4.3 38.3 ± 5.8 26.8 ± 6.3 9.0 ± 12.0 
Hepatic steatosis according 
to mean baseline data. -0.5 
All participants were post-pubertal. 
Participants were obese for ≥5 years and 
weight stable for ≥ 6 months. 
Notable exclusion criteria: 
Participation in organised school athletic 
programme or ≥ 45 minutes self-reported light 
to moderate physical activity. 
Any form of metabolic disease. 
Any medication (including contraceptives). 
1st degree relatives with diabetes. 
Morbid obesity (>50% body fat). 
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van der 
Heijden et al. 
(2010b) 
 
Uncontrolled 
Intervention 
Resistance 
2 times per 
week for 12 
weeks. 
Ex: 7 (NR) 16 ± 1 35.3 ± 1.9 42.6 ± 5.3 NR 13.9 ± 11.4 
Hepatic steatosis according 
to mean baseline measures 
but no formal diagnosis of 
NAFLD reported. 
2.6α 
All participants were post-pubertal. 
Participants were obese for ≥5 years and 
weight stable for ≥6 months. 
Notable exclusion criteria: 
Participation in any organised school athletic 
programme or ≥ 45 minutes self-reported light 
to moderate physical activity. 
Any form of metabolic disease. 
Any medication (including contraceptives). 
1st degree relatives with diabetes. 
Morbid obesity (>50% body fat). 
Zhang et al 
(2016) 
 
RCT 
Aerobic 
5 times per 
week for 24 
weeks. 
Ex1(Mod): 73 
(22/51) 
Ex2(Vig): 73 
(21/52) 
Con: 74 
(28/46) 
54 ± 7 
53 ± 7 
54 ± 7 
28.1 ± 3.3 
27.9 ± 2.7 
28.0 ± 2.7 
33.5 ± 5.5 
34.8 ± 5.3 
33.7 ± 7.1 
NR 
18.0 ± 9.9 
18.4 ± 9.9 
17.5 ± 11.0 
NAFLD diagnosed initially 
by ultrasound and the 
confirmed by 1H-MRS 
during screening 
-2.8 α,# 
-6.0 α,# 
-2.1 α, 
Notable exclusion criteria: 
History of other chronic liver diseases, 
hypertension, chronic kidney disease, 
hyperthyroidism, myocardial infarction (within 
6 month) or heart failure. 
Participation in weight loss programmes 
Data presented as mean ± SD or median (IQR); Sample sizes represent the number of individuals entered into analyses; *Study did not include 
‘standard care’ or ‘no intervention’ group. Patients were randomised to either exercise or dietary interventions; † Liver biopsy used. This number 
represent the percentage of hepatocytes affected by steatosis; ‡ Manuscript refers to same study as van der Heijden et al (2009); α significant 
difference from baseline (P < 0.05); # significant interaction between exercise and control groups (P < 0.05). 
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Table 10.6 Participant characteristics and outcome measures of studies assessing changes in HISI and %EGPsupp (continued overleaf) 
Ref. 
Study Design 
Intervention 
Overview 
Participant Characteristics at Baseline 
Comments N  
(M:F) 
Age 
(years) 
BMI  
(kg•m-2) 
Body Fat 
(%) 
Aerobic 
Capacity 
(ml•kg-
1•min-1) 
Fasted 
Glucose 
(mmol•L-1) 
Fasted 
Insulin 
(µU•mL-1) 
HISI 
(mg•m-2•min-1 
per µU•mL-1)  
EGP 
suppression 
(%) 
Clinical 
Conditions 
Cuthbertson  
et al. (2016) 
 
RCT 
Aerobic 
3 – 5 times 
per week for 
12 weeks. 
Ex: 12 
(8/3/1NR) 
Con: 7 
(3/4) 
44 ± 13 
50 ± 12 
31.0 ± 2.3 
29.0 ± 3.2 
30.4 
(25.9-32.1) 
31.0  
(26.5-37.7) 
28.1 ± 7.2 
24.2 ± 11.3 
4.79 ± 0.42 
4.84 ± 0.64 
17.4 ± 11.1 
13.4 ± 4.9 
1.11 ± 0.60 
1.00 ± 0.58 
50.1 ± 20.2 
46.5 ± 27.3 
Diagnosed 
NAFLD. 
See Table 4.2 for Notable exclusion 
criteria 
Insulin Dose and Infusion Duration: 
0.3 mU•kg-1•min-1 for 120 minutes. 
Potential Confounding Variables: 
Significant reduction in body weight 
and IHTG in the exercise group. 
Hickman et 
al. (2013) 
RCT* 
Resistance 
3 times per 
week for 24 
weeks. 
Ex: 13 (9/4) 50 ± 9 33 ± 6 39 ± 8 NR 5.5 ± 0.5 24 ± 22 0.85 ± 0.61 Not Measured 
Diagnosed 
NAFLD. 
85% met 
diagnostic 
criteria for 
NASH 
See Table 4.2 for Notable exclusion 
criteria 
NOTE: %EGPsupp was reported at 
high-dose insulin infusion (1 mU•kg-
1•min-1) and was improved by exercise 
training.  
Lee et al. 
(2013) 
 
RCT 
Ex 1:  
Aerobic 
Ex 2: 
Resistance 
3-4 times per 
week for 8 
weeks. 
Ex1:  
16 (0/16) 
Ex2:  
16 (0/16) 
Con:  
12 (0/12) 
15 ± 2 
15 ± 2 
15 ± 2 
32.9 ± 3.8 
36.4 ± 3.8 
35.3 ± 4.0 
47.8 ± 4.2 
51.5 ± 4.7 
51.3 ± 3.5 
28.5 ± 3.8 
24.3 ± 4.3 
23.9 ± 3.0 
5.18 ± 0.33 
5.24 ± 0.38 
5.39 ± 0.32 
28.6 ± 16.5 
45.8 ± 22.0 
31.1 ± 15.3 
24.2 ± 12.2† 
16.5 ± 10.5† 
22.9 ± 14.4† 
Not 
Measured 
None 
reported. 
Notable exclusion criteria: 
Endocrine disorders (PCOS, T2DM) 
Medication known to influence 
glucose metabolism or body 
composition. 
Potential Confounding Variables: 
No change in body weight in either 
group.  
IHTG significantly reduced in aerobic 
exercise group only. 
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Meex et al. 
(2010) 
 
Uncontrolled 
Intervention 
Combined 
(Aerobic + 
Resistance) 
3 times per 
week 
(2 Aerobic, 1 
Resistance) 
for 12 weeks. 
 
Ex1: 20 
(20/0) 
Ex2: 17 
(17/0) 
59 ± 1 
59 ± 1 
29.7 ± 3.6 
30.0 ± 3.4 
31.5 ± 1.4 
31.1 ± 1.4 
28.8 ± 4.5 
27.5 ± 5.1 
5.90 ± 0.45 
9.00 ± 1.70 
18.1 ± 10.7 
17.0 ± 5.3 
1.1 ± 0.5 
0.8 ± 0.3 
Not 
Measured 
Ex1: None 
reported. 
Ex2: T2DM 
diagnosed for 
at least 1 year 
prior to study 
participation 
Notable exclusion criteria: 
Cardiac disease, impaired liver or 
renal function, BMI > 35kg•m-2. 
Exogenous insulin therapies. 
Medications: 
All T2DM participants were on oral 
antidiabetic agents.  
Medication was unchanged 
throughout the duration of the study 
but discontinued for 7 days prior to 
each clamp assessment. 
Potential Confounding Variables: 
No change in body weight in either 
group.  
IHTG not measured. 
Sargeant et 
al. (2018) 
 
Controlled 
Longitudinal 
Intervention 
HIIT 
3 times per 
week for 6 
weeks. 
Ex: 8 (8/0) 40 ± 7 31.5 ± 3.3 28.1 ± 2.5 32.0 ± 5.1 4.7 ± 0.3 17.6 ± 4.5 0.68 ± 0.20 59.9 ± 17.4 
NAFLD 
defined as 
IHTG ≥ 5.56 
percent in the 
absence of 
reported 
secondary 
causes as 
determined 
during 
participant 
screening. 
See Table 4.2 for Notable exclusion 
criteria 
Insulin Dose and Infusion Duration: 
20 mU•m-2•min-1 for 120 minutes. 
Potential Confounding Variables: 
No change in body weight.  
IHTG significantly reduced from pre- 
to post-training. 
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Shojaee-
Moradie et al. 
(2007) 
 
RCT 
Aerobic 
3 times per 
week for 6 
weeks. 
Ex: 10 
(10/0) 
Con: 7 
(7/0) 
47 ± 9 
55 ± 11 
27.6 ± 1.9 
27.6 ± 2.4 
25.6 (est.) 
24.4 (est.) 
31.0 ± 3.2 
27.0 ± 5.3 
NR 
NR 
10.6 ± 6.3 
11.4 ± 7.6 
2.09 ± 1.03 
1.91 ± 0.87 
57.0 ± 15.1 
62.0 ± 18.9 
None 
reported. 
Notable exclusion criteria: 
T2DM, hyperlipidaemia 
Lipid-lowering medications 
Those already engaged in regular 
physical activity.  
Insulin Dose and Infusion Duration: 
0.3 mU•kg-1•min-1 for 120 minutes. 
Potential Confounding Variables: 
No change in either body weight or 
IHTG in either group. 
van der 
Heijden et al. 
(2009)‡ 
 
Uncontrolled 
Intervention 
Aerobic 
4 times per 
week for 12 
weeks. 
Ex: 15 (7/8) 16 ± 2 33.2 ± 3.5 38.3 ± 5.8 27.5 ± 6.3 5.0 ± 0.4 20.2 ± 9.6 0.87 ± 0.43 Not Measured 
Hepatic 
steatosis 
according to 
mean baseline 
measures. 
See Table 4.2 for Notable exclusion 
criteria 
Potential Confounding Variables: 
No change in body weight.  
IHTG not measured. 
van der 
Heijden et al. 
(2010b) 
 
Uncontrolled 
Intervention 
Resistance 
2 times per 
week for 12 
weeks. 
Ex: 12 (6/6) 16 ± 2 35.3 ± 2.4 42.6 ± 5.3 NR 5.10 ± 0.35 23.0 ± 6.4 0.63 ± 0.18 Not Measured 
Hepatic 
steatosis 
according to 
mean baseline 
measures. 
See Table 4.2 for Notable exclusion 
criteria 
Standardisation: 
Post-intervention assessments were 
performed 3 days after the final 
exercise training session. 
Potential Confounding Variables: 
Body weight significantly increased 
from baseline. Much of this was 
accounted for by an increase in LBM.  
IHTG not measured. 
Data presented as mean ± SD or median (IQR); Samples sizes represent the number of individuals entered into analyses; *Study did not include 
‘standard care’ or ‘no intervention’ group. Patients were randomised to either exercise or dietary interventions; † HISI presented as mg•kg-1•min-1 
per µU•mL-1; ‡ Manuscript refers to same study as van der Heijden et al (2010a); # baseline values not reported and unavailable upon request. 
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Table 10.7 Intervention characteristics of all included studies (continued overleaf) 
Ref. 
Study Design 
Exercise 
Type 
Intervention 
Duration 
Session 
Frequency Details of Exercise intervention Exercise Supervision 
Instructions to Control 
Groups / Details of 
Placebo Intervention 
Other Instructions 
Cassidy  
et al. (2016) 
 
RCT 
HIIT 12 weeks 3 times per week 
Sessions consisted of 5 cycling intervals at an intensity 
equating to ‘very hard’ (16-17) on a Borg RPE scale.  
Interval length progressed by 10 seconds per week from 
2 minutes in week 1 to 3 minutes 50 seconds by week 
12. 
Intervals were interspersed with 3 minutes consisting of 
90 seconds passive recovery, 60 seconds upper body 
resistance band exercise and 30 seconds preparation for 
the subsequent interval. 
The initial exercise session was 
supervised by a member of the 
research team after which 
instructions were provided via 
voice-recordings loaded onto an 
iPod (Apple, CA, USA).  
Adherence was monitored via 
exercise diaries. 
Continued standard 
care. 
Participants were instructed to 
continue their normal routine and 
medical care, making no changes to 
diet, habitual activity or medication. 
Cuthbertson  
et al. (2016) 
 
RCT 
Aerobic 12 weeks 
3 – 5 times 
per week 
Participants were given the choice of exercising on a 
treadmill, cross-trainer, cycle ergometer or rower.  
Intensity increased from 30% HRR at week 1 to 60% 
HRR by week 12.  
Frequency and duration progressed from 30 minutes, 3 
times per week during week 1 to 45 minutes, 5 times 
per week by week 12. 
One session per week was 
supervised by a trained exercise 
physiologist.  
The remaining sessions 
monitored via Wellness System™ 
(Technogym U.K. Ltd.) or by 
repeated telephone/email contact. 
Education and advice 
about the health 
benefits of exercise in 
NAFLD. 
Participants in the exercise groups 
were instructed to make no dietary 
modifications (confirmed by 3-day 
self-report food diaries) 
To avoid disturbance to behaviour, 
participants in the control group 
were given no instructions regarding 
diet or lifestyle. 
Hallsworth  
et al. (2011) 
 
RCT 
Resistance 8 weeks 3 times per week 
Sessions consisted of 8 whole-body exercises targeting 
large muscle groups performed as a circuit.  
Sessions progressed from 2 circuits at 50% 1RM during 
week 1 to 3 circuits at 70% 1RM by week 7.  
Participants were encouraged to increase the resistance 
each week if possible. 
Sessions were supervised 
biweekly.  
Heart rate was recorded during 
every session and exercise logs 
were completed to monitor 
adherence. 
Continued standard 
care. None reported 
Hallsworth et 
al. (2015) 
 
RCT 
HIIT 12 weeks 3 times per week 
Sessions consisted of 5 intervals on a cycle ergometer at 
an intensity equating to ‘very hard’ (16-17) on a Borg 
RPE scale.  
Interval length progressed by 10 seconds per week from 
2 minutes in week 1 to 3 minutes 50 seconds by week 
12. 
Intervals were interspersed with 3 minutes consisting of 
90 seconds passive recovery, 60 seconds upper body 
resistance band exercise and 30 seconds preparation for 
the subsequent interval. 
The first 2 exercise sessions were 
supervised by members of the 
research team after which 
instructions were provided via 
voice-recordings loaded onto an 
iPod (Apple, CA, USA).  
Exercise diaries were completed 
and reported completion of 33 out 
of 36 prescribed sessions was 
considered ‘adequate adherence’. 
Continued standard 
care. 
 
Participants were instructed to 
continue their normal routine and 
medical care, making no changes to 
diet, habitual activity or medication. 
Participants were asked to monitor 
and maintain body weight within 
1% of baseline. 
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Haus et al. 
(2013) 
Uncontrolled 
Intervention 
Aerobic 1 week 7 consecutive days 
Sessions lasted 50-60 minutes consisting of 40-50 
minutes of walking or running on a treadmill at 80-85% 
HRmax with appropriate warm-up and cool-down. 
All exercise sessions were 
supervised by an exercise 
physiologist. 
N/A 
Participants were instructed to 
maintain normal dietary habits and 
habitual physical activity. 
Hickman et 
al. (2013) 
 
RCT* 
Resistance 24 weeks 3 times per week 
Circuit-based sessions consisting of 15 moderate-
intensity (50% 1RM) resistance exercise covering the 
main muscle groups. Each exercise was performed for 
30 seconds with 30 seconds rest, during which 
participants moved to the next exercise. 
Sessions consisted of 1 circuit (12 min) during week 1 
and progressed to 5 circuits (60 min) by week 12. 
1RM was re-assessed every 4 weeks. 
All exercise sessions were 
supervised NA 
There were no prescribed dietary 
changes for the exercise intervention 
group. 
Houghton et 
al. (2017) 
 
RCT 
Combined 
(HIIT + 
Resistance) 
12 weeks 3 times per week 
A short HIIT session was performed made up of a 5 
minute warm-up followed by 3 x 2 minute intervals at 
an intensity equating to ‘very hard’ (16-18) on a Borg 
RPE scale. 
Intervals were interspersed with 1 minute rest.  
This was immediately followed by a resistance exercise 
circuit that comprised of 5 whole-body exercise 
targeting large muscle groups.  
Participants lifted a weight that equated to an RPE of 
14-16 (‘hard’). 
All exercise sessions were 
supervised by an accredited 
exercise specialist and recorded 
to ensure adherence. 
Continued standard 
care with maintenance 
of baseline weight. 
Participants were instructed to 
maintain normal dietary habits and 
habitual physical activity. 
Johnson et 
al. (2009) 
 
RCT 
Aerobic 4 weeks 3 times per week 
Each session lasted 30-45 minutes consisting of 15 
minute bouts of cycling with 5 minute recovery periods.  
Intensity was increased from 50% of pre-training V̇O2 
peak during week 1 to 60% in week 2 and 70% in 
weeks 3 and 4. 
All exercise sessions were 
supervised 
30 minute home-based 
whole-body stretching 
routine. 
Participants were instructed to 
maintain habitual diet throughout 
the study.  
24 hour food records were collected 
on the first and final three training 
sessions. 
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Keating et al. 
(2015) 
 
RCT 
Aerobic 8 weeks 
Ex1 (HI:LO):  
3 sessions per 
week 
Ex2 (LO:HI): 
4 sessions per 
week 
Ex1 (HI:LO): 2 laboratory-based cycling sessions and 1 
home-based brisk walking session per week all at the 
same intensity and duration. The programme progressed 
as follows: 
Week 1: 45 minutes at 50% V̇O2 peak. 
Week 2: Individual progression. 
Weeks 3-8: 60 minutes at 50% V̇O2 peak. 
Ex2 (LO:HI): 3 laboratory-based cycling sessions and 1 
home-based brisk walking session per week all at the 
same intensity and duration. The programme progressed 
as follows: 
Week 1: 30 minutes at 50% V̇O2 peak. 
Week 2: Individual progression. 
Weeks 3-8: 45 minutes at 70% V̇O2 peak. 
All laboratory exercise sessions 
were supervised by an accredited 
exercise physiologist.  
Adherence was 90, 96 and 94% in 
the HI:LO, LO:HI and control 
groups respectively. 
Stretching, self-
massage and ‘fitball’ 
programme. 1 session 
per week were 
performed in the 
laboratory and the 
remaining 2 at home. 
During the one 
supervised laboratory 
session participants 
performed 5 min of 
cycling 30 W to 
maintain ergometer 
familiarity. 
Participants were instructed to 
maintain habitual diet throughout 
the study.  
Participants completed 24 hour food 
records on 3 non-exercise days at 
baseline and during the final week 
of the intervention  
Participants also wore a tri-axial 
accelerometer for 2 weeks before 
and after the intervention. 
Langleite et 
al. (2016) 
 
Uncontrolled 
Intervention 
Combined 
(Aerobic + 
HIIT + 
Resistance) 
12 weeks 3 times per week 
Participants completed two whole-body strength 
training sessions and two sessions on a spinning bike 
per week.  
One bike session consisted of aerobic intervals for 
seven minutes at 85% HRmax with three minutes rest of 
active recovery against a light load between intervals. 
Participants completed three intervals in week one, four 
in weeks two-to-five and five from week six onwards. 
The second session consisted of two minute intervals 
at > 90% HRmax with two minutes rest of active 
recovery against a light load between intervals. 
Participants completed six intervals in week one, seven 
in weeks two-to-five and ten from week six onwards.  
All exercise sessions were 
supervised 
Mean attendance was 90%. 
N/A Participants recorded habitual diet before and after the intervention. 
Lee et al. 
(2013) 
 
RCT 
Ex1: Aerobic 
Ex2: 
Resistance 
13 weeks 3 times per week 
Ex1: Aerobic exercise were performed on treadmill 
and/or elliptical. The programme progressed as follows: 
Week 1: 40 minutes at HR equating to ~50% V̇O2 
peak. 
Weeks 2-8: 60 minutes at HR equating to ~70% V̇O2 
peak. 
Ex2: 10 whole-body exercises targeting large muscle 
groups. All sessions were 60 minutes in duration. The 
programme progressed as follows: 
Weeks 1-4: 1-2 sets of 8-10 reps at 60% 1RM. 
Weeks 4-13: 2 sets of 8-12 reps to fatigue. 
All exercise sessions were 
supervised by exercise 
physiology graduates.  
4 participants did not complete 
exercise training (2 from each 
group). Mean (± SD) attendance 
was 95% (± 4.3%) and 97% (± 
2.8%) in aerobic and resistance 
groups respectively. 
Asked not to 
participate in any 
structured exercise 
activity 
To aid adherence, 
participants in control 
group were offered the 
opportunity to 
complete either 
exercise intervention 
following post-study 
assessment. 
Participants consumed a weight-
maintenance diet throughout the 
duration of the study. 
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Malin et al. 
(2013) 
Uncontrolled 
Intervention 
Aerobic 1 week 7 consecutive days 
Sessions lasted for approximately 60 minutes consisting 
of treadmill running at 85% HRmax. 
All exercise sessions were 
supervised and 100% adherence 
was reported. 
N/A 
Participants were instructed to 
maintain normal dietary habits and 
habitual physical activity. 
Meex et al. 
(2010) 
Uncontrolled 
Intervention 
Combined 
(Moderate 
Aerobic + 
Resistance) 
12 weeks 
3 times per 
week total  
(2 aerobic, 1 
resistance)  
Aerobic: 30 minutes at 55% Wmax. 
Resistance: 8 whole-body exercises targeting large 
muscle groups with 2 sets of 8 reps at 55% MVC. 
Training sessions were supervised 
with 4 participants exercising per 
session. 
N/A None reported 
Oh et al. 
(2014) 
 
Uncontrolled 
Intervention 
Vibration / 
Acceleration 6 weeks 
3 times per 
week 
Whole-body exercises were performed using a vertical 
vibration machine. 
Sessions lasted 40 minutes with 30 seconds in between 
each exercise.  
Each week, one ‘movement preparation’, one ‘strength 
and power’ and one ‘massage’ session were performed. 
Trained staff supervised all 
exercise sessions to ensure 
correct execution. 
N/A 
Participants received lifestyle 
counselling regarding diet and 
physical activity for NAFLD for 12 
weeks prior to the intervention. This 
ceased at the beginning of the 
intervention. 
Participants completed 24 hour food 
records for 3 consecutive days and 
wore a uniaxial accelerometer for 2 
weeks at baseline and during the 
final week of the intervention. 
Pugh et al. 
(2014) 
 
RCT 
Aerobic 16 weeks 3 – 5 times per week 
Sessions consisted of a combination of treadmill and 
cycling exercise and progressed as follows: 
Weeks 1-4: 30 minutes at 30% HRR, 3 times per 
week. 
Weeks 4-8: 30 minutes at 45% HRR, 3 times per 
week. 
Weeks 8-12: 45 minutes at 45% HRR, 3 times per 
week. 
Weeks 12-16: 45 minutes at 60% HRR, 5 times per 
week. 
Weekly sessions were supervised 
by a trained exercise physiologist. 
Conventional care 
consisting of lifestyle 
advice from a 
consultant hepatologist 
or specialist nurse 
provided at a clinical 
consultation.  
No supervision or 
guidance was provided 
beyond this initial 
visit. 
Participants in the exercise group 
were instructed to make no dietary 
modifications throughout the 
duration of the study, confirmed by 
24 hour food diaries completed for 3 
days before and after the 
intervention. 
Sargeant et 
al. (2018) 
 
Controlled 
Longitudinal 
Intervention 
HIIT 6 weeks 3 times per week 
Sessions consisted of 30-second maximal sprints on 
cycle ergometer interspersed with 4.5-minute periods of 
active recovery at 50W. In addition participants 
completed a five-minute warm up and three-minute 
cool-down at 50W. 
Participants completed four intervals per session for the 
first two weeks after which an additional interval was 
added every two weeks, such that six intervals were 
completed per session in weeks five and six. 
All exercise sessions were 
supervised and session attendance 
was 100%. 
Each participant 
completed a six-week 
‘control phase’ before 
the start of the training 
intervention, before 
and after which all 
study were assessed. 
Participants were instructed to 
maintain habitual diet and lifestyle 
throughout the duration of the study. 
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Shojaee-
Moradie et 
al. (2007) 
RCT 
Aerobic 
(Vigorous) 6 weeks 
3 times per 
week 
Exercise performed at 60-85% V̇O2 max for a minimum 
of 20 minutes, 
1 session per week was 
supervised by an exercise 
physiologist. 
Participants were 
asked to continue their 
normal diet and 
lifestyle habits. 
Participants were instructed not to 
change dietary habits throughout the 
study. 
Sullivan et 
al. (2012) 
 
RCT 
Aerobic 16 weeks 5 times per week 
Sessions consisted of treadmill walking. 
During weeks 1-4, participants exercised for 15-30 
minutes at 45-55% of pre-training V̇O2 peak. Sessions 
progressed regularly until participants performed 30-60 
minutes of exercise at 45-55% V̇O2 peak and this was 
maintained for the remainder of the intervention. 
1 session per week was 
performed under direct 
supervision from a member of the 
research team. The remaining 
sessions were completed at home. 
Participants were 
instructed to maintain 
current activities of 
daily living and were 
contacted once per 
week to review 
compliance. 
None reported 
van der 
Heijden et al. 
(2010a)‡ 
 
Uncontrolled 
Intervention 
Aerobic 12 weeks 4 times per week 
Sessions consisted of treadmill, elliptical or cycle 
ergometer exercise. 
Sessions lasted approximately 50 minutes consisting of 
10 minutes warm-up, 10 minutes cool down and 30 
minutes exercise at a heart rate corresponding to 70% of 
baseline V̇O2 peak (mean ± SE: 86 ± 2% HRmax). 
2 exercise sessions per week were 
supervised by an exercise 
physiologist and the remaining 
were performed at home with 
adherence monitored by 
recording of heart rate. On 
average, participants completed 
91 ± 2% of prescribed sessions. 
N/A 
Participants were instructed to make 
no changes to dietary or physical 
activity habits during the duration of 
the study.  
Body weight was monitored two 
times per week to assure weight 
stability. 
van der 
Heijden et al. 
(2010b) 
 
Uncontrolled 
Intervention 
Resistance 12 weeks 2 times per week 
Sessions lasted 60 minutes and consisted of 10 whole-
body resistance exercises targeting large muscle groups. 
The programme progressed as follows: 
Weeks 1-2: 2-3 sets of 8-12 reps at 50% of 3RM. 
Weeks 3-8: individual progression increasing firstly 
by number of reps followed by weight. 
Weeks 9-12: 3 sets of 15-20 reps at 80-85% 3RM. 
All exercise sessions per week 
were supervised by an exercise 
physiologist.  
On average, participants 
completed 96 ± 1% of the 
prescribed sessions. 
N/A 
Participants were instructed to make 
no changes to dietary or physical 
activity habits during the duration of 
the study.  
Body weight was monitored two 
times per week to assure weight 
stability. 
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Zhang et al. 
(2016) 
 
RCT 
Aerobic 24 weeks 5 times per week 
Sessions lasted 30 minutes. 
In the moderate exercise group, participants walked 
briskly at approximately 120 steps per minutes so that 
their heart rate was 45 to 55% of predicted HRmax. 
In the vigorous exercise group, participants jogged at an 
intensity that elicited 65 to 80% of their predicted 
HRmax. 
Participants were supervised 
during the first two to four weeks 
of training to familiarise 
themselves with the correct 
exercise intensity. Participant also 
attended bi-weekly health 
education sessions. 
Participants then performed 
sessions at a local community 
centre and received twice-weekly 
telephone calls to assess 
adherence. Participants in the 
moderate group were given 
pedometers to monitor training 
step rate. 
Participants were 
instructed to maintain 
physical activity habits 
and attended bi-
weekly health 
education sessions that 
were held separately to 
those attended by the 
intervention groups. 
Participants were instructed to make 
no changes to their diet throughout 
the duration of the study. 
*Study did not include ‘standard care’ or ‘no intervention’ group. Patients were randomised to either exercise or dietary interventions; ‡ Manuscript 
refers to same study as van der Heijden et al (2009). 
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10.12  Appendix XII: Details of pooled hepatokine analyses 
10.12.1 Methods  
FGF21, follistatin and fetuin-A were measured in each laboratory-based study of this thesis 
(Chapters 4, 5 and 6), whilst LECT2 was investigated in Chapters 4 and 6 only. Samples pre-
treated with lithium heparin, which are required for the LECT2 ELISA used in this thesis, were 
not collected in Chapter 5. SeP was measured in Chapter 4 only and therefore could not be 
included pooled analyses.  
Fasted plasma hepatokine concentrations and other common descriptive variables were pooled 
from each laboratory-based experimental chapter and were assessed for their suitability for 
parametric statistical testing as outlined in General Methods (see Section 3.16). Due to 
heterogeneous variances between groups, Kruskal-Wallis tests were used to explore 
differences in participant characteristics and fasted hepatokine concentrations between the 
groups of individuals recruited in each chapter. The two groups in Chapter 4 were included 
separately. Significant main effects were explored post hoc using Mann-Whitney U tests and 
P-values were adjusted for multiple comparisons using the Holm-Bonferroni correction (Holm, 
1979). Pearson’s and Spearman’s correlations were performed, as appropriate, to explore 
relationships between fasted hepatokine concentrations and markers of adiposity or insulin 
resistance, as well as circulating lipids (TG and total cholesterol) and cardiorespiratory fitness. 
10.12.2 Results 
Participant characteristics of each group are presented in Table 10.8. By design, the individuals 
in each of the overweight/obese groups had greater BMI, BF% and WC, compared to the 
normal weight individuals (Figure 10.1a-b; all post-hoc pairwise comparisons P ≤ 0.004). BF% 
was greater still in the individuals with overweight or obesity and dysglycaemia compared to 
those with overweight or obesity alone (P = 0.045) and circulating lipids were also higher in 
each of the overweight/obese groups (P < 0.04). HOMA-IR was greater in individuals with 
dysglycaemia or NALFD compared to those without (Figure 10.1d; P ≤ 0.003) and there was 
a progressive increase in Adipo-IR throughout the groups, with the highest value detected in 
the individuals with NAFLD (P < 0.04).  
Absolute V̇Ȯ2 peak was lower only in the overweight/obese dysglycaemic individuals 
compared to the other three groups (P < 0.04) but these individuals were also significantly 
older (P < 0.001). Conversely, individuals with dysglycaemia or NAFLD had lower relative 
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V̇Ȯ2 peak (normalised to total body weight) compared with the normal weight normoglycaemic 
participants (P < 0.01). It should be noted that relative V̇Ȯ2 peak was significantly lower in the 
overweight/obese normoglycaemic individuals compared to the normal weight 
normoglycaemic group when these data were analysed in isolation (Chapter 4). Furthermore, 
in these pooled analyses, the uncorrected P-value for the pairwise comparison between these 
groups was also statistically significant (P = 0.027), but became non-significant (P = 0.08) after 
correction for multiple comparisons. 
Compared to normal weight individuals, FGF21 was greater in each of the overweight or obese 
groups (Figure 10.1c; P ≤ 0.024), but there were no further differences between 
overweight/obese individuals with normoglycaemia, dysglycaemia or NAFLD (P ≥ 0.81). As 
reported in Chapter 4, fasted LECT2 was higher in the overweight/obese participants than the 
normal weight controls, when all individuals were normoglycaemic (P = 0.023). However, 
fasted concentrations in individuals with NAFLD were not significantly different from either 
of the normoglycaemic groups (unadjusted P = 0.07). Conversely, fasted concentrations of 
follistatin were greater in individuals with dysglycaemia or NAFLD (Figure 10.1e; P < 0.0001) 
but, as presented in Chapter 4, there were no differences between normal weight or 
overweight/obese individuals with normal glycaemic control (P = 0.19). Fasted concentrations 
of plasma fetuin-A were greater in individuals with dysglycaemia compared to 
overweight/obese individuals with normal glycaemic control (Figure 10.1f; P = 0.01) but there 
were no other differences between groups, including the normal weight individuals (unadjusted 
P ≥ 0.07). 
Table 10.9 presents details of significant correlations between fasted circulating hepatokine 
concentrations (FGF21, follistatin and fetuin-A only) and markers of cardiometabolic health. 
Circulating concentrations of FGF21, follistatin and fetuin-A were positively associated with 
one another and each were positively correlated with markers of adiposity (BMI, WC and/or 
BF%). There were no relationships between fasted hepatokine concentrations and fasted 
circulating glucose (|r| or |rho| ≤ 0.26, P ≥ 0.10) and only follistatin was positively correlated 
with circulating NEFA. However, each hepatokine was positively associated with circulating 
insulin and, in turn, with HOMA-IR and Adipo-IR (all P < 0.01). Circulating fetuin-A was 
negatively associated with absolute V̇Ȯ2 peak, whilst the relationships with follistatin and 
FGF21 approached statistical significance (Table 10.9). Each hepatokine was, however, 
significantly negatively correlated with V̇Ȯ2 peak normalised relative to body weight.
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Table 10.8 Participant characteristics, including fasted circulating hepatokines, in participants recruited in exercise laboratory-based 
experimental chapter of this thesis 
 
Chapter 4 
Normal Weight 
Normoglycaemic 
Chapter 4 
Overweight/Obese 
Normoglycaemic 
Chapter 5 
Overweight/Obese 
Dysglycaemic 
Chapter 6 
Overweight/Obese 
NAFLD 
P-value  
n 11 11 12 9  
Sex (M/F) 11/0 11/0 6/6 9/0  
Age (years) 30 (24 – 52) 51 (33 – 56) 69 (67 – 71) γ 39 (35 – 50) <0.001 
Anthropometry              
BMI (kg·m-2) 23.4 (22.4 – 24.0) α 29.2 (27.0 – 31.5) 28.8 (28.4 – 32.5) 32.0 (29.1 – 33.6) <0.001 
Body fat (%) 16.9 ± 3.6 α 26.4 ± 4.0 35.7 ± 6.0 γ 28.7 ± 3.0 <0.001 
Waist circumference (cm) 81.6 ± 5.3 α 96.0 ± 7.8 101.7 ± 6.4 111.3 ± 7.5 δ <0.001 
Insulin Sensitivity      
Fasted circulating glucose (mmol·L-1)* 4.9 ± 0.2 5.0 ± 0.3 5.4 ± 0.5 ε 4.7 ± 0.3 0.002 
Fasted plasma NEFA (mmol·L-1) 0.40 ± 0.18 0.58 ± 0.14 0.51 ± 0.16  0.59 ± 0.14  0.06 
Fasted circulating insulin (mU·L-1)* 26.1 (22 – 33.8) 32.9 (23.0 – 39.1) 63.7 (50.5 – 99.1) γ 101.2 (83.3 – 127.7) δ <0.001 
HOMA-IR 0.95 ± 0.39 1.21 ± 0.67 2.89 ± 1.19 ζ 3.67 ± 0.96 ζ <0.001 
Adipo-IR 12.6 ± 9.0 α 22.0 ± 13.0 β 35.2 ± 12.5 γ 61.8 ± 20.4 δ <0.001 
Cardiorespiratory Fitness              
Absolute V ̇Ȯ2 peak (L·min-1) 3.46 ± 0.74 3.21 ± 1.21 2.19 ± 0.50 γ 3.23 ± 0.41 0.001 
Relative V ̇Ȯ2 peak (mL·kg-1·min-1) 50.1 ± 11.9 38.5 ± 9.7 26.5 ± 4.6 η 31.8 ± 4.8 η <0.001 
Circulating Lipids              
Triglyceride (mmol·L-1) 0.89 (0.64 – 1.33) α 1.79 (1.11 – 2.31) 1.36 (1.19 – 2.31) 2.18 (1.27 – 2.60) 0.004 
Total Cholesterol (mmol·L-1) 4.12 ± 0.73 α 4.91 ± 0.89 5.18 ± 0.91 4.88 ± 0.59 0.034 
Hepatokines              
FGF21 (pg·mL-1) 64 (32 – 144) α 183 (133 – 266) 143 (133 – 386) 176 (110 – 505) 0.007 
Follistatin (pg·mL-1) 795 ± 257 670 ± 154 2077 ± 480 ζ 2381 ± 909 ζ <0.001 
Fetuin-A (µg·mL-1) 541 ± 137 497 ± 99 682 ± 141 θ 608 ± 138 0.016 
LECT2 (ng·mL-1) 30.8 ± 9.9 α 47.6 ± 17.2 Not Measured 40.0 ± 4.9 0.023 
*In Chapter 4 and 5, glucose and insulin are measured in plasma. In Chapter 6, glucose and insulin were measured in whole blood and serum, respectively. α 
normal weight normoglycaemic group significantly different from each other group (P < 0.05); β overweight/obese normoglycaemic group significantly different 
from each other group (P < 0.05); γ overweight/obese dysglycaemic group significantly different from each other group (P < 0.05); δ overweight/obese NAFLD 
group significantly different from each other group (P < 0.05); ε significantly different from normal weight normoglycaemic and overweight/obese NAFLD 
groups (P < 0.05); ζ significantly different from both normoglycaemic groups (P < 0.05); η significantly different from normal weight normoglycaemic group 
(P < 0.01); θ significantly different from overweight/obese normoglycaemic group. 
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Figure 10.1 Comparisons of adiposity, insulin resistance and fasted hepatokine 
concentrations in laboratory-based experimental studies (Chapters 4, 5 and 6). Data 
presented as mean ± SD unless otherwise stated; # indicates that one of more groups were not 
normally distributed and thus data presented as median (IQR). To allow consistent presentation, 
some data may appear as a different summary statistic to that reported in the respective chapter 
of this thesis. 
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Table 10.9 Statistically significant relationships (and selected others) between fasted hepatokines concentrations and makers of 
cardiometabolic health in the pooled population of individuals recruited in this thesis. 
 Fasted Circulating FGF21 Fasted Circulating Follistatin Fasted Circulating Fetuin-A 
 Correlation Co-efficient (P-value) 
Correlation Co-efficient 
(P-value) 
Correlation Co-efficient 
(P-value) 
Age  rho = 0.37 (P = 0.014)  
Anthropometry ~ ~ ~ 
Body weight r = 0.57 (P < 0.001)    
BMI r = 0.58 (P < 0.001) rho = 0.21 (P = 0.009)  
BF% r = 0.47 (P = 0.002) rho = 0.52 (P < 0.001) r = 0.43 (P = 0.005) 
WC r = 0.66 (P < 0.001) rho = 0.54 (P < 0.001)  
Insulin Sensitivity ~ ~ ~ 
Fasted Circulating Glucose    
Fasted Circulating Insulin rho = 0.46 (P = 0.002) rho = 0.70 (P < 0.001) r = 0.46 (P = 0.002) 
HOMA-IR rho = 0.46 (P = 0.002) rho = 0.71 (P < 0.001) r = 0.45 (P = 0.003) 
NEFA r = 0.55 (P < 0.001)   
Adipo-IR r = 0.67 (P < 0.001) # rho = 0.65 (P < 0.001) r = 0.42 (P = 0.006) # 
Circulating Lipids ~ ~ ~ 
Fasted Plasma Triglyceride r = 0.47 (P = 0.001) # rho = 0.35 (P = 0.02)  
Total Cholesterol    
Cardiorespiratory Fitness ~ ~ ~ 
Absolute V̇O2 peak [rho = -0.30 (P = 0.053)] [rho = -0.28 (P = 0.071)] r = -0.34 (P = 0.003) 
Relative V̇O2 peak r = -0.59 (P < 0.001) rho = -0.44 (P = 0.003) r = -0.36 (P = 0.002) 
Hepatokines ~ ~ ~ 
Fasted Circulating FGF21 ~ rho = 0.36 (P = 0.02) r = 0.36 (P = 0.02) # 
Fasted Circulating Follistatin ~ ~ rho = 0.51 (P = 0.001) 
Shaded areas represent no significant correlations between variables. FGF21 and fetuin-A data were log transformed prior to parametric analyses; follistatin 
data were not normally distributed even when log transformed so non-parametric analyses were performed; # indicates independent variable was log transformed 
prior to analysis. 
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